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ABSTRACT 
Hypoxia is a common feature of solid tumors and one of the hallmarks of tumor microenvironment. Tumor hypoxia 
plays an important role in angiogenesis, malignant progression, metastatic development, chemo-radio resistance and 
favours immune evasion by the emergence of tumor variants with increased survival and anti-apoptotic potential. 
There is very little work done on the impact of tumor hypoxia on the regulation of tumor susceptibility to the lysis 
induced by cytotoxic antitumor response. Therefore, we asked whether hypoxia confers tumor resistance to 
cytotoxic T lymphocyte (CTL)-mediated killing.   
We demonstrated that exposure of target cells to hypoxia has an inhibitory effect on the CTL-mediated autologous 
target cell lysis. Such inhibition was not associated with an alteration of CTL reactivity and tumor target recognition. 
We also showed that the concomitant hypoxic induction of Signal transducer and activator of transcription 3 
(STAT3) phosphorylation on tyrosine 705 residue (pSTAT3) and hypoxia inducible factor 1 alpha (HIF-1α) is 
functionally linked to the alteration of Non small cell lung carcinoma (NSCLC) target susceptibility to CTL-
mediated killing.  
We also showed that hypoxia-induced resistance of lung tumor to CTL-mediated lysis was associated with 
autophagy induction in target cells. Inhibition of autophagy resulted in impairment of pSTAT3 (via inhibition Src 
kinase) and restoration of hypoxic tumor cell susceptibility to CTL-mediated lysis. Moreover, in vivo inhibition of 
autophagy by hydroxychloroquine (HCQ) in B16F10 tumor bearing mice and mice vaccinated with TRP2 peptide 
dramatically increased tumor growth inhibition. Collectively, the current study establishes a novel functional link 
between hypoxia-induced autophagy and the regulation of antigen specific T cell lysis and points to a major role of 
autophagy in the control of in vivo tumor growth. 
Finally, as resistance of tumor targets to killer cells is likely to be regulated by multiple factors, we further aimed to 
identify the microRNA’s regulated by hypoxia in NSCLC and melanoma and their putative involvement in the 
regulation of tumor susceptibility to antigen-specific CTL-mediated killing. MicroRNA-210 (miR-210) was 
significantly induced in a HIF-1α dependent manner in NSCLC and melanoma cells and miR-210 was expressed in 
hypoxic zones of human NSCLC tissues. Moreover, we demonstrated that hypoxia-induced miR-210 regulates 
tumor cell susceptibility to CTL-mediated lysis in part by suppressing PTPN, HOXA1 and TP53I11 expression 
indicating that miR-210 plays a potential role in the regulation of anti-tumor immune response. 
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PREFACE 
Cancer Immunotherapy has developed a lot during the 90’s. The discovery of tumor 
associated antigen (TAA) has brought a new revolution in this field. However the results of 
the clinical studies remained in the background because of the existing conflict/interactions 
between the immune system of the host, its tumoral system and its microenvironment, which 
is able to neutralize the antitumor cytotoxic effectors of various types. It has become clear that 
by analysing the interactions between the immune system and the tumoral system could 
facilitate the development and emergence of new approaches in antitumor immunotherapy. 
Several reports indicated that tumor cells evade adaptive immunity by a variety of 
mechanisms including development of hypoxia (low oxygen tension) [1]. Tumor hypoxia 
plays an important role in angiogenesis, malignant progression, metastatic development, 
chemo-radio resistance [2] and favours the emergence of tumor variants with increased 
survival and anti-apoptotic potential [3]. There is very little work done on the impact of tumor 
hypoxia on the regulation of tumor susceptibility to the lysis induced by cytotoxic antitumor 
response.  
The first section of this manuscript introduces the topic by providing an overview of our 
actual knowledge about tumor hypoxia and hypoxia inducible factors (HIF) with special focus 
on their contribution in the field of tumor development and progression. It also deals about 
how hypoxia by modulating tumor and immune system, favours immune evasion. It outlines 
how hypoxic stress confers resistance to tumor cells, and describes the molecular aspects of 
the cross-talk between hypoxia induced factors (HIF-1-α, p-stat3 and miR-210 etc) and 
resistance to cytotoxic treatments. Furthermore, how cells of the immune system (both innate 
and adaptive) respond to hypoxia in terms of their survival and effector functions and the 
ways in which hypoxia promotes their recruitment, activation, and survival are also discussed. 
Finally, anti-tumor immune response and different mechanisms of immune evasion are also 
explained in detail.  
In the second section, the various results obtained during this thesis are presented and 
discussed. The published articles are included in this section.  
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INTRODUCTION 
I. HYPOXIA   
Hypoxia is defined as a reduction in the normal level of tissue oxygen tension [4]. It occurs in 
a variety of conditions such as stroke (acute and chronic vascular disease), tissue ischaemia, 
inflammation, pulmonary disease and cancer. Severe or prolonged hypoxia can lead to cell 
death in both normal and cancer cells [5]. Hypoxia differs from anoxia which is the total 
absence of oxygen within a body tissue. Normal ambient air is 21% oxygen (partial pressure 
of oxygen (pO2) 150 mm Hg) and most of the mammalian tissues exist at 2% to 9% oxygen 
(on average 40 mm Hg). Hypoxia is defined as ≤ 2% oxygen (10-15mmHg), and severe 
hypoxia or anoxia is defined as ≤ 0.02% oxygen (< 10mmHg) [6] [2].  
 
A. History of research on hypoxia  
Joseph Priestley was the first person to demonstrate the importance of molecular oxygen for 
animal life in 1774 when he placed a burning candle in a bell jar alongside a mouse. The 
burning candle consumed oxygen leading to low levels of oxygen in the jar and the ultimate 
death of the unfortunate rodent [7]. 
The foundations of research on hypoxia in tumor biology were laid down by radiobiologist 
Gottwald Schwarz and colleagues in the early 20th century. As early as 1909, Schwarz and 
colleagues observed that normal mammalian cells irradiated in the presence of oxygen were 
more sensitive to irradiation than those irradiated under conditions of hypoxia or anoxia [8] 
[9] (Figure 1).  
Pioneering work by many scientists exposed important effects of tumor hypoxia on tumor 
biology. The research on hypoxia has provided significant advancement in our understanding 
of the molecular pathways by which oxygen influences tumour proliferation, angiogenesis 
and resistance to radiation, chemotherapy and immune system. A timeline of the history of 
research on tumor hypoxia is summarized in Figure 2.    
 
 
 
 
 
Figure 1: Article describing the first clinical observation of the importance of hypoxia. 
Gottwald Schwarz (1880-1959) findings were used to introduce the concept of 
“kompressionsana¨mie” by which the skin was made anemic, thereby allowing a higher dose de 
given to deeply situated tumors, a biologic concept in “Röngtentiefenterapie”. In 1914, he also 
observed the magnitude of the oxygen enhancement ratio 2: “Kompressionsana¨mie der Haut 
setzt die Röntgenempfindlichkeit derselben auf ein Drittel herab,” but without realizing that 
oxygen was the causal factor.
Figure 2. Timeline: The history of research on tumor  hypoxia
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B. Tumor Hypoxia  
Tumor hypoxia commonly refers to a condition in tumors where the oxygen pressure is less 
than 5 to 10 mmHg [4]. Hypoxia is a common feature of almost all of the solid tumors and 
mainly occurs due to a mismatch between tumor growth and angiogenesis [5]. Tumor 
Hypoxia is one of the hallmarks of cancer [10]. 
1. Normoxic, hypoxic and necrotic zones  
Nearly 55 years ago, in 1955, Thomlinson and Gray reported that cancer cells grow in cords 
around blood vessels. They noticed the presence of a central necrotic core surrounded by a 
region of viable cells near a blood vessel. They also proposed that the edges of such necrotic 
cores harbour viable hypoxic tumor cells [11]. It is now well established that solid tumors 
contain areas of variable oxygen concentrations [5] (Figure 3A). Tumor cells require oxygen 
and nutrients for their survival and therefore should be located within 100 to 200 µm of blood 
vessels which is the diffusion limit for oxygen. Tumor cells closest to a perfused blood vessel 
have relatively high O2 concentrations, which decline as the distance from the vessel increases 
[12]. Hence, in solid tumors there are areas which are well oxygenated, poorly oxygenated 
and finally necrotic in which cancer cells have died due to inadequate oxygenation [5] [13] 
(Figure 3B and 3C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                  
Figure 3: Tumor hypoxia (normoxic, hypoxic and necrotic zones)
A) Graph showing the relationship between the distance of tumor cells from nearby 
partial pressure of oxygen (blu
Med.) B) Pseudocolour immunoflourescense
bound pimonidazole (green), a 2
CD31 (red) in B16-F10 melanoma xenograft. 
squamous cell carcinoma of larynx 
(green) and hypoxia-inducible factor 1 (HIF
endogenous marker of hypoxia
A
B
e line) and acidosis (red line) (Helmlinger et al., 1997 Nature 
showing the difference in distribution of covalently 
-nitroimidazole hypoxia marker, and the endothelial cell marker, 
C) Immunoflourescense
showing the difference in distribution of pimonidazole 
1)-regulated carbonic anhydrase IX
(William et al., 2011 NATURE REVIEWS CANCER
C
vessels and 
staning of a human 
(CAIX; red), an 
). 
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2. Types of tumor hypoxia  
The tumor microenvironment is highly dynamic and consists of a heterogeneous population of 
cancer cells. These subpopulations of cancer cells have highly dynamic gradients of oxygen 
levels, genomic content, genomic stability, cellular pH and cellular metabolism. Hence solid 
tumors may contain group of cells that have been exposed to varying levels of oxygen for 
minutes to hours or to even days and then reoxygenated. This phenomenon is called ‘cycling 
hypoxia’ and occurs frequently in solid tumors. Tumor cells in hypoxic microenvironment can 
be exposed to fluctuating levels of cycling hypoxia at different oxygen gradients for different 
periods of time [14]. These fluctuations determine tumor cell fate depending on the severity, 
duration and outcome of hypoxia (whether ended by cell death or reoxygenation). Similarly, 
in tumors, the abnormal vascular architecture and blood flow that arises owing to unregulated 
angiogenesis is also an important factor in the development of hypoxia [15].   
Depending on these two factors (cycling hypoxia and abnormal vasculature); tumor hypoxia 
can be broadly divided into two types: acute/transient or perfusion-limited hypoxia and 
chronic or diffusion-limited hypoxia  
a. Acute/transient or perfusion-limited hypoxia 
In acute hypoxia, tumor cells have been differentially exposed to low intracellular oxygen 
levels for minutes to hours and then reoxygenated. 
Acute hypoxia occurs when abnormal/aberrant blood vessels suddenly shut down leading to 
the development of severe hypoxia at the site innervated by it. This can also cause blood flow 
to be reversed [16]. This shut down is normally transient and closed blood vessels can be 
reopened, leading to reperfusion of acute hypoxic tissue with oxygenated blood. Reperfusion 
with oxygenated blood leads to a process known as 'reoxygenation injury' characterized by a 
sudden and sharp increase in free radicals, tissue damage and activation of stress-response 
genes [17]. Free radicals contain oxygen and have unpaired electrons in their outer orbit 
which makes them a source of damage to cells and tissues. Free radicals can react with and 
modify the molecular structures of lipids, carbohydrates, proteins and DNA [18]. They are 
produced during the process of cellular metabolism but their rate is significantly increased 
under acute hypoxia (or ischaemia followed by reperfusion) [19]. Acute hypoxia can also be 
caused by increases in the surrounding interstitial fluid pressure [16] [20].   
18 
 
b. Chronic or diffusion-limited hypoxia  
In chronic hypoxia, tumor cells (at a distance of >100–200 µm from nearby vessel) are 
exposed to a more prolonged hypoxia for hours to days and ultimately undergo cell death or 
are reoxygenated. These perinecrotic regions of a tumor are located at a median distance of 
130 µm from blood vessels, reflecting the limit in oxygen diffusion [21]. 
In solid tumors tumor angiogenesis lags behind tumor growth. This uncontrolled proliferation 
causes tumors to outgrow their blood vessels which results in the formation of large hypoxic 
zones with few or none blood vessels. The diffusion of oxygen and nutrients is limited in 
these zones and the tumor cells are under continuous severe hypoxia named as chronic 
hypoxia [22].  
c. Acute versus chronic hypoxia  
One of the major limitations of the studies performed to describe the effects of hypoxia on 
tumor cell biology (angiogenesis, chemo-radioresistance, cell survival and apoptosis etc) is 
that in vitro assays usually mimic short term acute hypoxia followed by rapid reoxygenation. 
However tumor cell biology (especially survival) may be entirely different when cells are 
exposed to (greater than 24h) and maintained under chronic hypoxia. 
In this regard, it was shown that acutely hypoxic tumor cells irradiated immediately after 
reoxygenation are more radiosensitive as compared to cells irradiated under acute hypoxia 
alone [23]. Similarly, irradiated chronically hypoxic cells (maintained under hypoxia for up to 
72 h) acquire increased radiosensitivity when compared with irradiated cells exposed to acute 
hypoxia (4–24 h) [24]. These studies also showed that radiosensitization with drugs 
(misonidazole or SR2508) were increased in chronically hypoxic cells when compared with 
the toxicity in acutely hypoxic cells (despite the same level of oxygen at the time of 
irradiation). Later on, it was proposed that this differential sensitization could be partially 
explained by relative ability of DNA repair among acutely hypoxic and chronically hypoxic 
tumor cells [22].  
 Another interesting question is that whether exposure to acute or chronic hypoxia will 
differentially regulate the hypoxia-induced increased potential of tumor cells (for example 
metastasis potential) and whether it also depends upon the severity of hypoxia. Rofstad et al., 
using human melanoma xenografts demonstrated that acute hypoxic exposure might have a 
more important role than chronic hypoxia in metastasis induction [25]. Similar results showed 
that acute hypoxia in vivo could increase the metastasis in both rodent and human xenograft 
models [26] [27].   
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The outcome of acute or chronic hypoxia was shown to depend on the relative tumor cell 
proliferation, distance from nearby vasculature, and transient time through oxygen gradient 
and tumor cell adaptation to the microenvironment [22 ]. Comparisons of differential gene 
expression of acute versus chronic hypoxia are needed to address this issue.    
3. Hypoxia inducible factors (HIF’s) as master regulators of adaptation to hypoxia  
Tumor hypoxia has long been correlated with poor prognosis, resistance to radiotherapy and 
chemotherapy and increased malignancy [28], fuelling exhaustive research into tumor cell 
response to limited oxygen concentrations. Over the years, a particular interest has been taken 
in studying the mechanisms by which hypoxic tumor cells alter their transcriptional profiles to 
modulate proliferation, survival, glycolysis and invasion to persist under conditions of 
hypoxic stress [2]. Pioneering work by Peter Vaupel and colleagues showed convincingly for 
the first time the direct evidence of hypoxia in human cancers. They studied tumor oxygen 
supply using oxygen electrodes [29] and also showed that low oxygen tension in tumors was 
associated with increased metastasis and poor survival in patients suffering from squamous 
tumors of the head and neck, cervical or breast cancers. Tumor cells undergo a variety of 
biological response in response to hypoxia. In a hypoxic cell, one of the earliest responses is 
the shift from aerobic to anaerobic metabolism [30]. Hypoxia also induces erythropoietin 
(EPO) and vascular endothelial growth factor (VEGF), which induces neo-angiogenesis (new 
blood vessel formation) [28]. One important question is how cells sense oxygen and responds 
to it and what are the signalling pathways with mediate cellular oxygen responses?   
4. Molecular Biology of HIF family  
Scientist began looking for one or more factors that cells might use to respond to reduced 
oxygen levels and would be oxygen sensors. These investigations led to the discovery of one 
of the most striking responses to hypoxia-the induction of the hematopoietic growth hormone 
erythropoietin (EPO) [31]. At high altitude or in anemia, the blood oxygen content is reduced 
and the EPO production in renal interstitial fibroblasts is rapidly activated. This induction 
(more than several 100 folds) of EPO mRNA and protein induces erythropoietic responses 
that directly increase blood oxygen transport [31]. 
In early 1990’s, several groups identified a cis-acting hypoxia response element (HRE) (5′-
TACGTGCT-3′) in the 3′-flanking region of this locus that confers oxygen regulation of EPO 
expression [32] [33] [34] [35]. Gregg Semenza and Guang Wang in 1992 discovered a nuclear 
factor that is induced by hypoxia, binds to the EPO HRE and promotes transcriptional 
activation of EPO in oxygen-starved cells [36] [37]. It was designated hypoxia inducible 
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factor 1 (HIF-1) by Semenza and Wang. Later on, HIF-1 binding site within the EPO HRE 
was used for purification of HIF through DNA affinity chromatography and the cloning of 
cDNAs encoding the HIF-1α and HIF-1β subunits was done in 1995 [38].  
Three isoforms of HIFα have been identified: HIF-1α, HIF-2α, and HIF3α. HIF-1α and HIF-
2α (also known as EPAS1) have the same structure and are very well characterized. HIF3α 
mostly acts as a negative regulator of HIF-1α and HIF-2α [39]. HIF-1α is ubiquitously 
expressed in all mammalian cells, whereas HIF-2α and HIF3α are selectively expressed in 
certain tissues such as vascular endothelial cells, type II pneumocytes, renal interstitial cells, 
liver parenchymal cells, and cells of the myeloid lineage [40]. 
It has become clear now that HIF family of transcriptional factors is the key regulators of 
hypoxic response in all mammalian cells. HIF family has a critical role in development, 
physiology, cancer and other diseases. In tumor biology, HIF’s mediate pathways like 
angiogenesis, metabolic adaptation, cell growth, cell survival and apoptosis etc. [41] [2].  
5. Structure of Hypoxia inducible factors   
Hypoxia inducible factors (HIF’s) are the main mediators of primary transcriptional responses 
to hypoxic stress in normal and transformed cells. They are DNA binding basic helix-loop-
helix proteins of the PAS family (PER, AHR, ARNT and SIM family) [38]. HIF are obligate 
heterodimers consisting of oxygen-labile α-subunit (HIF-1α, HIF-2α (encoded by EPAS1) or 
HIF3α) and a stable β-subunit (HIF-1β; also known as ARNT) [42]. HIFα contains two 
oxygen dependent degradation domains (ODDD): a N-terminal (N-ODDD) and a C-terminal 
portion (C-ODDD), [33, 43]. HIF-1α and HIF-2α have two transactivation domains (TADs): 
an N-terminal TAD (which overlaps with the C-ODDD) and a C-terminal TAD [44] (Figure 
4).  
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Figure 4: Structure of Hypoxia inducible factors.   
Schematic structure of two HIFα and one HIFβ isoforms. The PAS and bHLH domains are 
dedicated to dimerization and recognition of target DNA sequences. bHLH, basic helix-loop 
helix-domain; PAS, per arnt sim domain subdivided into PAS A and PAS B; ODD, oxygen-
dependent degradation domain; TAD, transactivation domain. HIF-1α and HIF-2α have two 
distinct TAD, in the C- (C-TAD) and N- (N-TAD) terminal domains. (From Simon et al. 2008 
Nature Reviews Molecular Cell Biology).   
6. Oxygen dependent regulation of HIFα  
HIFα subunits under normoxic conditions have a short half life of less than 5 minutes [45]. 
Normoxic cells constantly synthesize HIFα proteins and degrade them. However, the 
degradation of HIFα is retarded under low levels of oxygen conditions [46].  
a. Role of prolyl hydroxylase domain in the regulation of HIFα protein degradation 
HIFα in the presence of oxygen is hydroxylated on proline residue 402 and/or 564 by prolyl 
hydroxylase domain protein 2 (PHD2) in the ODDD [47] [43]. This oxygen dependent 
hydroxylation results in the binding of HIFα with von Hippel–Lindau tumor suppressor 
protein (pVHL). pVHL is the recognition component of an E3 ubiquitin-protein ligase 
complex that eventually targets HIFα for proteolysis by the ubiquitin–proteasome pathway 
[48]. Enzymes regulating HIFα proteasomal degradation were first identified to be related to 
egl-9 in Caenorhabditis elegans and termed prolyl hydroxylase domain (PHD) enzymes 
(PHD1–PHD3) [49] [50]. PHDs are non-heme Fe (II)- and 2-oxoglutarate-dependent 
dioxygenases that split molecular oxygen. PHD2 uses oxygen as a substrate, and thus, its 
activity is inhibited under hypoxic conditions [50]. In the reaction, one oxygen atom is 
inserted into the prolyl residue, and the other atom is inserted into the co substrate α-
ketoglutarate, splitting it into CO2 and succinate [47]. Other components of HIFα-pVHL 
complex are elongin B, elongin C, and Cul2, which also participate in other E3 ubiquitin 
ligase complexes [51] (Figure 5A). 
Under hypoxic conditions, prolyl hydroxylation is inhibited and HIFα protein proteasomal 
degradation is inhibited. HIFα rapidly accumulates, translocates to the nucleus and dimerizes 
with HIFβ. HIFα HIFβ heteromeric dimer HIF binds to the HRE in target genes, recruits co-
activators and activates transcription [2] (Figure 5B). PHD’s are the main oxygen sensors and 
hypoxia inhibits PHD activity through various mechanisms, including substrate limitation 
[52].  
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Similar to HIF-1α, HIF-2α is also regulated by oxygen-dependent hydroxylation [53]. HIF-1α 
and HIF-2α are structurally similar in DNA binding and dimerization domains but differ in 
their transactivation domains [54]. Consistently, they share overlapping target genes, whereas 
each also regulates a set of unique targets [55]. By using genome wide chromatin 
immunoprecipitation combined with DNA microarray (ChIP-chip) or DNA sequencing 
(ChIP-seq), it was shown that more than 800 genes are direct targets of HIF (one in 30 of all 
human genes) [56] [57]. HIFs are also shown to regulate a number of hypoxia-regulated 
microRNAs (HRM) [58] and chromatin modifying enzymes [59]. 
HIF-3α lacks the transactivation domain and may function as an inhibitor of HIF-1α and HIF-
2α and its expression is transcriptionally regulated by HIF-1 [39].  
b. Role of factor-inhibiting HIF (FIH) in the regulation of HIFα transactivation 
Oxygen regulates the stability as well as the transcriptional activity of HIFα subunits [2].The 
transcriptional activity of HIFα is regulated by the hydroxylation of a C-terminal asparagine 
residue (Asn 803 in human HIF-1α) [60]. This hydroxylation reaction is carried out by an 
asparaginyl hydroxylase termed FIH. This enzyme is oxygen dependent and represents 
another component of the oxygen-sensing machinery. FIH represses HIF-1α transactivation 
function [61] by using O2 and a-ketoglutarate as substrates, thereby blocking the association 
of HIF-1α C-TAD with the CH-1 domain of the transcriptional coactivator protein p300 [60] 
[62].Thus, in contrast to the prolyl hydroxylation that enables protein–protein interaction 
(HIFα stability), the asparaginyl hydroxylation prevents protein recruitment (HIFα 
transactivation).  
 
 
 
 
 
 
 
 
 
 
Figure 5: Oxygen dependent regulation of hypoxia-inducible factor
A) Under normoxia, HIFα is subject to oxygen-dependent PHDs mediated degradation by the 26S proteasome. STAT3 and mTOR 
upregulate HIFα at the mRNA level. B) Under hypoxia, HIFα is stabilized and dimerizes with nuclear HIFβ. The HIF-α protein binds 
to HRE elements in the promoters of HIF-responsive genes. PHD, prolyl-hydroxylase domain; NO, nitric oxide; SIRT1/3/6, sirtuin 
1/3/6; FIH, factor inhibiting HIF; OH, hydroxyl group; mTOR, mammalian target of rapamycin; STAT3, signal transducer and 
activator of transcription 3; pVHL, von Hippel-Lindau protein; ROS, reactive oxygen species; HIF, hypoxia-inducible factor; (Taken 
from Greer et al. 2012 The EMBO Journal). 
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7. Oxygen independent regulation of HIFα (pseudo hypoxia or hypoxia like 
normoxia)   
Apart from strict oxygen dependent regulation of HIF’s, HIF-1α and HIF-2α are also 
regulated by several oxygen independent mechanisms [63] (Figure 6). In addition to 
intratumoral hypoxia, loss-of-function (LOF) for tumor suppressor genes (most notably, 
pVHL), and gain-of-function (GOF) for oncogenes and viral transforming genes increases 
HIFα protein levels and their activity in tumor cells. These constitutively active HIF-1α and 
HIF-2α in normoxic cells seems to be cell specific [28].    
 
 
 
 
 
 
 
 
 
 
  
Figure 6: Regulation of HIF-1 activity by oncoproteins and tumor suppressors
HIF-1 activity is stimulated by oncoproteins (red) gain-of-function. HIF-1 activity is inhibited by tumor suppressors (green) and their 
loss-of-function therefore stimulates HIF-1 activity. Transforming proteins encoded by Epstein-Barr virus (EBV), hepatitis B virus 
(HBV), human papilloma virus (HPV), and Kaposi sarcoma herpesvirus (KSHV) also activate HIF-1. (From Semenza et al. 2012 
TRENDS in pharmacological science). 
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a. The tumor suppressor gene LOF contributes to increased levels of HIFα  
Both HIF-1α and HIF-2α protein levels are increased in tumor cells due to LOF of different 
tumor suppressors. These LOF may result in either increased HIF-1α synthesis or decreased 
HIF-1α degradation. Mutations of pVHL, PTEN, B-RAF, SDH, FH and MITF are able to 
regulate HIF-1α and HIF-2α under normal level of O2 (hypoxia like normoxia) resulting in 
HIFα stabilized and activated (Table 1). This stability of HIFα under normoxia leads to its 
increased transcriptional activity, promotes tumor growth and may have a huge impact on cell 
biology and cancer development [2, 63].       
 
Table 1: Tumor suppressor gene LOF contributes to increased HIF-1α in human 
cancers. 
 
 
Abbreviations: ↓ decreased; ↑ increased; TSG, tumor suppressor gene, RCC, Renal cell carcinoma 
Modified from Semenza et al. 2010 oncogene.  
 
b. Regulation of HIF-1 activity by oncoproteins          
Apart from intratumoral hypoxia, GOF for oncogenes and viral transforming genes also 
regulates HIFα protein levels and their activity in cancer cells (Table 2). Interestingly, a large 
number of oncoproteins (proteins encoded by transforming viruses that form tumors) in 
human have been shown to induce HIF-1α activity [2] [64]. Most of these oncoproteins 
regulate HIF-1α activity by either decreasing HIF-1α protein degradation [65] [66] or by 
increasing HIF-1α protein [67] [68]. Most extraordinary is the case of Kaposi’s sarcoma 
herpes virus (KSHV) which completely mimics the effects of hypoxia [69]. KSHV infection 
TSG Tumor(s) with TSG loss of function Effect on HIF-1α 
PVHL RCC, hemangioblastoma ↓ ubiquitination 
SDHB Paraganglioma ↓ hydroxylation 
SDHC Paraganglioma ↓ hydroxylation 
SDHD Paraganglioma ↓ hydroxylation 
FH Leiomyoma, RCC ↓ hydroxylation 
IDH1 Glioblastoma ↓ hydroxylation 
P53 Colon adenocarcinoma  ↓ ubiquitination 
TSC2 Tuberous sclerosis ↑ synthesis 
PTEN Glioblastoma, others ↑ synthesis 
LKB1 Gastrointestinal hamartoma ↑ synthesis 
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results in the formation of a highly vascularized tumor. KSHV encodes 03 different 
oncoproteins which together increases HIF-1α protein half-life, nuclear localization and 
transactivation under normoxic conditions [70] [71].      
 
Table 2: Proteins of oncogenic viruses increase HIF-1 activity. 
 
 
Abbreviations: EBV, Epstein–Barr virus; KSHV, Kaposi’s sarcoma herpesvirus, Adapted from 
Semenza et al. 2010 oncogene.  
 
8. Diverse factors which regulate HIFα  
Several other factors which modulate the HIF pathway including metabolites, Redox, 
inflammatory mediators, microRNAs and oncogenes/tumor suppressors have been 
summarized in (Table 3).  
 
 
 
 
  
Viral oncoprotein Effect on HIF-1α 
EBV latent membrane protein 1 ↓ degradation 
Hepatitis B virus X protein ↓ degradation 
Human papillomavirus E6/E7 proteins ↑ HIF-1α protein 
Human T-cell leukemia virus tat protein ↑ HIF-1α protein 
KSHV G-protein-coupled receptor ↑ transactivation 
KSHV latency-associated nuclear antigen ↑ nuclear localization 
KSHV latency-associated nuclear antigen ↓ degradation 
KSHV viral interferon regulatory factor 3 ↓ degradation 
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Table 3: Diverse regulators of HIF activity. 
 
Abbreviations: ↓, decreased; ↑, increased, adapted from Simon et al. 2010 Molecular Cell. 
HIF regulators Effect on HIF-1α and  HIF-2α   
 
Siah1a/2 
 
↑ HIF-1α stability; promotes degradation of PHD1/3 in hypoxia 
RSUME ↑ HIF-1α stability; enhances SUMOylation 
SENP1 ↑ HIF-1α stability; removes SUMO moieties 
HSP90 ↑ HIF-1α stability 
COMMD1 ↓ HIF-1α stability and disrupts HIFα/β dimerization 
HSP70/CHIP ↓ HIF-1α stability but not HIF-2α stability 
CITED2 ↓ HIF-1α activity 
Metabolites/Related  
2-oxoglutarate,  
Ascorbate and Fe2+ 
↓ HIFα stability as PHD cofactor 
IRP ↓ HIF-2α mRNA translation in response to high intracellular iron  
NO Modulates HIFα expression 
Intermittent hypoxia ↑ HIF-1α stability but ↓ HIF-2α stability  
Redox  
ROS ↑ HIFα stability; observed in inflammatory cells 
Sirt1 ↓ HIF-1α and ↑ HIF-2α transcriptional activity  
Sirt6 Binds to and ↓ HIF-1α stability/activity  
MicroRNAs 
 
miR-107 microRNA leads to ↓ ARNT expression 
miR-17-92 miRNA cluster; microRNAs lead to ↓ HIF-1α expression 
Oncogenes 
 
PI3K/Akt ↑ HIF-1α expression 
mTORC1 ↑ HIF-1α mRNA translation 
GSK3β ↓ HIF-1α stability 
p53 ↓ HIF-1α/ARNT expression 
β-catenin Binds to HIF-1α; ↑ HIF-1α transcriptional activity 
Ras ↑ HIF-1α expression by ROS generation 
ERβ ↓ HIF-1α stability  
Inflammation 
 
NF- κB ↑ HIF-1α transcription  
p44/42 MAPK ↑ HIF-1α expression downstream of LPS 
IFN-γ and IL-4 ↑ HIF-1α and HIF-2α(?) expression  
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C. Hypoxia (HIF-1α and HIF-2α) and cancer  
1. Clinical data linking HIF-1α and HIF-2α levels to patient mortality 
A large number of clinical data shows a strong positive relation between patient mortality and 
hypoxia-induced HIF-1α and HIF-2α [2] summarized in Table 4.   
It has been shown that early stages of breast, cervical, and endometrial cancers are associated 
with good prognosis but as the tumor grows, tumor hypoxia increases (HIF-1α or HIF-2α) and 
it significantly increases patient mortality [2].  
Table 4: Correlation of prognosis and HIF-1α or HIF-2α expression in human cancers.  
 
GIST, gastrointestinal stromal tumor; HIF, hypoxia-inducible factor; NC, no correlation; ND, not 
determined; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma. Modified from Simon et 
al. 2012 Nature Reviews Cancer.  
Cancer type Prognosis Prognosis 
 HIF-1α expression HIF-2α expression 
Astrocytoma Poor Poor 
Bladder Poor ND 
Breast Poor Poor 
Cervical Poor Poor 
Colorectal Poor Poor 
Gastric Poor NC 
 
Poor ND 
GIST Poor ND 
Glioblastoma ND Poor 
Glioma NC Poor 
Head and neck Poor Poor 
Hepatocellular ND Poor 
NSCLC Poor Poor 
 
Poor ND 
 
NC Poor 
Melanoma Poor Poor 
Neuroblastoma Favourable Poor 
Ovarian Poor ND 
 
Poor Poor 
Pancreatic Poor ND 
Prostate Poor Poor 
RCC Favourable ND 
 
Poor ND 
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2. Role of HIF-1α and HIF-2α in cancer progression   
In accordance with the clinical data, a large set of experimental data clearly demonstrates that 
both HIF-1α and HIF-2α promotes tumor progression by regulating shared and unique genes. 
HIF-1α and HIF-2α LOF or HIF-1α and HIF-2α GOF have opposite effects on tumor growth, 
vascularization and metastasis [63] as summarized in Table 5.   
 
Table 5: Mouse models testing altered expression of HIFα proteins in tumor growth.  
 
EC, endothelial cell; MMTV, mouse mammary tumor virus; NO, nitric oxide; PyMT, polyoma middle 
T antigen; RCC, renal cell carcinoma. Modified from Simon et al. 2012 Nature Reviews Cancer. 
Tumor or cell type HIF-1α status HIF-2α status Phenotypes 
Xenograft tumors   
 
Teratoma Loss-of-function 
knockout 
Wild-type ↓ growth and angiogenesis 
Teratoma Wild-type Loss-of-function 
knockout 
↑ growth 
Fibrosarcoma Loss-of-function 
knockout 
Wild-type ↓ growth 
RCC Gain of function Wild-type ↓ growth 
RCC Wild-type Gain of function ↑ growth 
Autochthonous tumors    
MMTV-PyMT 
mammary tumors 
Conditional 
knockout 
Wild-type ↓ metastasis 
KRAS-driven NSCLC Conditional 
knockout 
Wild-type No effect 
KRAS-driven NSCLC Wild-type Conditional knockout ↑ tumor burden and progression 
p53-driven thymic 
lymphoma 
Heterozygous 
germline knockout 
Wild-type ↓ tumor incidence 
Tumor-associated 
stromal cells 
   
Tumor-associated 
macrophages 
Conditional 
knockout 
Wild-type ↓ NO, ↑ T cell-mediated immunosurveillance  
and ↓ autochthonous mammary tumor growth 
Tumor-associated 
macrophages 
Wild-type Conditional knockout ↓ macrophage infiltration into autochthonous  
liver and colon tumors and tumor growth 
Vascular ECs Conditional 
knockout 
Wild-type ↓  xenograft tumor angiogenesis and growth 
Vascular ECs Wild-type Conditional knockout Non-productive angiogenic sprouting and impaired 
vessel remodelling 
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3. Effects of genes regulated by HIFs on different aspects of cancer biology   
HIFs play a major role in many critical aspects of cancer biology including angiogenesis [72], 
metabolic reprogramming [73], epithelial-mesenchymal transition [74] [75], invasion [75] 
[76], metastasis [77, 78] [79], resistance to radiation therapy [80] and chemotherapy [81], 
selection of genotypes favouring survival under hypoxia–re-oxygenation injury (such as TP53 
mutations) [82] [64], pro-survival changes in gene expression that suppress apoptosis (down-
regulation of Bid and Bax) [83], supports autophagy [84, 85], autocrine growth factor 
signaling [86] [87] and stem cell maintenance [88] [89]. In addition, hypoxia also contributes 
to loss of genomic stability through the increased generation of reactive oxygen species 
(ROS) [90] and the downregulation of DNA repair pathways [22] as well as suppressing 
immune reactivity [91] [3].Several specific HIF-regulated genes that play key roles in crucial 
aspects of cancer biology have been summarized in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Effect of HIF on multiple steps of tumor cell development and biology 
HIF activity in cancer has been associated with (1) cancer ‘‘stem’’ cell maintenance and 
increased expression of genes involved in (2) proliferation and survival, (3) metabolism, (4) 
angiogenesis, (5) recruitment of infiltrating cells such as tumor associated macrophages (TAMs)
and bone marrow-derived cells, and (6) tumor cell invasion and metastasis. Some examples of 
HIF-regulated genes and oncogenic pathways are given in parentheses (From Simon et al. 2010 
Molecular Cell).
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4. Gene expression regulation by HIF-1α and HIF-2α 
Work from many laboratories has revealed that HIF-1α or HIF-2α could regulate the 
expression of same hypoxia induced targets and each HIFα can have its unique target genes 
[92] [93] (Table 6).  
Interestingly, it was proposed that HIF-1α and HIF-2α transcriptional specificity is regulated 
by post-DNA binding mechanisms [55] and resides in the N-TAD suggesting that differential 
interactions with transcriptional cofactors probably determine differential gene activation [54] 
[55]. 
In MCF-7 breast cancer cells, a direct comparison of HIF-1α and HIF-2α binding sites 
demonstrated that some sites bind HIF-1α exclusively, many others bind both HIF-1α and 
HIF-2α with equal affinity, despite the fact that HIF-2α contributes to the hypoxic expression 
of relatively few genes in these cells [94]. It is surprising to note that HIF-1α and HIF-2α 
were shown to bind preferentially to specific genes that each factor is known to preferentially 
regulate. HIF-1α has a relatively higher level of binding with glycolytic pathway genes [57] 
and HIF-2α for stemness gene like OCT4 [95].  
Interestingly, HIF-1α and HIF-2α can have opposing effects on the cell cycle and on cell 
proliferation. The best example of this is in clear cell renal carcinoma, in which HIF-2α is 
described to drive the tumor growth while HIF-1α may restrict proliferation [96]. This 
opposite effect of HIF-1-α and HIF-2-α could be related to the mechanism involving the 
regulation of c-Myc. Indeed, it has been suggested that HIF-1α antagonizes the activity of 
Myc while HIF-2α enhances Myc activity [97].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
34 
 
 
Table 6: Gene expression regulation by HIF-1α and HIF-2α. 
ADRP, adipose differentiation-related protein; ALDA, fructose-bisphosphate aldolase A; ARG, Abelson-related 
gene protein; CA, carbonic anhydrase; DLL4, delta-like 4; EC, endothelial cell; ESC, embryonic stem cell; 
GLUT1, glucose transporter 1; IL, interleukin; iNOS, inducible nitric oxide synthase; LDHA, lactate 
dehydrogenase A; NO, nitric oxide; NOS, nitric oxide synthase; NSCLC, non-small-cell lung cancer; PGK1, 
phosphoglycerate kinase 1; PLIN2, perilipin 2;  RCC, renal cell carcinoma, TGF, transforming growth factor; 
VEGFA, vascular endothelial growth factor A. . Modified from Simon et al. 2012 Nature Reviews Cancer. 
 
Gene (protein) Function HIF-1α 
target 
gene 
HIF-2α 
target 
gene 
Cell type 
SLC2A1 (GLUT1) Glucose transport + + RCC and mouse ESCs 
PLIN2 (ADRP) Lipid metabolism + + RCC 
CA12 (CAXII) pH homeostasis + + RCC 
FLG (filaggrin) Cytoskeletal structure + + RCC 
IL6 (IL-6) Immune cytokine + + RCC 
ADM (adrenomedullin) Angiogenesis + + RCC 
VEGFA (VEGFA) Angiogenesis + + RCC and Hep3B cells 
 
Angiogenesis + − Mouse ECs and 
mouse ESCs 
BNIP3 (BNIP3) Autophagy and apoptosis + − RCC 
HK1 (hexokinase 1) Glycolysis + − Mouse ESCs 
HK2 (hexokinase 2) Glycolysis + − RCC and mouse ESCs 
PFK (phosphofructokinase) Glycolysis + − RCC and mouse ESCs 
ALDOA (ALDA) Glycolysis + − RCC and mouse ESCs 
PGK1 (PGK1) Glycolysis + − RCC and mouse ESCs 
LDHA (LDHA) Glycolysis + − RCC and mouse ESCs 
NOS2 (iNOS) NO production + − Macrophages 
ABL2 (ARG) Inhibitor of NO production − + Macrophages 
EPO (erythropoietin) Erythropoiesis − + Kidney and liver 
POU5F1 (OCT4) Stem cell identity − + Mouse ESCs 
SCGB3A1 (secretoglobin 
3A1) 
Growth-inhibitory cytokine? − + NSCLC 
TGFA (TGFα) Growth factor − + RCC  
CCND1 (cyclin D1) Cell cycle progression − + RCC 
DLL4 (DLL4) NOTCH signalling and EC 
branching 
− + Mouse ECs 
ANGPT2 (angiopoietin 2) Blood vessel remodelling − + Mouse ECs 
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5. Hypoxia (HIF-1α, HIF-2α) and p53 
P53 is accumulated within hypoxic regions of solid tumors and is correlated with apoptosis 
[98]. Transcriptionally active wild-type p53 is stabilized through a physical association with 
HIF-1α [82].   Murine double minute (MDM2) oncogene acts as bridge and mediates the 
interaction between p53 and HIF-1α [99]. Whereas HIF-1α fails to bind p53 in vitro, it 
directly binds MDM2, which suppresses the MDM2-dependent ubiquitylation of p53 in vivo 
and p53 nuclear export. Surprisingly, MDM2 overexpression promotes p53 accumulation and 
the transcription of p53 target genes when HIF-1α is activated in hypoxic cells [99]. HIF-1α 
seems to enhance the activation of p53 by ionizing radiation, which results in increased 
phosphorylation of p53 and increased p53-mediated apoptosis [100]. Ionizing radiation 
increases HIF-1α activity in tumors by increasing production of ROS and reactive nitrogen 
species. This relationship between HIF-1α and p53 provides a potential negative feedback 
loop for HIF-1α activity. Ravi et al. [101] suggested that p53 can induce HIF-1α turnover by 
promoting MDM2-mediated ubiquitylation and proteasomal degradation of HIF-1α.  
In contrast to HIF-1α, HIF-2α does not bind MDM2 [102], and seems to inhibit p53 indirectly 
by multiple mechanisms [103]. Increased HIF-2α expression inhibits p53 phosphorylation and 
stabilization in RCC cell lines, whereas knocking down HIF-2α expression increased p53 
transcriptional activity and target gene expression. HIF-2α expression in RCC tumor samples 
correlated with decreases in p53 phosphorylation and p53 target gene expression, and may 
contribute to radioresistance in HIF-2α-expressing RCCs [102]. One very interesting question 
is why these two HIFα subunits have opposite effects on certain pathways (MYC, p53 and 
mTORC1) in the same cell?  
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D. Detection and measurement of tumor hypoxia  
In the past few decades a lot of progress has been made in the development of imaging 
approaches for the detection and quantification of tumor oxygenation levels in vivo. 
Especially the field of nuclear medicine has contributed a lot by the development of several 
radiolabeled hypoxia markers. Although hypoxia also occurs in other pathologic conditions 
including myocardial ischemia and stroke, hypoxia imaging is much more advanced in 
oncology applications such as prediction of response to therapy and overall prognosis.  
Imaging hypoxia is now routinely used in the clinics and has developed from a mere detection 
method to a potential tool for monitoring personalized chemo-radiotherapy. Since its first 
observation by Tomlinson and Gray in 1955, tumor hypoxia has become a central issue in 
cancer treatment [63]. Therefore, the ability to detect hypoxia within tumors has significant 
implications for cancer management and therapy. The extent of hypoxia in tumor levels 
depends on the methods used to detect it (Table 7). Tumor hypoxia can be detected by direct 
and indirect methods. 
 
Direct measurement of oxygen concentration: Eppendorf oxygen electrode 
 
Indirect measurement of oxygen concentration: Methods based on the measurement of 
endogenous markers (such as HIF-1α, HIF-2α, CAIX, Glut-1 and measurement of levels of 
plasma osteopontin) and Exogenous probes (Pimonidazole and EF5).  
 
More recently, several non-invasive imaging techniques for hypoxia include the use of 
radiolabelled 2-nitroimidazoles and other probes imaged with positron emission tomography 
(PET), single photon emission computed tomography (SPECT), functional computed 
tomography (CT SCAN) and blood oxygenation level dependent magnetic resonance imaging 
(BOLD MRI) [104] [22] [105]. Apart from Eppendorf oxygen electrode, all other methods are 
non-invasive techniques. Functional imaging provides anatomical information in addition to 
tumor perfusion and vascular permeability [16] [106]. 
The current gold standard for in vivo measurement of tumor oxygenation is the Eppendorf 
needle electrode system, which allows for direct measurement of pO2 in tumors [29]. 
However, it is an invasive procedure that often requires ultrasound-guided placement of the 
electrode, and its use is limited to easily accessible tumors [107]. Therefore, evaluation of 
hypoxia in clinic is rapidly shifting to monitoring of endogenous markers, especially HIFs and 
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their transcriptional targets (CAIX, VEGF, Glut-1 etc) and exogenous 2-nitroimidazole 
probes (pimonidazole: binds covalently to SH-containing molecules (thiols) and forms protein 
adducts in hypoxic tissues- pO2 levels below 10 mm Hg) [16] [108]. It was shown that 
although both pimonidazole and CAIX staining correlated significantly with the stage of 
patients with larynx carcinomas, CAIX had only limited value for measuring hypoxia and was 
not as robust as pimonidazole [109].  
In summary, in vivo measurement of tumor hypoxia using these methods could be helpful in 
identifying patients with worse prognosis or patients that could benefit from appropriate 
treatments. Such strategies have now been applied in the treatment of several cancer types, for 
example NSCLC and head and neck cancers [110] [111] [112] [113] [114, 115]. Although the 
search for an ‘ideal’ hypoxia marker in not yet over, current PET hypoxia imaging methods 
have already shown promise for the selection of patients who are likely to benefit from 
therapies targeting hypoxia.  
 
Table 7: Different methods of detection and measurements of tumor hypoxia.  
 
 
 
 
 
 
 
 
 
 
 
CAIX, carbonic anhydrase IX; EF5, etanidazole pentafluoride and HIF, hypoxia-inducible factor.  
Modified from William R. Wilson & Michael P. Hay 2011 Nature Reviews Cancer 
 
  
Measure of hypoxia Probe 
Oxygen concentration Eppendorf  oxygen electrode 
Endogenous markers HIF-1α 
 
HIF-2α 
 
CAIX 
 
Osteopontin 
 
Lysyl oxidase 
 
Hypoxic gene signature 
Exogenous probes Pimonidazole 
 
EF5 
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II. HYPOXIA: A KEY PLAYER IN TUMOR 
MICROENVIRONMENT  
Tumor microenvironment is a complex and highly dynamic environment, providing very 
important clues to tumor development and progression [116]. It is now acknowledged that 
tumor cells and their stroma co-evolve during tumorigenesis and tumor progression [117].  
Therefore, tumor growth and spread depend as much on the host response as on the biologic 
characteristics of the tumor itself and on the influence of the tumor microenvironment [116].  
Hypoxia through HIF’s plays a key role in radioresistance, chemoresistance and tumor 
stemness.  HIF-1α overexpression is associated with poor treatment response in many human 
tumors [2] [105]. To some extent, because of these effects on tumor cell development and 
biology, hypoxia has been shown to be implicated in resistance to therapy through multiple 
mechanisms (Table 8).  
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Table 8: Mechanisms of resistance (and sensitivity) of hypoxic cells to cytotoxic therapy.  
 
 
 
BAX, BCL2-associated X protein; BID, BH3 interacting domain death agonist; DHFR, dihydrofolate reductase; 
DSB, double strand break; HR, homologous recombination; MDR1, multidrug resistance protein 1; MMR, 
mismatch repair; NER, nucleotide excision repair; NHEJ, non-homologous end joining; PARP, poly(ADP-
ribose) polymerase. Taken from William R. Wilson & Michael P. Hay 2011 Nature Reviews Cancer.   
 
  
Effect of hypoxia Resistance or 
sensitivity? 
Mechanism Agents affected Example 
Lack of oxidation of 
DNA free radicals by O2 
Resistance Failure to induce DNA 
breaks 
Ionizing radiation 2–3-fold increase in 
ionizing radiation 
   
Antibiotics that induce DNA 
breaks 
Bleomycin 
Cell cycle arrest in G1 or 
G2 phase 
Resistance Repair before 
progression to S or M 
Cycle-selective 
chemotherapy drugs 
5-Fluorouracil 
Cell cycle arrest in S 
phase 
Sensitivity Collapse of stalled 
replication forks 
PARP inhibitors‡ Veliparib (ABT-888) 
Distance from vasculature 
(indirect) 
Resistance Compromised drug 
exposure 
Drugs extensively bound in 
tumor cells 
Taxanes 
Extracellular acidification 
(indirect) 
Resistance Decreased uptake Basic drugs Doxorubicin 
 
Sensitivity Increased uptake Acidic drugs Chlorambucil 
Resistance to apoptosis Resistance Genetic selection 
of TP53mutants 
Multiple   
  
Downregulation of BID 
and BAX 
Multiple Etoposide 
Genomic instability Resistance Mutagenesis Multiple DHFR amplification 
and methotrexate 
Suppression of DNA 
repair 
Resistance Downregulation of MMR DNA methylating agents   
 
Sensitivity Downregulation of NER Bulky DNA monoalkylating 
and crosslinking agents 
  
  
Downregulation of HR DNA crosslinking agents Cisplatin 
HIF-1 stabilization Resistance Expression of ABC 
transporters 
ABC transporter substrates MDR1 and 
doxorubicin 
  
Downregulation of NHEJ Agents that induce DSBs Etoposide 
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A. Hypoxia increases resistance to cytotoxic drugs  
During tumor expansion, tumor angiogenesis lags behind growth resulting in malformed and 
malfunctioning tumor vessels leading to severe hypoxia [28]. Although some cells die 
because of extremely low oxygen levels, a small fraction of tumor cells survive the hypoxic 
stress and adapt to the hypoxic microenvironment. These hypoxic cells become more 
aggressive and resistant to cell death during cancer therapy [106] [5] (Table 9). Hypoxic 
tumor microenvironment favours the emergence of tumor variants with increased metastatic 
and invasive potential [75].   
 
Table 9: Overview of HIF-1-mediated drug resistance mechanisms. 
 
 
4-HPR, N-(4-Hydroxyphenyl)retinamide; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous 
cell carcinoma; OSCC, oral squamous cell carcinoma. Adapted from Nadine Rohwera and Thorsten Cramer 
2011 Drug Resistance Updates.  
  
(Cancer) Cell model Drug/molecule Resistance phenotype Molecular basis (if known) 
Glioma cells Etoposide, doxorubicin Drug efflux MRP1 
HeLa cells 4-HPR Autophagy induction Beclin1 
Gastric cancer cells 5-Fluorouracil Apoptosis inhibition p53, NF-κB 
Breast cancer cells Paclitaxel Apoptosis inhibition Caspases 3, 8, 10, Bak, 
TNFRSF10A, Mcl-1 
Prostate cancer cells Flutamide Apoptosis inhibition Bcl-xL 
Glioblastoma cells, colon 
cancer cells 
Adriamycin Apoptosis inhibition Bcl-2 
HCC cells Etoposide Apoptosis inhibition Bak 
Fibrosarcoma cells Cisplatin Apoptosis inhibition Bid 
Gastric cancer cells Multiple drugs Apoptosis inhibition Bcl-2, Bax 
Breast cancer cells Docetaxel Apoptosis inhibition Survivin 
Pancreatic cancer cells 5-Fluorouracil, doxorubicin, 
gemcitabine 
Apoptosis inhibition Survivin 
Fibrosarcoma cells, colon 
cancer cells 
Etoposide Apoptosis inhibition Bid 
HNSCC cells Paclitaxel Apoptosis inhibition Bid 
Colon cancer cells Etoposide, oxaliplatin Apoptosis inhibition Bid 
Breast cancer cells, 
prostate cancer cells 
Etoposide DNA damage 
inhibition 
Topoisomerase II alpha 
OSCC cells 5-Fluorouracil, cisplatin ROS decrease HO-1, MnSOD, Ceruplasmin 
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B. Hypoxia increases cell proliferation and survival 
One of the first differences between cancer cells and normal cells is the increased rate of cell 
proliferation and decreased rate of cell death as a result of increased expression of 
survival/growth factors. Cancer cells express cognate membrane receptors for growth factors 
resulting in increased autocrine signalling and thus increasing the cell survival/growth of its 
neighbors. HIFs are well known to promote cell immortalization, cell survival, autocrine 
growth signals and stem cell renewal by regulating genes like erythropoietin (EPO), vascular 
endothelial growth factor (VEGF), endothelin 1 (EDN1), transforming growth factor α 
(TGFα), adrenomedullin (ADM), insulin-like growth factor 2 (IGF2) and octamer binding 
protein 4 (OCT4 [POU5F1]) etc [63].      
One of the well known HIF target, EPO and its receptor has been shown to increase the 
growth and survival of human melanoma, breast, prostate and renal cancers [118]. Similarly, 
VEGF has been shown to mediate tumor cell function via activation of its receptors on tumor 
cells [119] [120] in colorectal, gastric, and pancreatic cancer. Other HIF regulated genes 
which are also to participate in autocrine signalling are: TGFα in clear-cell renal carcinoma 
[121], IGF2 in colorectal carcinoma [122], EDN1 in breast, prostate, and ovarian cancer [123] 
and ADM in pancreatic and prostate cancer [124]. Human telomerase (hTERT) promoter 
activity was shown to be regulated by HIF-1 and represents a mechanism for trophoblast 
growth under hypoxia [125], thereby suggesting a novel mechanism of telomerase activation 
in cancers and hypoxia-induced tumor progression. Hypoxia can also favor increased survival 
of tumor cells by inducing human embryonic stem cells (hESC) like transcriptional program.  
HIF have been shown to induce hESC markers NANOG (NANOG) and OCT4 in primary 
glioma cells [126]. Factors which block cellular senescence such as the glycolytic enzymes 
glucosephosphate isomerase (GPI) and phosphoglycerate mutase (PGM) [127] are also 
regulated by HIF. 
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C. Hypoxia: pro-survival versus pro-cell death? 
In cancer cells, hypoxia can induce multiple cellular responses directing them towards 
survival or cell death. These cellular responses might be HIF-1 dependent and/or independent 
[128] [5]. The precise roles of HIF-1 in the regulation of apoptosis are highly complex and are 
shown to be dependent upon the biological background of cells. Most of the primary cells 
respond to decreased oxygen levels by inducing cell cycle arrest and ultimately apoptosis in a 
HIF-1 dependent manner [129]. But already primary cells display great differences in 
response to hypoxia. Inflammatory cells such as neutrophils and macrophages must survive in 
highly inflamed, infected or wounded areas to function properly. So these cells have evolved 
strategies to resist and survive in these hypoxic inflamed areas. Neutrophils are key effector 
cells of the innate immune response and are required to migrate and function within adverse 
microenvironmental conditions. In this regard, it has been shown that HIF-1 can regulate 
neutrophils survival under hypoxia by stabilization of NF-κB and subsequent expression of 
anti-apoptotic NF-κB target genes [130].  
Tumor cells have developed many mechanisms to evade HIF-1-mediated cell death under 
hypoxic conditions. One of the first examples of HIF-1 as a promoter of cell survival and drug 
resistance is the direct evidence that hypoxia via HIF-1 downregulated Bid and Bax in colon 
cancer [83], in HNSSC [131] and fibrosarcoma cells [132] [133]. Similarly hypoxia had a 
direct protective effect on apoptotic cell death by HIF-1 mediated down regulation of 
proapoptotic mitochondrial proteins  like Bak [134] and death caspases (CASP3, CASP8, 
CASP10) [135].   
On the other hand, HIF-1 induces expression of several well established anti-apoptotic 
proteins like survivin in pancreatic cancer [136] and in breast cancer cells [137] and inhibitor 
of apoptosis-2 gene (IAP2) [138]. More interestingly, HIF-1 regulates the expression of Bcl-
xL in prostate cancer cells [139] and Bcl-2 in gastric cancer [140] and other cancer cells 
[141].  
Hypoxia via HIF-1α acts as robust suppressor of apoptosis and the down regulation of HIF-1α 
results in enhanced cell death upon treatment with chemotherapeutic agents in different 
cancer models [81].   
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III. HIF INHIBITORS FOR CANCER THERAPY  
Given its central role in tumor progression and resistance to therapy, tumor hypoxia has 
always been considered as a high priority target for cancer therapy. 
In early 1960s, several attempts were made to exploit oxygen to promote the efficiency of 
radiation treatment of cancer patients. Churchill-Davidson and colleagues were the first to use 
hyperbaric oxygen and they made some encouraging observations in cancer patients treated 
with radiation in combination with hyperbaric oxygen [142] [143]. Hyperbaric oxygen, RBC 
transfusion and erythropoietin administration were attempted to increase tumor oxygenation 
but these approaches gave conflicting reports of their clinical efficacy [144].      
Over 20 years ago, Tirapazamine was described as a hypoxia-activated prodrug in 
combination with radiation but clinical trials showed limited benefit [145] [146]. Later on, 
clinical trials with this agent in combination with radiation or chemotherapy have 
demonstrated benefits in patients with lung cancer or head and neck cancer [147] [148].  
Over the years, many new strategies have been developed to identify novel inhibitors of HIFs. 
Some of these are presently being tested in clinical trials. The different therapeutic agents can 
be divided into three different groups depending on how they alter the hypoxia pathway 
(Figure 8).  
1) Upstream targets of HIF  
2) Direct HIFs (HIF-1α and HIF-2α) targets 
3) Downstream targets of HIF transcriptional activity 
 
 
 
 
 
 
 
 
 
 
Figure 8: Diverse strategies for targeting the hypoxia response pathway.
HIF-α pathway can be targeted at multiple levels; upstream, downstream of HIF’s and by inhibiting HIF-α binding to hypoxia 
responsive genes. VEGF, glucose transporter type 1 (GLUT1) and carbonic anhydrase IX (CAIX); EPO: Erythropoietin; G3PD: 
Glyceraldehyde-3-phosphate dehydrogenase; HK2: Hexokinase 2; LDH-A: Lactate dehydrogenase A; MCT4: Monocarboxylate 
transporter 4; PDGF: Platelet-derived growth factor; PDK1: Pyruvate dehydrogenase kinase, isozyme 1; PF2K: Phosphofructo-2-
kinase; PGK1: Phosphoglycerate kinase 1; TGF-α: Transforming growth factor-α. (Taken from Harris et al. 2012 EXPERT OPINION)
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A. Upstream targets of HIF  
Upstream targets of HIFα modulate HIFs by regulating different hypoxia signalling pathways.  
HIFs expression and activity can be regulated by many factors. Apart from PHDs, these 
factors include PI3K/Akt/mTOR pathway, Trx, microtubules, topoisomerases, Hsp90, p53 
and HDAC.  
B. Direct targets of HIFs (HIF-1α and HIF-2α)  
The HIF signalling pathway regulators modulate multiple pathways, their inhibition may have 
off target effects. On the contrary, specific and direct targeting of HIFs will result in a more 
precise and direct response with a fewer on none off target effects.    
A growing number of chemical compounds have been shown to block tumor xenograft 
growth and inhibit HIF activity through a wide variety of molecular mechanisms, including 
decreased HIF-1α mRNA levels, decreased HIF-1α protein synthesis, increased HIF-1α 
degradation, decreased HIF subunit hetero-dimerization, decreased HIF binding to DNA, and 
decreased HIF transcriptional activity (Figure 9). Many of these are drugs that are in clinical 
cancer trials or are already approved for the treatment of cancer or other diseases [63].  
 
 
 
 
 
 
 
 
Figure 9: Molecular mechanism of action of drugs that inhibit HIF-1. 
The steps required for the transactivation of target genes by HIF-1 are shown in the colored 
ovals and the drugs that inhibit each step are shown below (From Semenza et al. 2012 Trends 
in Pharmacological Sciences). 
1. HIF-α antisense, dominant negative HIF-α and viral vectors 
EZN-2968 is an antagonist of HIF-1α mRNA, selectively reduces HIF-1α mRNA expression, 
and causes a reduction in expression of HIF-1α regulated genes in vitro and in vivo [149]. It is 
composed of 16 nucleotide residues and is completely complementary to mouse and human 
HIF-1α mRNA. EZN-2968 in vitro results in the inhibition of tumor cell growth and 
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downregulation of HIF-1α-regulated genes and in vivo has been shown to decrease tumor 
growth in models of human prostate cancer [149]. Currently, EZN-2968 is being tested in 
Phase I clinical trials in patients with advanced solid tumors and potential activity has been 
observed in one patient with metastatic renal cell carcinoma and one patient with 
hepatocellular carcinoma (http://enzon.com/files/HIF-1α-2.pdf). Very recently, EZN-2208 has 
shown superior antitumor activity in glioma xenografts [150]. Another potent approach is to 
use adenovirus with siRNA against HIF-1α or dominant negative HIF-1α [151] [152] [153].   
2. Small molecules that inhibit HIF at multiple sites 
Of the small-molecule inhibitors of HIF, YC-1 and PX-478 have been widely studied and are 
presently in clinical trials [154] [155]. YC-1 inhibits HIF-1α synthesis, blocks HIF-1α–p300 
interaction, promotes HIF-1α degradation [154] [156] [157] and sensitizes tumor xenografts 
to radiation therapy [158]. PX-478 can also inhibit HIF-1α by inhibiting HIF-1α 
transactivation and translation, by decreasing HIF-1α protein and mRNA levels [155] and by 
inhibiting HIF-1α deubiquitination leading to increase in the levels of polyubiquitinated HIF-
1α [159]. Both YC-1 and PX-478 target both HIFs [160] and have shown impressive activity 
in tumor xenograft models. PX-478 is presently in Phase I clinical trial against advanced solid 
tumors and lymphoma [155]. The results so far have been promising, where a high proportion 
of patients achieved stable disease and a dose-dependent inhibition of HIF-1α following 
treatment with PX-478. 
C. Downstream targets of HIF 
It has been shown that more than 800 genes are direct targets of HIF’s (one in 30 of all human 
genes) [56] [57].The number of inhibitors presently under development, being tested or in use 
in clinical settings is extensive. Hypoxia-regulated processes can be targeted by targeting 
angiogenic growth factors, metabolism and pH regulation [161]. 
D. HIF-1α vs HIF-2α targeting? 
Many of the HIF inhibitors effectively downregulate HIF expression and activity but fail to 
distinguish between HIF-1α and HIF-2α subunits that are expressed in different cell types. For 
example, drug like THS-044 was specifically designed to bind to the PAS-B domain of HIF-
2α and not HIF-1α, and inhibit its binding to HIF-2β [162]. Hence it is important to assess 
whether targeting both HIF-1α and HIF-2α or either variant selectively will provide better 
therapeutic effect in specific tumor types.  
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E. Can HIF inhibitors improve current therapies? 
HIF inhibitors could improve the efficacy of classic chemotherapy regimens. A number of 
molecular mechanisms underlie this effect in a cell type and chemotherapy specific manner.  
1) HIFs have been shown to regulate the expression of genes encoding ATP-binding 
cassette multidrug transporters, including MDR1 (ABCB1) and BCRP (ABCG2), 
which efflux chemotherapy drugs from cancer cells [163] [164]. 
2) HIF-1 inhibits expression of proapoptotic mitochondrial proteins (BAX, BID) and 
caspases (CASP3, CASP8 and CASP10) and induces expression of antiapoptotic 
proteins (BCL2, BIRC5) [83] [137] [132] [140] [135].  
3) HIF-1 inhibits chemotherapy-induced cancer cell senescence [165].  
4) HIF-1 prevents chemotherapy-induced DNA damage by inhibiting the expression of 
topoisomerase-IIa protein [166] or the DNA dependent protein kinase complex [167].  
5) HIF-1-dependent metabolic reprogramming [2] [168] [169] [170] may decrease ROS 
levels and thereby inhibit chemotherapy-induced cell death [171]. 
Only a few HIF inhibitors have been shown to work in vivo and to have significant anti-tumor 
activity, so understanding the mechanism of action of these inhibitors on the HIF pathway is 
of importance when used in combination with other drugs or as a single therapy against a 
particular type of tumor.   
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IV. ANTI-TUMOR IMMUNE RESPONSE 
The major feature of the immune system is its ability to recognize “self” from “foreign” and 
to destroy the latter, potentially dangerous for host homeostasis. In this context, the 
recognition and elimination of tumor cells, different from their normal counterparts 
nevertheless self-derived, was controversial for almost a century. Initially proposed by Paul 
Ehrlich in 1909, who suggested that the immune system could control tumor development 
[172], the concept of tumor immunosurveillance is now well established [173] [174], and 
immune response is considered as an important biomarker in cancer [175]. Despite early 
skepticism, major progress in tumor immunology has ensued since the 1980s, together with 
growing understanding of the immune system in general and development of new 
methodologies e.g. hybridoma technology [176], propagation of human DC [177] and T cells 
[178], discovery of critical reagents e.g. interleukine-2 [179] and establishment of relevant 
animal models. One of the major breakthroughs came with the identification by Thierry 
Boon’s group of a tumor Ag recognized by CTL in humans [180], the finding of which 
stimulated a productive effort to identify numerous tumor-specific and tumor-associated 
antigens [181]. Soon, the concept of tumor immunogenicity was supported by growing 
evidence demonstrating that an effective immune response can be elicited against the 
development of spontaneous and chemically induced tumors [182] [173]. These outcomes 
revived enthusiasm in the field of tumor immunology and gave rise to discussion about 
beneficial versus deleterious consequences of immune response to cancer. This led to the re-
formulation of the tumor immunosurveillance hypothesis into “immunoediting” theory, which 
recognized the selective pressure of the immune system on malignant cells resulting in the 
emergence of resistant variants and tumor escape [173].  
A. Cancer Immuno-surveillance theory 
The cancer immunosurveillance theory was formulated nearly 50 years ago by Burnet and 
Thomas [183] [184-186]. They proposed that nascent transformed cells, arising could be 
recognized and eliminated by lymphocytes before they became clinically detectable. This 
would represent an extrinsic tumor suppression mechanism acting when the intrinsic ones, 
like DNA repair or apoptosis, failed. However, convincing evidence supporting this 
hypothesis was only obtained much later, with the development of transgenic 
immunodeficient mouse models. Original experiments based on athymic nude mice, had not 
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provided satisfactory results [187] [188-191]. It was due to some degree of immunity, 
mediated by NK cells, although reduced in number, still functional in these mice [192, 193].  
1. Experimental studies 
The highest incidence of spontaneous or carcinogen (such as methylcholanthrene (MCA))-
induced tumors, was clearly demonstrated in mice in which immune effector mechanisms 
were systematically eliminated by gene deletion, compared to wild-type counterparts. Thus, 
mice insensitive to IFN-γ [194-196], lacking perforin [197-199] or deprived of functional T, B 
and NKT cells resulting from a deficiency in the recombinase-activating gene (RAG)-1 and 2, 
responsible for the rearrangement of lymphocyte antigen receptors, [200-202], provided 
incontestable evidence that tumor development in mice was controlled by components of the 
immune system.  
2. Clinical evidence 
Further evidence in favor of cancer immunosurveillance theory came from clinical studies. 
Much more difficult to obtain because of the requirement for a large number of patients with 
long-term follow-up, these data are often indirect or correlative and can be problematic in 
interpretation. Nevertheless a few lines of evidence emerge from accumulating studies:  
a. Patients with congenital or acquired immunodeficiency’s display higher incidence of 
virally induced malignancies [203, 204]. 
b. Incidence of non-viral cancer is more prevalent in Immuno-suppressed transplant 
recipients than in matched immunocompetent control groups [205].  
c. Tumor-specific lymphocytes and antibodies (Ab) have been detected in cancer 
patients, suggesting the generation of spontaneous immune response [180, 206, 207]. 
d. The presence of tumor-infiltrating lymphocytes (TIL) is a positive prognostic factor 
for patient survival [208, 209]. 
e. The presence of T cells in the resected tumor has an impact on cancer recurrence and 
was shown to be predictive for the clinical outcome after the surgery [210, 211].  
B. The cancer Immuno-editing hypothesis 
Evidence was provided that the immune system controlled not only tumor occurrence but also 
tumor quality (i.e., immunogenicity) [182]. Experimental data from a study done in 2001 
show that a significant portion (40%) of Methylchloranthen (MCA)-induced sarcomas derived 
from immunodeficient Rag2−/− mice was spontaneously rejected when transplanted into 
naive syngeneic wild-type mice, whereas all MCA sarcomas derived from immunocompetent 
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wild-type mice grew progressively when transplanted into naive syngeneic wild-type hosts 
[182]. Thus, tumors formed in the absence of an intact immune system are more 
immunogenic than tumors that arise in immunocompetent hosts. These results show that the 
immune system not only protects the host against tumor formation, but also edits tumor 
immunogenicity. These data caused a refinement of the cancer immunosurveillance concept 
and led to the formulation of the cancer immunoediting hypothesis, which heightens the dual 
host-protective and tumor-sculpting effects of immunity on developing tumors. 
Cancer immunoediting is now viewed as a dynamic process comprising three phases: 1) 
elimination, 2) equilibrium, and 3) escape. During elimination, innate and adapative immunity 
works together to detect and destroy nascent tumors. However, tumor cell variants may not be 
completely eliminated, leading to an equilibrium phase where the immune system controls net 
tumor outgrowth. A dynamic balance between the immune system and the tumor cells 
characterize the equilibrium phase, where antitumor immunity contains, but does not fully 
eradicate, a heterogeneous population of tumor cells, some of which have acquired means of 
evading immune-mediated recognition and destruction. This phase may correspond to a 
latency period clinically silent, that may remain for an indefinite time. Equilibrium may be the 
immunoediting phase where immunity selects for the tumor cells acquiring the most 
immunoevasive mutations, potentially leading to clinically detectable disease. Finally, due 
tumor-induced immunosuppression or immune system breakdown, tumor cell variants begin 
to grow in an immune unrestricted manner leading to the escape phase and emergence of 
cancer [173] (Figure 10).   
Figure 10: The three phases of cancer immunoediting. 
Cancer immunoediting is the result of three processes that function either independently or in sequence to control 
and shape cancer. CTLA-4, cytotoxic T lymphocyte associated protein-4; IDO, indoleamine 2,3-deoxygenase; IFN, 
interferon; IL, interleukin; M, macrophage; MDSC, myeloid-derived suppressor cells; NK, natural killer; NKG2D, 
NK group 2, member D; PD-L1, programmed cell death 1 ligand 1; TGF-β, transforming growth factor-β; TRAIL, 
tumor necrosis factor-related apoptosis-inducing ligand; Treg, regulatory T cell. (Figure from Smyth et al. 2011 The 
Annual Review of Immunology).
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C. The antitumor immune response 
The generation of an effective immune against a developing tumor response results from 
coordinated interactions between innate and adaptive immunity [212] (Figure 11). 
The innate immune response represents the first line of defense against tumors and provides 
the biological context for the adaptive immune response. Innate immunity is mediated by cells 
and soluble factors naturally present in tissues and body fluids, and can interfere with tumor 
cell target growth and survival. Cellular effectors of innate immunity includes macrophages, 
granulocytes, NK cells (CD3-CD56+), non-MHC restricted T cells (CD3+CD56-), and γδ T 
cells [213]. Serum factors, including complement proteins, C-reactive protein, mannose-
binding protein and serum amyloid protein also play a role in the innate immune response 
[214]. Other serum factors such as natural antibodies with specificities for surface component 
of tumor cells might be present in the sera of patients with cancer [215]. The adaptive immune 
response is mediated by CD3+ T-cell receptor+ (TCR+) T cells recognizing tumor cell-
derived peptide bound to self MHC-molecules present at the surface of antigen-presenting 
cells (APC). 
  
Figure 11: Generation and regulation of antitumor immunity.
Antitumor immune responses begin by the capture of tumor associated antigens, processing and 
cross-presentation on MHC class II and class I molecules by dendritic cells (DC) which then 
migrate to draining lymph nodes. Depending on the presence of an immunogenic maturation 
stimulus, DC will either induce or inhibit antitumor effector T-cell response. An effective 
antitumor T-cell response also depends on the interaction of T-cell co-stimulatory molecules 
with their surface receptors on dendritic cells. Interaction of CD28 with CD80/86 will promote 
potentially protective T-cell responses, while interaction of CTLA4 with CD80/86 or PD-1 with 
PD-L1/PD-L2 will suppress T-cell responses, and possibly promote Treg formation. These 
antigen-educated T cells (along with B cells and NK cells) then exit the lymph node and enter 
the tumor bed where they encounter various immunosuppressive mechanisms. (Taken from 
Glenn Dranoff et al. 2011 Nature).
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1. The adaptive immune response 
The adaptive immune response is mediated by lymphocytes. It is initiated in secondary 
lymphoid organs, and is mainly based on the recognition by CD4+ (helper or Th) and CD8+ 
(cytotoxic or CTL) T cells of peptide-MHC complexes expressed on APCs. 
a. CD4+ T cells 
The CD4+ T cells are primed following recognition of a cognate peptide presented via MHC 
class II molecules and play a major role in anti-tumor immunity. Injection of either a CD4+ T-
cell-activating cancer vaccine [216] or in vitro generated tumor-antigen-specific CD4+ T cells 
[217] has been shown to clear established tumors from mice. In addition, CD4+ T cells are 
critically involved in the initiation and/or maintenance of the CD8+ CTL response [218]. As 
well, a more efficient antitumor response is observed when CD4+ and CD8+ T cells act 
together [219]. The auxiliary signal delivered by activated CD4+ T cells is largely based on 
the activation of the CD40 receptor of DC (Figure 12). Besides, following activation, CD4+ T 
cells can differentiate into several subpopulations with potentially oppposing functions. The 
most studied are Th1 and Th2 CD4+ T cells. Th1 cells secrete mainly IFN-γ, IL-2, TNF-α and 
TNF-β and are involved in inhibition of tumor growth. In this respect, the production of IFN-γ 
[220] seems to be one important mechanism by which CD4+ Th1 cells kill tumor cells and 
prevent or suppress the development of cancers. IFN-γ, indeed, is reported to increase the 
infiltration of CD8+ cytotoxic T cells into the tumor [217]. Th2 cells preferentially produce 
IL-4, IL-5, IL-10, IL-13 and TGF-β (Transforming Growth Factor β) and are proposed to 
promote tumor growth. This pro-tumoral effect is largely attributed to IL-10-mediated 
inhibition of DC antigen processing and presentation, and activation of an 
immunosuppressive CD4+ subset called regulatory T cells [221]. However, evidence show 
that CD4+ Th2 cells can decrease tumor growth and induce anti-tumor immune activity via 
production of IL-4 [222] and recruitment of eosinophils [223]. Recently, another subset of 
CD4+ T cells has been indentified in patients with ovarian carcinoma [224] [225].  CD4+ Th17 
T cells produce IL-17, IL-21, and IL-22, which promote tissue inflammation. Despite their 
presence has been found to correlate with a favorable prognosis [224], their role in anti-tumor 
immunity remains controversial (Figure 12).  
 
 
 
 
Figure 12: CD4+ T cells are required for certain cytotoxic T lymphocyte (CTL) responses. 
An antigen-presenting cell (APC), often a dendritic cell (DC), might acquire cellular antigen by 
phagocytosis of an apoptotic or necrotic cell that carries helper (that is, MHC class-II-restricted) 
and killer (that is, MHC class-I-restricted) antigens. Phagocytosed antigen is presented to CD4+ 
T cells, which activate the APC through CD40–CD40-ligand (CD40L) interactions. The 
activated DC can then promote the CD8+ T-cell response, generating cytotoxic effector T cells 
and memory cells. (From Bevan et al. 2004 Nature Reviews Immunology).
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b. CD8+ T cells (Cytotoxic T lymphocyte)  
The principal cellular effector mechanisms of anti-tumor immunity are mediated by tumor-
specific CD8+ CTL, relying on their ability to recognize and directly (by cytolytic factor 
release) or indirectly (by effector cytokine secretion) kill tumor cells that present antigenic 
peptides in the context of MHC class I molecules (MHC-I) [226]. Anti-tumor CD8+ T 
lymphocytes were first identified in mice through their specificity to peptides derived from 
mutated antigens not detected on healthy tissues [227]. In humans, the presence of anti-tumor 
CD8+ T cells was demonstrated in peripheral blood and tumor tissues of patients suffering 
from different types of cancer, including lung carcinoma [228-230]. The identification of 
TAA and the presence of antigen-specific CD8+ TIL in spontaneously regressing tumors 
provided irrefutable evidence for the existence and the importance of CTL-mediated anti-
tumor immune response [231]. Moreover, a positive correlation between patient survival and 
important tumor infiltration by CD8+ lymphocytes, despite some controversy, has been 
established [173, 232]. It is actually acknowledged that this prognostic factor depends highly 
on the environmental context of the infiltrate and is associated with better outcomes in the 
absence of immunosuppressive mechanisms abrogating CTL effector functions. To further 
emphasize the major role of CD8+ T cells, it has been proposed that tumor infiltration by 
antigen-specific CTLs triggers the invasion by other immune effectors, including neutrophils, 
macrophages and NK cells, resulting in amplification of anti-tumor immune responses [233]. 
c. CTL killing mechanisms  
TCR-mediated recognition of antigenic peptides [234] leads to the generation of tumor-
reactive CTLs equipped with lytic granules and able to secrete effector cytokines upon re-
activation [235]. CTL effector mechanisms proceed by: 
Direct cell contact-mediated cytotoxicity inducing an apoptotic response in the target cell 
triggered by: 
- calcium-dependent pore-forming perforin and several serine esterases called granzymes 
from specialized secretory lysosomes into the synaptic cleft between T cells and target cell 
(perforin/granzyme-mediated pathway) (Figure 13). 
- Calcium-independent exposition of transmembrane proteins, such as FasL in the T cell-
target cell contact area (FasL-mediated pathway) (Figure 13). 
The secretion of effector cytokines and chemokines, including IFN-γ or TNF, CCL3 and 
CCL5, which may have a direct effect on tumor cells or indirectly change the tumor 
microenvironment by angiogenesis inhibition or immune cell recruitment and activation 
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To exert their function, CD8+ T cells have to physically engage their target in an Ag-
dependent manner. The specific TCR-mediated recognition of peptide-MHC complexe on 
tumor cells is required either for killing by perforin and FasL-dependent pathways as well as 
for cytokine secretion. Nevertheless, while lytic granule release takes place within minutes 
after specific Ag recognition, cytokine secretion occurs hours after initial recognition and 
requires sustained TCR signaling [236].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: CTL-mediated cytotoxic pathways. 
The CTL uses two different types of cytotoxic mechanisms for killing specific target cells. 
Death receptor expressed on tumor cells (Fas, TNFRI, DR4, DR5) and exocytosis of cytotoxic 
granules (Perforin and GranzymeB B).  
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d. The immunological synapse (IS) 
i. Formation of the immunological synapse 
Naïve CD8+ T cells continuously traffic though secondary lymphoid organs where they 
systematically scan the surface of DCs searching for TAAs. TA are peptides produced by 
degradation of cytosolic proteins via the immunoproteasome and are transported to the 
endoplasmic reticulum through the transporter TAP (Transporter Associated with Antigen 
Processing) where they bind to MHC class I or class II molecules. The encounter of naïve T 
cells with DC that present cognate TCR ligand results in the formation of stable, long-lasting 
conjugates [237].  This involves the organization of a specialized adhesive cell-cell junction, 
termed an immunological synapse (IS), considered crucial for full-fledged T-cell priming 
[236, 238]. At the molecular level, IS consists in cognate interaction-dependent, ordered 
segregation of TCRs, as well as co-stimulatory and adhesion molecules, in the interface 
between the T cell and APC (Figure 14). Upon initial TCR engagement by an antigenic 
peptide-MHC complexe (pMHC), highly dynamic receptor microclustering and early 
signaling indicate an immature IS organization. Subsequently, centripetal transport of 
peripherally engaged TCR, with a concurrent process of LFA-1 and ICAM-1 exclusion, 
results in the formation of supramolecular activation clusters (SMAC) and establishment of 
mature IS. The central region of the SMAC, named “central SMAC” (cSMAC), is thus 
enriched in TCR-pMHC complexes accompanied by costimulatory receptors, like CD28 and 
CD2 on T cells, interacting with their respective ligands CD80/86 and CD48/CD58 on DCs. 
A ring of adhesion molecules with high density of LFA-1 and ICAM-1 complexes, referred to 
as peripheral SMAC (pSMAC), surrounds the cSMAC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Schematic model of mature immunological synapse. 
A) A profile view of key molecules involved in T cell-APC interactions. B) The face on view of 
the synapse with the concentrically organized zones including the central region of the cSMAC 
surrounded by peripheral domain, the pSMAC, and the distal region of the dSMAC. Signaling 
(TCR/CD3 - pMHC) and co-stimulation (CD28 - CD80/CD86) molecules enriched in the 
cSMAC are depicted as well as some of downstream signaling effectors (PKC-θ, ZAP-70, LCK). 
Adhesion molecules (LFA-1 - ICAM-1) accumulate in the pSMAC and large proteins (CD43 
and CD45) are excluded. Secretory domain within the cSMAC for polarized exocytosis of 
effector molecules such as some cytokines or lytic granules in the case of CTLs, is specified. 
According to (Huppa and Davis, 2003) 
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ii. The lytic synapse (polarization of lytic granules) 
The release of cytotoxic granules, containing preformed soluble cytotoxic mediators, such as 
perforin and granzymes, represents one of the major target cell killing strategies used by 
CTLs [239]. At the subcellular level, it has been demonstrated that upon even a brief contact 
with a cognate Ag-expressing target cells, CTLs rapidly reorganize their adhesion and 
signaling proteins into an immunological synapse (IS), termed lytic synapse. A notable 
difference between IS formed by naive and effector T cells is the discrete signaling reflected 
by a spike-like pattern of calcium mobilization and the formation of secretory domains within 
the cSMAC of CTLs. The secretory domain localizes immediately opposite the target cell and 
appears to be involved in the polarization of the lytic granules to the contact site, culminating 
in the exocytosis of cytolytic contents in the cleft formed between the CTL and target cell 
[240, 241]. The polarization of the MTOC associated with the Golgi apparatus toward the 
contact site represents an important step in lytic granule reassembly for exocytosis [242]. 
Indeed, the granules move along microtubules towards the polarized MTOC, however, their 
directional secretion does not require actin or microtubule motors, but centrosome-mediated 
delivery of these organelles to the contact site [243]. In the final step of secretion, cytotoxic 
granules fuse with exocytic vesicles, which are endosomal in nature, directly at the plasma 
membrane [244]. The entire process is completed within minutes succeeding TCR stimulation 
and does not exhaust the entire complement of lytic granules. Thus, the CTL can undergo 
repeated cycles of Ag recognition, polarization and cytolysis, a process known as serial killing 
[245] (Figure 15).  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15:CD8+ T cell secretory response 
Ag recognition triggers microtubule network reorientation toward the target (grey) and synapse 
formation. The granules move in a minus-end direction toward the polarized MTOC (black dot) 
and accumulate at cell:cell contact site.  Within less than 10 min after Ag encounter, the granules 
content is release into the secretory cleft (yellow). Cytokine secretion typically occurs hours after 
initial Ag recognition and can be synaptic (pink arrows) or multidirectional (blue arrows). 
Synaptic secretion is facilitated by Golgi apparatus (green) polarization at the IS. Cytokines 
destined for multidirectional secretion are actively transported. According to (Stinchcombe and 
Griffiths, 2007) and (Huse et al., 2008) 
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It has further been speculated that certain adhesion molecules, organized in pSMAC, can also 
play an important function in granule polarization. In this context, LFA-1 interactions with its 
cognate ligand ICAM-1, initially considered to provide an adhesive barrier that protect 
bystander cells from cytotoxic damage [241], were found to be necessary for polarization of 
lytic machinery and subsequent directional exocytosis required for target cell lysis. In the 
absence of LFA-1–ICAM-1 interactions, another adhesion couple αEβ7–E-cadherin has been 
proposed to substitute the LFA-1-mediated role in promoting anti-tumor CTL activity [246].  
Although it has been clearly demonstrated that IS can indeed be formed between CTLs and 
tumor cells [245], its importance for cytotoxicity remains controversial. This relies on 
observations suggesting that efficient target cell killing, at least in vitro, can occur with only 
rudimentary or without IS formation at all [247]. These contradictory results indicate the 
necessity of further investigation of the IS requirement in target cell killing, particularly in in 
vivo studies. 
e. Mechanism of cytotoxic granule killing 
CTL use the granule exocytosis pathway to induce target cell death. The major constituents of 
cytotoxic granules are perforin and granzymes, which combine to promote rapid cell death 
when delivered to the target cell cytosol. The pore-forming protein, perforin, was originally 
thought to facilitate granzyme entry into target cells by physically forming holes in the cell 
membrane through which granzymes may pass [248]. Studies using knockout mice have 
unequivocally demonstrated the crucial role that this protein has in granzyme-mediated 
cytotoxicity [249].  As effector cell lacking perforin cannot deliver granzymes to target cells, 
perforin deficiency translates into a complete loss of cytotoxic granzyme function, with 
perforin-deficient CTLs defective for target cell killing [249].   
Granzymes are a distinct family of serine proteases, with different members harbored by 
humans and mice. Granzyme B is one of the most abundant granzymes and, consequently, 
granzyme B-mediated cytotoxicity has been intensively studied [250]. Effector cells lacking 
granzyme B kill targets at a much slower rate than do wild-type cells, which demonstrates the 
important role that this protease has in executing the timely demise of infected or tumorigenic 
cells [251]. The efficiency of granzyme B-dependent killing is largely due to the ability of this 
protease to activate in target cells the  intrinsic cell death proteases or caspases, either directly 
or indirectly (Figure 16). Direct proteolysis and activation of caspases 3 and -7 by granzyme 
B leads to the caspase mediated degradation of hundreds of cellular protein substrates, which 
promotes fast and efficient apoptosis [252].  
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Granzyme B can also promote caspase activation through the well-defined cytochrome 
c/Apaf-1 pathway in which proteolysis and activation of the BH3-only protein BID by 
granzyme B promotes BID-mediated opening of the BAX/BAK channel in the mitochondrial 
outer membrane (Figure 16). This important event leads to BAX/BAK-mediated release of 
cytochrome c from the mitochondrial intermembrane space into the cytosol, where it binds to 
and activates a caspase-activating platform, called the apoptosome. In turn, the apoptosome 
activates downstream caspase leading to cell death [253]. Importantly, experimental 
inactivation of caspases does not inhibit granzyme B mediated cell death, which still takes 
place although with much slower kinetics. This results from BID-mediated mitochondrial 
dysfunction, together with proteolysis of other substrates by granzyme B such as ICAD and b-
tubulin (Figure 16) [254] [255]. Effector cells lacking granzyme B retain cytotoxic activity 
through the actions of the remaining granzymes, of which granzyme A is the most abundant 
and promotes target cell death through multiple pathways [256].  
Granzyme K shows tryptase-like activity and has been shown to process similar substrates 
than granzyme A [257]. Evidence of a role for granzyme C in promoting cell death is scarce, 
although it may be cytotoxic in some contexts [258].  The Metase, granzyme M, has been 
shown to promote a caspase- and mitochondria independent mechanism of cell death [259].  
Problems associated with studies relating to the cytotoxic activity of various granzymes are 
whether the concentrations of granzymes used to induce cytotoxicity are achievable under 
physiological settings. Whereas granzyme B displays cytotoxic activity at low nanomolar 
concentrations, many studies have used granzymes at micromolar concentrations that may not 
be attainable in vivo. Because the concentration of granzymes that are delivered at the 
immunological synapse is unknown, it remains to be determined whether all granzymes are 
truly cytotoxic at physiological levels or have other roles in T cell mediated processes. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Pathways of granzyme B-mediated cell death.  
Granzyme B, together with other granzymes, enters the target cell by a perforin-dependent 
mechanism. Upon entry into the target cell cytosol, granzyme B promotes apoptosis through two 
main pathways, either through BID-dependent mitochondrial permeabilization or through direct 
caspase processing and activation. Granzyme B-mediated proteolysis of the BH3-only protein 
BID exposes a myristolyation signal in this protein, targeting it to mitochondria, in which it 
induces oligomerization of BAX and/ or BAK in the mitochondrial outer membrane. The latter 
event facilitates cytochrome c release into the cytosol, assembly of the apoptosome, with 
subsequent caspase-9 activation and the ensuing caspase cascade. Note that antiapoptotic BCL-2 
family members can inhibit cytochrome c release and block this pathway. Granzyme B can also 
directly process effector caspases 3 and -7 to promote apoptosis. Direct activation of the latter 
effector caspases leads to a caspase activation cascade and proteolysis of numerous caspase 
substrates, resulting in the efficient death of the target cell. Granzyme B can also directly cleave 
ICAD, the inhibitor of a DNase (CAD), which can promote internucleosomal DNA hydrolysis 
that is synonymous with this mode of killing.  
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f. Death domain receptor-mediated killing  
CTLs use ligands of TNF superfamily, such as FasL, on their cell surface to bind and 
eliminate target cells expressing the corresponding receptors [260]. FasL is present in the 
granules of CTL [261]. FasL is a type II transmembrane protein present in two froms: a 
membrane form and a soluble form resulting from cleavage of the membrane form by 
metalloproteases [262] (Figure 17). The expression of FasL is limited to activated 
lymphocytes and NK cells. Expression on tumor cells remains controversial [263]. FasL 
mediates its cytotoxic action by binding its cognate receptor Fas on the surface of target cells. 
Fas is a type I transmembrane receptor ubiquitously expressed in normal cells, tumor cells, 
and on activated lymphocytes where it mediates activation-indcued cell death 
(AICD). Stimulation of Fas by FasL homotrimers leads to the rapid formation of receptor 
microaggregates (Figure 17). It results in the clustering of cytoplasmic death-domain of Fas, 
creating a plate-forme for the recruitment of the adapter protein FADD (Fas Associated Death 
Domain) through homolog interactions between the death domain of Fas and the death 
domain of FADD located in C-terminal [264]. The death-effector domain (DED) of FADD, in 
its N-terminal, enables then the recruitment of pro-initiator caspases, including pro-caspase-8 
[265]. The multiprotein complex thus formed is called "death inducing signaling complex" or 
DISC. In the DISC, pro-caspases 8 undergo trans-proteolytic cleavage after aspartate residues 
to generate active caspase-8. In type I cells, sufficient amounts of active caspase-8 are 
produced to directly cleave and activate effector caspases such as caspase-3,-6 and -7 [266]. 
Effector caspases in turn cleave a series of cellular substrates, of which ICAD (Inhibitor of 
CAD (capsase-activated DNAse)), releasing CAD that translocates to the nucleus and degrade 
DNA in apoptosis-specific oligonucleosomic fragments.  Type II cells produce very little 
active caspase-8 at the DISC and rely completely on the mitochondrial amplification of the 
Fas signal, which is proposed to be mediated by the pro-apoptotic BH3 domain only 
containing Bcl-2 family member Bid [267] [268]. Bid cleavage by caspase-8 results in its 
translocation to the mitochondria where it induces the release of the mitochondrial factors, 
ultimately enhancing the apoptotic signal. As these cells rely on the apoptotic functions of 
mitochondria, expression of Bcl-2/Bcl-xL protects from Fas-mediated apoptosis in type II 
cells expressing these proteins display a significant blockade in cleavage of proteins 
associated with apoptosis [266].  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Fas/FasL Pathways.  
 
FasL mediates its cytotoxic action by binding its cognate receptor Fas on the surface of target 
cells. See text for details.  
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2. Mechanisms of tumor escape to the immune system 
The genetic instability of tumor cells [269] combined with the selection pressure exerted by 
the immune system lead to the emergence of tumors resistant variants to the immune 
response. Avoiding immune destruction is one of the hallmarks of cancer [10] 
and represents a significant barrier to effective immunotherapy protocols (Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Emerging hallmarks of cancer. 
An increasing body of research suggests that an additional emerging hallmark of cancer is 
involved in the pathogenesis of some and perhaps all cancers. It allows cancer cells to evade 
immunological destruction, in particular by T and B lymphocytes, macrophages, and natural 
killer cells (From Douglas Hanahan and Robert A. Weinberg 2011 Cell).  
a. Tumor escape mechanisms inherent to tumor cells  
Many studies have evidenced different mechanisms allowing tumors to escape or to interfere 
with the antitumor immune response [270] [271]. The escape mechanisms can be classified 
into several categories, depending whether they are inherent to the tumor cells, the immune 
cells, or present in the tumor microenvironment (Figure 19). 
 
 
 
 

Figure 19: Tumor escape mechanisms. 
Tumors have evolved different mechanisms to elude or inhibit immunity by both intrinsic and extrinsic means. Intrinsic alterations 
within tumor cells evade immunity by down regulating antigen presentation (MHC), up regulating inhibitors of apoptosis (Bcl-XL, 
FLIP), or expressing inhibitory cell surface molecules that directly kill cytotoxic T cells (PD-L1, FasL). In addition, tumor cells 
secrete factors that inhibit effector immune cell functions (TGF-β, IL-10, VEGF, LXR-L, IDO, gangliosides, or soluble MICA) or 
recruit regulatory cells to generate an immunosuppressive microenvironment (IL-4, IL-13, GM-CSF, IL-1β, VEGF, or PGE2). Once 
recruited, regulatory cells attenuate antitumor immunity through the liberation of immunosuppressive cytokines and alterations in the 
nutrient content of the microenvironment. (Abbreviations: ARG1, arginase 1; Bcl-XL, B cell lymphoma extra long; CTLA-4, 
cytotoxic T lymphocyte associated protein-4; DC, dendritic cell; FasL, Fas ligand; FLIP, apoptosis-stimulating fragment-associated 
protein with death domain-like interleukin-1 converting enzyme-like inhibitory protein; GM-CSF, granulocyte macrophage colony–
stimulating factor; IDO, indoleamine 2,3-deoxygenase; IL, interleukin; iNOS, inducible nitric oxide synthase; LXR-L, liver X receptor 
ligand; MDSC, myeloid-derived suppressor cells; MHC, major histocompatibility complex; MICA, MHC class I polypeptide-related 
sequence A; PDGF, platelet-derived growth factor; PD-L1, programmed cell death 1 ligand 1; PGE2, prostaglandin-E2; TGF-β, 
transforming growth factor-β; Treg, regulatory T cell; VEGF, vascular endothelial growth factor (Figure from Smyth et al. 2011 The 
Annual Review of Immunology).
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i. Escape to recognition by immune system 
Antigen presentation by MHC molecules is crucial both for the initiation of the T cell 
response and the maintenance of this response. Alterations in processing and/or presentation 
of the antigenic peptide were reported frequently in many tumors. Indeed, antigen 
presentation in tumor cells may be partially or totally altered due to mutations and/or 
deletions of one or more genes coding for the peptide processing machinery. Complete loss of 
MHC molecules was observed in many types of cancers such as breast, prostate or lung 
cancers [272]. The most common mechanism leading to loss of expression of MHC class I 
molecules is mutation or deletion of genes coding the β2 microglobulin (β2M) [273]. Selective 
loss of haplotype, locus or HLA allel has also been described. The decreased expression of 
TAP1 and TAP2 genes, involved in the transport of the peptide from the cytoplasm to the 
endoplasmic reticulum, and decreased expression of components of the immunoproteasome 
such as subunits LMP2 and LMP7, involved in the production of antigenic peptide [274], are 
also frequent mechanisms of tumor escape [275], causing alterations of antigen presentation 
and processing. Finally, the loss of expression of tumor antigens is an important mechanism 
of escape to T cell-mediated immune response. This phenomenon was particularly well 
demonstrated in a study realized in melanoma patients with recurrent metastases treated by 
adoptive transfer of MART-1-specific T cells. In three out of five patients, metastatic cells 
have lost the expression of MART-1, whereas the expression of other antigens such as gp100 
or tyrosinase remained normal [276]. 
ii. Resistance to T cell mediated-lysis 
Tumor cell susceptibility to lysis by the immune system remains ineluctably a determining 
element of the effectiveness of anti-tumor immune responses. Several mechanisms of 
resistance to cytotoxic functions of CTLs and NK cells, involving especially the perforin- 
granzyme and the death receptor pathways have been described [277]. 
Resistance to the perforin-granzyme pathway 
Several mechanisms of resistance to lysis induced by the perforin-granzyme pathway have 
been described in different tumor models. These mechanisms interfere with the pro-apoptotic 
signaling of this cytotoxic pathway. For example, some tumors escape death induced through 
perforin-granzyme by expressing the Serpin PI9/SPI6, a cellular inhibitor of granzyme B 
[278]. In humans, in vivo expression of serpin was found in 39% of T-cell lymphomas, 27% 
of B-cell lymphomas and 10% of Hodgkin lymphoma [279]. Various alterations in 
mitochondrial signaling pathways (overexpression of Bcl-2, Bcl-XL, IAPs, and mutations of 
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Bax, Bak, or Apaf-1) are frequently observed in tumor cells and may alter the response to the 
perforin-granzyme pathway, mediating resistance to lysis.  
Resistance to death receptor pathway 
Resistance to apoptosis induced by FasL-Fas induced pathway has been demonstrated in 
many tumors. Several mechanisms have been described, including a lack of Fas 
expression. Indeed, it was shown that its expression is frequently reduced or even absent in 
many tumor types [280] [281]. In sera of patients with T-cell lymphoma or solid tumors, high 
levels of soluble Fas are found to interfere with membrane Fas [282]. Finally, overexpression 
of the molecule cFLIP in tumor cells, which acts as a dominant negative inhibitor of caspase8, 
prevents apoptosis induced by Fas. 
iii. Expression of inhibitory molecules 
B7-H1 and RCAS1 molecules 
The expression by tumor cells of the B7-H1 molecule (also called programmed death ligand 1 
(PD-L1)) that targets PD-1 on the surface of antigen-specific T cells has been described in 
many types of cancers [283] [284]. The engagement of B7-H1 with its receptor induces the 
apoptosis of activated T cells [285]. Also, triggering by PD-L1 positive tumor cells of PD-1 
on T cells increases tumor cell resistance to immune-induced death [286], demonstrating that 
cancer cells can use receptors on immune cells to induce resistance. In addition, the presence 
of B7-H1 protein has been demonstrated by immunohistochemistry in a wide range of human 
cancers [287]. Another ligand expressed by tumor cells, RCAS1 (Receptor Binding Cancer 
Antigen-Face value on Siso cells), could also be involved in the inhibition of the cytotoxic 
response. The expression of RCAS1 has been demonstrated in cancers of the ovary and 
uterus. This molecule has recently been described as capable of inducing apoptosis of T cells 
and NK cells, especially in a glioma model [288]. 
The non-classic MHC molecules 
In vitro studies have shown that HLA-G molecule, a non-classical MHC-I molecule belonging 
to the MHC- class Ib sub-group, is expressed in cell lines derived from various types of 
cancers (gliomas, melanomas, renal cell carcinoma). Through binding to many receptors such 
as ILT-4 (Immunoglobulin-Like Transcript 4) (expressed by macrophages, monocytes and 
DC) or KIR2DL4/p49 (expressed by NK), HLA-G plays a key role in the establishment and 
maintenance of immune tolerance by inhibiting the functions of immunocompetent cells 
(differentiation, proliferation, cytotoxicity, cytokine secretion) [289]. Exosomes secreted by 
melanoma cells expressing HLA-G also exhibit membrane expression of HLA-G [290] and 
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negatively modulate the antitumor immune response, particularly by inducing apoptosis of 
activated CD8+T cells through Fas/FasL. The expression of HLA-G in ovarian carcinoma 
cells induces resistance to lysis mediated by CD8+ T cells [291]. Similarly, the soluble and 
membrane expression of another non-classical MHC molecule, HLA-E, by melanoma cells, 
decreases their susceptibility to lysis induced by CTL [292]. 
iv. Absence of co-stimulatory signals 
Lymphocyte anergy results in functional impairment of naive T cells activated by a cognate 
antigen to proliferate when re-stimulated with the same antigen [293]. It is now recognized 
that full activation of T cells requires two signals. The first is the antigen presentation by 
MHC molecules and is responsible for the specificity of the immune response. The second is 
called « co-stimulatory signal ». Blocking this co-stimulatory signal inhibits in vitro and in 
vivo activation of T lymphocytes. Therefore, a lack of expression of co-stimulatory molecules 
such as B7-1 and B7-2 by cancer cells could lead to T cell anergy.  
v. Constitutive activation of signaling pathways 
Activated STAT3 has anti-apoptotic functions and promotes tumor cell proliferation. Its 
functions in negative regulation of inflammation, DC and T cell activities are also described 
[294] [295]. NF-KB (nuclear factor-κ B) is constitutively active and promotes the expression 
of many target genes involved in cell cycle progression, survival, cell adhesion, angiogenesis, 
immune responses and inflammation [296] [297]. NF-κB interferes with CTL-induced death 
pathways by inducting the expression of anti-apoptotic genes such as Flip [298], Bcl-xL [299] 
and IAP [300] [301].   
vi. Tumor cytoskeleton disorganization 
Tumor cells can shift their cytoskeletal organization as a strategy to promote resistance after 
CTL selection pressure [302]. This phenomenon is associated with an overexpression of the 
Ephrin-A1 and Scinderin, and an inactivation of the protein kinase FAK, involved in focal 
adhesion and stress fiber formation [303].  
vii. Metastatic tumoral resistance 
Metastatic tumoral resistance involves multiple factors against apoptosis mediated by 
cytotoxic inducers (TRAIL, FasL, TNF, and CTL) [304]. Downregulation of ICAM-1 on 
metastatic melanoma cells is reported to decrease their sensitivity to CTL- and granzyme B-
mediated lysis [305]. This down-regulation of ICAM-1 is correlated to a decreased PTEN 
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activity and subsequent activation of PI-3K/Akt pathway suggesting that PI3K/AKT pathway 
also plays an important role in the control of tumor susceptibility to CTL-mediated tumor cell 
killing. 
viii. Epithelial-to-mesenchymal transition (EMT) 
The hallmark of EMT is the downregulation of epithelial markers (E-cadherin) and the 
upregulation of mesenchymal markers (Vimentine, Fibronectine, the transcription factors 
Snail, Slug, Twist) leading to an organized disassembly of epithelial cell-cell contacts and an 
acquisition of mesenchymal motile phenotype [306]. A study by Kudo-Saito and colleagues 
demonstrate that Snail-induced EMT accelerates cancer metastasis through not only enhanced 
invasion but also induction of immunosuppression by inducing Treg and impairing DC 
maturation. In addition, although Snail expressing melanoma did not respond to 
immunotherapy, intratumoral injection with snail-specific siRNA significantly inhibited 
tumor growth and metastasis following increase of tumor-specific tumor-infiltrating 
lymphocytes and systemic immune responses [307].  
b. Immune escape mechanisms inherent to immune system or tolerance  
i. Ignorance or lack of presentation by DC 
Naive T cells can not recognize a cognate antigen if it is not presented by DC. Indeed, DCs 
infiltrating tumors have an immature phenotype characterized by low production of 
proinflammmatory cytokines and low expression of co-stimulatory and MHC molecules. The 
major pathway responsible for this immature phenotype is the STAT3 pathway. Indeed, 
constitutively active STAT3 in DCs induces the production of factors such as VEGF and IL-
10, which inhibit DC maturation [308]. Inhibition of STAT3 activity in DC progenitor cells 
reduces the accumulation of immature DC in the tumor microenvironment [309].  
ii. Dysfunctions of CD8+ T cells 
The expression by CD8+ T cells of inhibitory receptors similar to those of NK cells alters their 
activation leading to tumor escape. Indeed, the expression of CD94/NKG2A receptors 
belonging to the family of KIR (p58.1/KIR2DL1 and p58.2/KIR2DL2) inhibits the lytic 
activity of tumor-specific T cells [310, 311]. Tumor cells secreting soluble form of MICA 
resulted in the endocytosis and degradation of NKG2D in T cells leading to impaired 
activation of CD8+ T cells [312]. 
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iii. Deletion of T cells 
The deletion of tumor-specific T cells results in a state called "peripheral tolerance". Two 
main mechanisms are involved.  First model is the "counter-attack model" when FasL 
expressed on tumor cells induced apoptosis of tumor-infiltrating lymphocytes expressing the 
Fas receptor [263]. Similarly, the expression of FasL on the surface of microvesicles secreted 
by melanoma cells induces apoptosis of Jurkat cells in vitro [313]. Nevertheless, the counter-
attack model is controversial due to conflicting reports casting doubts on its relevance in vivo 
[263] and rather proinflammatory role of FasL leading to a massive infiltration of neutrophils 
by tumor and subsequent tumor rejection [263]. Activation-induced cell death (AICD) is the 
second mechanism inducing antitumor T cell deletion and involves FasL/Fas. Precisely, 
activated T cells strongly express FasL causing their own death (suicide) or the death of 
surrounding T cells (Fratricide) [314]. Moreover, continuous stimulation of T cells by tumor 
cells over-expressing the cognate antigens can induce AICD of these effectors, leading to 
their deletion [315].  
iv. Regulatory T cells 
In 1995, the group of Sakaguchi identified a population of CD4+ CD25+ immunoregulatory T 
cells (Treg) involved in preventing physiological autoimmune diseases and inducing self-
tolerance [316]. CD4+CD25+ forkhead box P3 (FOXP3) + are thought to be the major Tregs 
population [317].Treg cells are characterized by the secretion of TGF-β and IL-10. It results 
in inhibition of activation and proliferation of CD4+ and CD8+ and specific production of IL-2 
[318]. In addition, some Treg cells express PD-1, which by binding to its ligang B7-H1 on DC 
suppresses the production of IL-12 by the latters, decreasing their ability to induce 
the immune response [319]. The presence of Treg in human cancers correlates with decreased 
survival in patients with ovarian cancer [320]. On the other hand, in some hematological 
malignancies, especially B-cell lymphoma, elevated number of FOXP3+ cells was shown to 
correlate with improved survival [321]. Other studies consider the ratio of CD8+ T cells to 
CD4+CD25+FOXP3+ T cells and propose that a reduced ratio, as well as Tregs numbers in 
tumors, correlates with poor prognosis in patients with breast, gastric, ovarian, and colon 
cancer [317].   
c. Tumor microenvironment 
Diverse immunosuppressive factors present into the tumor microenvironment and derived 
from tumor cells as well as stromal cells contribute to immune suppression [322].     
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i. Immunosuppressive cytokine 
Several immunosuppressive cytokines such as TGF-β, IL-10, IL-6, VEGF and M-CSF are 
secreted by many tumors. In a in vivo mouse model, selective inhibition of TGF-β signaling 
pathway in T cells has been reported to be necessary for the eradication of tumors secreting 
this cytokine [323]. IL-10 inhibits antitumor response by altering antigen presentation, T cell 
proliferation, cytokine production by Th1 CD4+ T cells and secretion of IL-12. IL-10 also 
blocks the recruitment of DC in response to a vaccine based on the use of GM-CSF [324]. IL-
6 and M-CSF (Macrophage Colony Stimulating Factor) produced by tumor cells, are capable 
of inhibiting the differentiation of myeloid progenitor cells into DC [325]. IL-6, by binding to 
its receptor on tumor cells, activates STAT3 [295].  
ii. Metabolites 
Indolemine 2, 3-dioxygenase (IDO) can suppress effector T-cell functions and may cause T 
cell apoptosis [326] [327] [328]. Some mucins (MUC1 and MUC2) have the ablity to inhibit 
T cell proliferation and to increase metastatic properties of tumor cells [329]. Similarly, some 
gangliosides including GM3 and GD3 can inhibit NK cytotoxicity [330] and DC 
differentiation [331]. Inducible nitric oxide synthase (iNOS) is one of the three enzymes 
responsible for synthesis of nitric oxide (NO) by arginine oxidation. NO plays an important 
role in tumor growth and metastasis formation [332] but is also able to strongly inhibit T cell-
mediated cytoxicity at the tumor site [333].  
iii. Hypoxia affecting the immune system  
It is well known that immune system can effectively inhibit tumor growth [334]. However, 
tumors are known to establish diverse potent mechanisms, which help them to escape the 
immune system [270, 319, 335, 336]. Emerging evidence indicates a link between hypoxia 
and tolerance to immune system [3] [337].  
Hypoxic zones in tumors attract a variety of immune cells in which HIF stabilisation is 
associated with the acquisition of both pro-angiogenic and immunosuppressive phenotype [3] 
[338]. In addition, a direct link between tumor hypoxia and tolerance through the recruitment 
of regulatory cells has been established [339]. The effects of hypoxia on immune cells are 
proposed to be critical factors for the development of tumor immune escape. The innate and 
adaptive immune systems respond differentially to decreased oxygen levels with a global 
amplification of the innate responses and a direct or indirect (via the innate system) 
shortcoming of the adaptive ones (Figure 20).  
 
Figure 20: Influence of hypoxia on the innate and adaptive immune systems. 
Diverse effects of hypoxia on innate immune system (Macrophage, DC, MDSC, NK and neutrophil) and adaptive immune system 
(CTL, T reg and B cells). In general, hypoxia amplifies the activity of innate immune cells while suppressing the response of the 
adaptive immune system. DC: dendritic cells, MDSC: myeloid derived suppressor cells, NK: Natural killer cells, CTL: cytotoxic T 
lymphocyte and T reg: T regulatory cells. 
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AIMS OF STUDY 
Despite the impressive progress over the past decade, in the field of tumor immunology, such 
as the identification of tumor antigens and antigenic peptides, there are still many obstacles in 
eliciting an effective immune response to eradicate cancer. Cytotoxic T lymphocytes (CTLs) 
are important effector cells in tumor rejection [340]. Accumulating evidence indicated that 
tumor cells play a crucial role in the control of immune protection [341] [342] and tumor cell 
growth in vivo is not only influenced by CTL- tumor cell recognition, but also by tumor 
susceptibility to cell-mediated death [343]. The efficacy of antitumor CTL critically depends 
on functional processing and presentation of tumor antigen by the malignant cells but also on 
their susceptibility to CTL-induced lysis.  
Cancer Immunotherapy has developed a lot during the 90’s. The discovery of TAA has 
brought a new revolution in this field. However the results of the clinical studies remained in 
the back ground because of the existing conflict/interactions between the immune system of 
the host, its tumoral system and its micro environment, which is able to neutralize the 
antitumor cytotoxic effectors of various types. It has become clear that by analysing the 
interactions between the immune system and the tumoral system could facilitate the 
development and emergence of new approaches in antitumor immunotherapy. Several reports 
indicated that tumor cells evade adaptive immunity by a variety of mechanisms including 
development of hypoxia (low oxygen tension) [1]. Tumor hypoxia plays an important role in 
angiogenesis, malignant progression, metastatic development and chemo-radio resistance [2]. 
It is now well established that hypoxic tumor microenvironment favours the emergence of 
tumor variants with increased survival and anti-apoptotic potential [3].  
There is very little work done on the impact of tumor hypoxia on the regulation of tumor 
susceptibility to the lysis induced/carried out by cytotoxic antitumor response. Since hypoxia 
is a common feature of solid tumors and one of the hallmarks of tumor microenvironment 
[63], we asked whether hypoxia confers tumor resistance to CTL-mediated killing.  This work 
was carried out in vitro starting from tumor lines and their autologous cytotoxic T lymphocyte 
clones (NSCLC and melanoma cancer model) and eventually in vivo in mouse models (Figure 
30).  
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Figure 21: Experimental model.  
A tumor cell line was established from a tumor biopsy of a lung carcinoma patient and CD8+ 
TIL clones were generated by limiting dilution. Only tumor cell line (IGR-Heu) was kept 
under hypoxia.   
The primary objectives of this project are:  
1. To study the functional consequences of inductions of hypoxia and HIFs on the tumor 
cell susceptibility to CTL-mediated lysis 
2. To dissect the potential involvement of HIF-1-α and P-STAT3 in the acquisition of a 
tumoral resistance to CTL-mediated lysis under hypoxia  
3. To examine the role of hypoxia induced autophagy on the tumor cell susceptibility to 
CTL-mediated lysis and to describe the underlying mechanisms involved 
4. As resistance of tumor targets to killer cells is likely to be regulated by multiple 
factors, we will further explore whether hypoxia (as inducer of HRM) is an important 
determinant involved in the control of target sensitivity to CTL-mediated lysis.  
Hence the project of this doctorate was to study the effect/role of tumor hypoxic stress on 
antitumor cytotoxic response in vitro and in vivo. During this project, we focused on the 
impact of hypoxia on the regulation of the anti-tumor response and the subsequent tumor 
progression. We strongly believe that by manipulating hypoxia, we can modulate effector 
function and behavior of tumor cells.   
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A. Article 1: “The cooperative induction of hypoxia-inducible factor-1 
alpha and STAT3 during hypoxia induced an impairment of tumor 
susceptibility to CTL-mediated cell lysis” 
Cytotoxic T lymphocytes (CTLs) are important effector cells in tumor rejection [340]. 
Accumulating evidence indicated that tumor cells play a crucial role in the control of immune 
protection [344] [342] and tumor cell growth in vivo is not only influenced by CTL- tumor 
cell recognition, but also by tumor susceptibility to cell-mediated death [343]. Several reports 
indicated that tumor cells evade adaptive immunity by a variety of mechanisms including 
development of hypoxia (low oxygen tension) [1].  
Since hypoxia is a common feature of solid tumors and one of the hallmarks of tumor 
microenvironment, we asked whether hypoxia confers tumor resistance to CTL-mediated 
killing. We demonstrate that exposure of target cells to hypoxia has an inhibitory effect on the 
CTL clone (H171) induced autologous target cell lysis. Such inhibition correlates with HIF-
1α induction. While hypoxia had no effect on p53 accumulation, it induced the 
phosphorylation of STAT3 in tumor cells by a mechanism at-least in part involving VEGF 
secretion. While numerous findings provided compelling evidence that a causal relationship 
exists between signal transducer and activator of transcription (STAT3) activation and HIF-1α 
dependent angiogenesis [345], their relationship in regulating tumor cell susceptibility to CTL 
mediated specific lysis under hypoxic conditions is not yet known. STAT3 contributes to 
malignant transformation and progression by regulating genes involved in proliferation, 
survival, self-renewal, invasion, angiogenesis and immune evasion [295]. Interestingly, gene 
silencing of STAT3 by siRNA resulted in HIF-1α inhibition and a significant restoration of 
target cell susceptibility to CTL-induced killing under hypoxic conditions by a mechanism 
involving at least in part down-regulation of AKT phosphorylation. Moreover knock down of 
HIF-1α resulted in the restoration of target cell lysis under hypoxic conditions. This was 
further supported by DNA microarray analysis where STAT3 inhibition resulted in a partly 
reversal of the hypoxia-induced gene expression profile. The present study demonstrates that 
the concomitant hypoxic induction of pSTAT3 and HIF-1α are functionally linked to the 
alteration of NSCLC target susceptibility to CTL-mediated killing. Considering the eminent 
functions of STAT3 and HIF-1α in the tumor microenvironment, their targeting may represent 
novel targets for immunotherapeutic intervention.  
  
The Cooperative Induction of Hypoxia-Inducible Factor-1
and STAT3 during Hypoxia Induced an Impairment of Tumor
Susceptibility to CTL-Mediated Cell Lysis1,2
Muhammad Zaeem Noman,* Ste´phanie Buart,* Jos Van Pelt,† Catherine Richon,*
Meriem Hasmim,* Nathalie Leleu,* Wictoria Maria Suchorska,* Abdelali Jalil,* Yann Lecluse,‡
Faten El Hage,* Massimo Giuliani,§ Christophe Pichon,* Bruno Azzarone,§ Nathalie Mazure,¶
Pedro Romero, Fathia Mami-Chouaib,* and Salem Chouaib3*
Hypoxia is an essential component of tumor microenvironment. In this study, we investigated the influence of hypoxia (1% PO2)
on CTL-mediated tumor cell lysis. We demonstrate that exposure of target tumor cells to hypoxia has an inhibitory effect on the
CTL clone (Heu171)-induced autologous target cell lysis. Such inhibition correlates with hypoxia-inducible factor-1 (HIF-1)
induction but is not associated with an alteration of CTL reactivity as revealed by granzyme B polarization or morphological
change. Western blot analysis indicates that although hypoxia had no effect on p53 accumulation, it induced the phosphorylation
of STAT3 in tumor cells by a mechanism at least in part involving vascular endothelial growth factor secretion. We additionally
show that a simultaneous nuclear translocation of HIF-1 and phospho-STAT3 was observed. Interestingly, gene silencing of
STAT3 by small interfering RNA resulted in HIF-1 inhibition and a significant restoration of target cell susceptibility to
CTL-induced killing under hypoxic conditions by a mechanism involving at least in part down-regulation of AKT phosphoryla-
tion. Moreover, knockdown of HIF-1 resulted in the restoration of target cell lysis under hypoxic conditions. This was further
supported by DNA microarray analysis where STAT3 inhibition resulted in a partly reversal of the hypoxia-induced gene ex-
pression profile. The present study demonstrates that the concomitant hypoxic induction of phopho-STAT3 and HIF-1 are
functionally linked to the alteration of non-small cell lung carcinoma target susceptibility to CTL-mediated killing. Considering
the eminent functions of STAT3 and HIF-1 in the tumor microenvironment, their targeting may represent novel strategies for
immunotherapeutic intervention. The Journal of Immunology, 2009, 182: 3510–3521.
C ytotoxic T lymphocytes are important effector cells intumor rejection and have been described to play a cru-cial role in host defense against malignancies in both
mouse and human (1). The major effector function of CTL is
mediated through directional exocytosis of cytotoxic granules,
primarily containing perforin and granzymes, into the target
leading to cell death (2, 3). It is established that their antitumor
response is regulated at several effector-target interaction levels
involving both intracellular and extracellular stimuli (3). Accu-
mulating evidence indicated that tumor cells play a crucial role
in the control of immune protection (4) and contain many over-
lapping mechanisms to maintain their functional disorder and
evasion. In this regard, it has been suggested that tumor cell
growth in vivo is not only influenced by CTL-tumor cell inter-
action but also by tumor susceptibility to cell-mediated death
(5). Even though the resistance of tumor cells to cell-mediated
cytotoxicity remains a drawback in the immunotherapy of can-
cer, its molecular basis is poorly understood. A great deal of
effort has been focused on trying to understand the tumor escape
to immune surveillance and to understand the molecular basis
of tumor tolerance.
Several reports indicated that tumor cells evade adaptive immu-
nity by a variety of mechanisms, including development of hyp-
oxia (low oxygen tension) (6), and that the adaptation of these cells
to an hypoxic environment results in an aggressive and metastatic
cancer phenotype associated with a poor treatment outcome (7).
Hypoxic microenvironments are frequent characteristics of solid
tumors and are the consequences of morphologically and function-
ally inappropriate neovascularization, irregular blood flow, ane-
mia, and high oxygen consumption of rapidly proliferating malig-
nant cells. Solid tumors characteristically contain areas of hypoxia,
which is a powerful stimulus for the expression of genes involved
in proliferation, glycolysis, and angiogenesis (8). The molecular
signaling pathways mediating gene induction by hypoxia have
been elucidated and extensively reviewed (9). Hypoxia-inducible
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factor-1 (HIF-1)4 is an 11 heterodimer specifically recognizing
hypoxia-response elements of oxygen-regulated genes. Several
studies have shown that under hypoxic conditions, HIF-1 be-
comes constitutively up-regulated in many cancer types and plays
a major role in tumor progression, mostly as a result of inhibition
of protein degradation. In response to physiological hypoxia,
HIF-1 becomes rapidly stabilized and is localized to the nucleus,
where it specifically binds to a short DNA sequence (HREs, hyp-
oxia response elements), thereby controlling the transcription of
many genes that are critical for continued cellular function under
hypoxic conditions (10, 11). Whereas the potential involvement of
this factor in mediating resistance to radiation and drug therapy
(12, 13) has been reported, the mechanisms underlying this resis-
tance still need deeper understanding. Although the resistance of
hypoxic cells to killing and the aggressiveness of highly hypoxic
tumors are, in part, due to the overexpression of HIF-1 (14, 15),
the consequences of HIF-1 induction on specific lysis of human
tumor cells by CTL remain unknown. Therefore, since hypoxia is
a common feature of solid tumors and one of the hallmarks of
tumor microenvironment, we asked whether hypoxia confers tu-
mor resistance to CTL-mediated killing.
While numerous findings provided compelling evidence that a
causal relationship exists between STAT3 activation and HIF-1-
dependent angiogenesis (16), their relationship in regulating tumor
cell susceptibility to CTL-mediated specific lysis under hypoxic
conditions is not yet known. There is strong evidence that STAT3
contributes to malignant transformation and progression by trans-
activation of host target genes involved in fundamental events of
tumor development, including proliferation, survival, self-renewal,
invasion, and angiogenesis (17–19). STAT3 is critical for these
processes, because its inhibition by a variety of means can exert an
anticancer progression (20). In this context, STAT3 signaling has
been shown to inhibit apoptosis and to induce a more aggressive
phenotype through the activation of specific signaling pathways
(21).
The primary focus of the current study was to examine the im-
pact of hypoxia on specific lysis of tumor cells by CTL. Our results
show that the cooperative induction of STAT3 and HIF-1 is func-
tionally linked to the acquisition of tumor cell resistance to CTL-
mediated killing under hypoxic conditions by autologous CTL.
Targeting STAT3 resulted in a significant attenuation of this re-
sistance, thus providing a lead for therapeutic modulation of hy-
poxia-mediated immunoresistance.
Materials and Methods
Reagents and Abs
Protease inhibitors were purchased from Roche Applied Science. Bicin-
choninic acid protein assay reagent was obtained from Pierce. CHAPS was
obtained from Sigma-Aldrich. For the detection of HIF-1 protein, two
different Abs were used. For confocal microscopy, anti-HIF-1 (antiserum
2087) as previously described (22) was used. For Western blots, HIF-1
Ab (BD Transduction Laboratories) was purchased. Abs against STAT3
and phospho-STAT3 (p-STAT3) were purchased from Cell Signaling
Technology. Actin (clone c-11) and Abs against p53, AKT and p-AKT
were purchased from Santa Cruz Biotechnology. Cucurbitacin I (CCB-I)
(JSI-124; National Cancer Institute NCI identifier: NSC 521777) was pur-
chased from Indofine Chemical and kept as a stock solution of 50 mM in
DMSO. Avastin (Bevacizumab) was purchased from Genentech.
Culture of tumor cells and CTL
The IGR-Heu lung carcinoma cell line was derived and maintained in
culture as described previously (23). Heu171 cell clone was derived from
autologous TIL (24, 25). IGR-Heu lung carcinoma cell line was grown in
DMEM/F12 medium supplemented with 10% FCS (Seromed), 1% Ultroser
G (Life Technologies), 1% penicillin-streptomycin, and 1 mM sodium
pyruvate.
Hypoxia treatment and HIF-1 induction
For the induction of HIF-1, cell cultures were incubated in a hypoxia
chamber (InVivo2 400 Hypoxia Workstation; Ruskinn) in a humidified
atmosphere containing 5% CO2 and 1% O2 at 37°C (26). Once hypoxic
conditions were optimized, cells were always exposed to the same opti-
mized hypoxic conditions (1% O2, 5% CO2, and 94% N2) at 37°C (16 h)
for the optimal induction of HIF-1. Cell culture medium and cells for
protein analysis were harvested while in the hypoxia workstation and were
not reoxygenated before harvesting.
Cytotoxicity assay
The cytotoxic activity of the CTL clone (Heu171) was measured by a
conventional 4-h 51Cr release assay by using triplicate cultures in round-
bottom 96-well plates. Different E:T ratios were used. Briefly, E:T ratios
30:1, 10:1, 3:1, and 1:1 were used on 1000 target cells per well, and after
4 h of coculture at 37°C, the supernatants were transferred to LumaPlate 96
wells (PerkinElmer), dried down, and counted on a Packard’s TopCount
NXT. Percent-specific cytotoxicity was calculated conventionally as de-
scribed earlier (27). All cytotoxicity experiments with 51Cr were performed
under normoxic conditions.
TNF production assay
TNF- release was measured as described previously (28); briefly, TNF-
was detected by measuring the cytotoxicity of the culture medium on the
TNF-sensitive WEHI-164c13 cells, with an MTT colorimetric assay.
4 Abbreviations used in this paper: HIF-1, hypoxia-inducible factor-1; CCB-I, cucur-
bitacin-I; MHC-I, MHC class I; NSCLC, non-small cell lung cancer; p-STAT3, phos-
pho-STAT3; PKB (also called AKT), protein kinase B; RNAi, RNA interference;
siRNA, small interfering RNA; VEGF, vascular endothelial growth factor.
FIGURE 1. Hypoxic stress on IGR-Heu tumor cells induces HIF-1
and decreases susceptibility to CTL (Heu171)-mediated lysis. A, IGR-Heu
tumor cells were incubated in normoxia (21% PO2) and hypoxia (1% PO2)
for different time intervals. After hypoxic exposure, whole-cell lysates (30
g) were subjected to SDS-PAGE, blotted, and probed with Abs, as indi-
cated. Actin was used as the loading control. B, The consequence of hy-
poxic stress on IGR-Heu tumor cells to CTL-mediated lysis was studied.
IGR-Heu tumor cells were incubated in normoxia (21% PO2) and hypoxia
(1% PO2) for 16 h. Cytotoxicity was determined by a conventional 4-h 51Cr
release assay at different ratios. Heu171 (TIL-derived T cell clone) was
used as effectors. Bars, SD.
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RNA interference (RNAi)
Gene silencing of STAT3 and HIF-1 expression by the IGR-Heu cell line
was performed by using chemically synthesized, double-stranded small
interfering RNA (siRNA). STAT3 siRNA was obtained from Santa Cruz
Biotechnology (sc-29493), which is a pool of three target-specific 20–25 nt
siRNA designed to knock down gene expression (29). HIF-1 siRNA was
purchased from Invitrogen Life Technologies (Validated stealth RNAi
DuoPak ref 1299003). Luciferase siRNA (siRNA duplex, C G U A C G C
G G A A U A C UU C G A dTdT, and U C G A A G U A U U C C G
C G U A C G dTdT), included as a negative control, was purchased from
Sigma-Proligo. Briefly, cells were transfected by electroporation with 50
nM siRNA in a gene Pulser Xcell electroporation system (Bio-Rad) at 300
V and 500 F, using electroporation cuvettes (Eurogentec) and then al-
lowed to grow for 72 h (30).
Confocal microscopy
For confocal microscopy analysis of localization of HIF-1 and p-STAT3,
IGR-Heu tumor cells were plated on poly-L-lysine-coated coverslips
(Sigma-Aldrich) in 6-well plates at a density of 5  104 cells/well and
incubated for 16 h at 37°C in two different conditions: normoxia (21%
PO2) and hypoxia (1% PO2). Afterward, cells were washed once with PBS,
fixed with 4% paraformaldehyde for 1 h, and permeabilized with ice-cold
100% methanol at 20°C for 10 min. Cells were then blocked with 10%
FBS for 20 min. Immediately after blocking, fixed cells were stained first
with either anti-p-STAT3 or anti-HIF-1 primary Ab and afterward with a
secondary Ab coupled to biotin (GAR IgG HL biotin-xx; Molecular
Probes) for 1 h. At last, cells were incubated with streptavidin Alexa Flour
488 (Molecular Probes) for 1 h. All Abs were diluted in PBS containing 1
mg/ml BSA. Nuclei were stained with TO-PRO-3 iodide (Invitrogen).
FIGURE 2. Hypoxic stress on IGR-Heu tumor cells does not affect CTL priming and cell morphology. A, Analysis of surface expression of HLA class
I (MHC-I) and HLA-A2.1 was conducted on IGR-Heu tumor cells kept in normoxia (21% PO2) and hypoxia (1% PO2) for 16 h. Isotypic control mAb was
included (IgG). B, Confocal microscopy analysis of granzyme B polarization in the contact area between tumor cells and CTL clone. IGR-Heu tumor cells
were placed in normoxia (21% PO2) and hypoxia (1% PO2), followed by immunofluorescence staining with Abs recognizing granzyme B. Nuclei were
counterstained with To-Pro-3 iodide. The confocal scanning fluorescence micrographs shown are representative of most of the cells analyzed (blue, nucleus;
green, granzyme B). C, Hypoxic stress had no effect on tumor cell morphology. IGR-Heu tumor cells were placed in normoxia (21% PO2) and hypoxia
(1% PO2) for 16 h. Immunofluorescence staining for phalloidin was done with appropriate Ab. Nuclei were counterstained with To-Pro-3 iodide. The
confocal scanning fluorescence micrographs shown are representative of most of the cells analyzed (green, phalloidin). D, TNF- production by the
autologous T cell clone in response to IGR-Heu stimulation. CTL clone Heu171 was cocultured in the presence of IGR-Heu cells placed in normoxia (21%
PO2) and hypoxia (1% PO2) for 24 h. The amount of TNF- produced by the CTL clone was measured using the TNF-sensitive WEHI-164c13 cells. Bars,
SD. E, Viability of IGR-Heu tumor cells under hypoxic and normoxic conditions. IGR-Heu tumor cells were placed in normoxia (21% PO2) and hypoxia
(1% PO2) for 16 h. Apoptosis was assessed by Annexin VFITC/propidium iodide staining.
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Coverslips were mounted with Vectashield (Vector Laboratories) and an-
alyzed using a fluorescence microscope (LSM-510; Carl Zeiss Micro Im-
aging) as described previously (31, 32).
IL-6, IL-10, and vascular endothelial growth factor (VEGF)
ELISA
IL-6, IL-10, and VEGF protein levels were assessed using ELISA. IGR-
Heu tumor cells were grown in 6-well plates (DMEM supplemented with
10% FBS) until they had reached 50–60% confluency. The media were
then replaced with DMEM supplemented with 0.5% FBS. These cells were
then kept under normoxia (21% PO2) and hypoxia (1% PO2) for an addi-
tional 24 h, whereupon their media were collected, filter sterilized, ali-
quoted, and stored at 80°C. Secretion of IL-6, IL-10, and VEGF was
quantified using ELISA kits obtained from R&D Systems (catalog nos.
D6050, D1000B, and DVE00, respectively). Each assay was performed per
the manufacturer’s instructions. Samples were assayed in triplicates. Error
bars represent  SD.
Flow cytometry analysis
Flow cytometry analysis was performed by using a FACSCalibur flow
cytometer. Data were processed using CellQuest software (BD Bio-
sciences). Anti-HLA-A2.1 (MA2.1), anti-HLA class I, or MHC class I
(MHC-I) (W6/32) were used as reported previously (28). For apoptosis
evaluation, the Annexin VFITC/propidium iodide assay kit (BD Bio-
sciences) was used according to the standard protocol.
Western blotting
Western blotting was performed as reported previously (32, 33). Briefly
cells were grown in two different conditions normoxia (21% PO2) and
hypoxia (1% PO2) for 16 h at 37°C. Cells were scrapped off, lysed in an
appropriate buffer containing 20 mM Tris-HCl (pH 7.5), 1% CHAPS,
150 mM NaCl, 10% glycerol, 1 mM Na3VO4, and a commercial pro-
tease inhibitor mixture (Complete Protease Inhibitor Mixture; Roche
Molecular Biochemicals). Cells were then placed on ice for 30 min,
centrifuged at 10,000  g for 30 min at 4°C, and their supernatants
were collected. Thirty micrograms of total protein extracts were re-
solved on 8 or 12% SDS-polyacrylamide gels. Proteins were transferred
onto nitrocellulose membrane by wet method, and unspecific binding
sites were blocked with 3% milk/Tween 20 Tris-buffered saline (TTBS;
50 mM Tris HCl, 140 mM NaCl, and 0.05% Tween 20 (pH 7.2)) for 1 h.
The primary Abs were added at a dilution of 1/1000 and incubated
overnight at 4°C. Afterward, nitrocellulose membranes were washed
three times for 5 min each with TTBS. For protein detection, blots were
incubated with a HRP-labeled anti-mouse or anti-rabbit secondary Abs
for 1 h at a dilution of 1/2000 and washed three times for 5 min each
with TTBS, followed by ECL detection analysis. Correction for back-
ground was performed with NIH Image software.
Microarray analysis
DNA Microarray was performed using (Agilent Human Whole Genome
Microarray: 44,000 spots) as previously reported (30) under two different
conditions, hypoxia vs normoxia (Hypo Normo) and siRNA STAT3 vs
siRNA-Luc (STAT3 CT) by using (Agilent Human Whole Genome Mi-
croarray: 44,000 spots). In both conditions, total RNA was extracted and
compared by using Agilent oligonucleotide dual-color technology, running
dye swap and duplicate experiments. Probe synthesis and labeling were
performed by Agilent’s Low Fluorescent Low Input Linear Amplification
Kit. Hybridization was performed on human whole-genome 44,000 oligo-
nucleotide microarrays (Agilent) by using reagents and protocols provided
by the manufacturer. Feature extraction software provided by Agilent (ver-
sion 7.5) was used to quantify the intensity of fluorescent images and to
normalize results using the linear and lowess subtraction method. Primary
analysis was performed by using Resolver software (Rosetta Laboratories)
to identify genes differentially expressed between resistant and sensitive
cell lines (IGR-Heu/IGR HeuR8) with a fold change  2 and a value of
p  105. For additional analysis, we used the GenMapp/Mapfinder soft-
ware package (www.genmapp.org; Gladstone Institute, University of Cal-
ifornia San Francisco).
Results
Hypoxic stress-induced HIF1 is associated with a decrease in
CTL-mediated tumor cell lysis
Hypoxia is a specific property of solid tumors and has been
widely documented to contribute to low apoptotic potential. To
investigate the influence of hypoxic stress on human tumor cell
susceptibility to CTL-mediated killing, we used the human non-
small cell lung carcinoma (NSCLC) cell line IGR-Heu and the
autologous CTL clone (Heu171), recognizing a mutated -ac-
tinin-4 peptide in an HLA-A2.1 context. As previously de-
scribed, IGR-Heu cells were lysed by the CTL clone through
the perforin/granzymes pathway (23, 34, 35). Because cancer
cells can adapt to hypoxia primarily through a transcriptional
response pathway mediated by the HIF-1-, its induction in
IGR-Heu cells under hypoxic conditions (1% PO2) was first
determined. As depicted in Fig. 1A, Western blot analysis
shows a HIF-1 induction upon culture of IGR-Heu under hy-
poxic conditions. Kinetic analysis indicated that optimal induc-
tion was obtained after 16 h of cell culture under hypoxic con-
ditions. Such an induction was associated with a dramatic
decrease (80% inhibition at E:T ratio of 30:1) in CTL-mediated
IGR-Heu killing (Fig. 1B). These results indicate that hypoxic
tumor cells are less susceptible to lysis induced by the autolo-
gous CTL clone.
Hypoxic stress does not affect CTL reactivity and tumor cell
morphology
To determine whether hypoxic stress-induced alteration of tar-
get susceptibility to CTL-mediated lysis involves an alteration
in CTL reactivity or a change in tumor cell morphology, we
have examined the influence of hypoxia on MHC-I molecule
expression using cytometry analysis and specific Abs. As
shown in Fig. 2A, no difference in staining with W6/32 (HLA
class I specific) and MA2.1 (specific for HLA-A2) Abs was
observed on hypoxic cells (1% PO2) as compared with cells
FIGURE 2. (continued)
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cultured under normoxic conditions (21% PO2). To examine the
recognition of hypoxic cells by the CTL clone, we examined the
reactivity of the CTL clone to hypoxic autologous target. Con-
focal microscopy analysis shown in Fig. 2B indicates the po-
larization of cytotoxic granules as defined by granzyme B ac-
cumulation in the contact area between the CTL clone and
hypoxic or normoxic IGR-Heu tumor cells. This indicates that
hypoxic tumor cells are efficient in triggering the reactivity of
the specific CTL clone that was further confirmed by TNF se-
cretion assay (Fig. 2D).
Because we have recently provided evidence that a change in
tumor cell morphology could lead to a decrease in their suscepti-
bility to CTL-induced tumor cell death (30), we asked whether the
inhibitory effect of hypoxia involves a tumor cell morphological
change that would be associated with the observed alteration of
their killing by Heu171 CTL clone. Results of confocal micros-
copy analysis shown in Fig. 2C indicate that the acquisition of
resistance to CTL following treatment of target cells with hypoxic
stress did not result in tumor cell morphological changes since
F-actin content, as revealed by Alexa Fluor 568-phalloidin stain-
ing, was similar in hypoxic and normoxic cells. This rules out that
the acquisition of hypoxic tumor resistance to CTL-mediated kill-
ing might result from a shift in the level of actin polymerization.
Furthermore, as depicted in Fig. 2E, the hypoxic stress had no
effect on IGR-Heu viability as revealed by annexin V/propidium
iodide staining.
STAT3 phosphorylation in tumor cells under hypoxic conditions
correlates with the acquisition of resistance to CTL-induced
lysis
The interaction of STAT3 with HIF-1 was identified in hy-
poxic tumor cells (16). Therefore, we wished to delineate the
respective involvement of these factors in the regulation of tar-
get cell susceptibility to specific lysis. For this purpose, total
extracts of IGR-Heu cultured under hypoxic or normoxic con-
ditions were subjected to Western blot analysis. While under
hypoxic conditions, a dramatic increase in STAT3 phosphory-
lation was observed; there was no effect on the tumor suppres-
sor protein p53 (Fig. 3A) and survivin (data not shown). Next,
we examined the temporal kinetics of HIF-1 and STAT3 nu-
clear translocation in IGR-Heu cultured under hypoxic condi-
tions from 2 to 20 h using confocal microscopy. Data shown in
Fig. 3B indicate that at least 16 h of hypoxic treatment are
required for nuclear translocation of both HIF-1 and STAT3.
In fact, before 16 h both HIF-1 and STAT3 are predominantly
present in the cytosol. At 16 h, the hypoxic cells exhibited an
optimal HIF-1 and STAT3 accumulation in the nucleus.
FIGURE 3. Hypoxic stress on
IGR-Heu tumor cells induced phos-
phorylation of STAT3 and simulta-
neous nuclear translocation of HIF-1
and p-STAT3. A, IGR-Heu tumor
cells were kept in normoxia (21%
PO2) and hypoxia (1% PO2). After
16 h of incubation, whole-cell lysates
(30 g) were subjected to SDS-
PAGE, blotted, and probed with Abs,
as indicated. Actin was used as the
loading control. B, Confocal micros-
copy analysis for nuclear transloca-
tion of HIF-1 and p-STAT3. IGR-
Heu tumor cells were placed in
normoxia (21% PO2) and hypoxia
(1% PO2), followed by immunofluo-
rescence staining with Abs recogniz-
ing HIF-1 and p-STAT3. A time
course study was done to follow the
cytoplasmic localization and, eventu-
ally, the hypoxia-mediated nuclear
translocation of HIF-1 and p-
STAT3. It was observed that both
HIF-1 and p-STAT3 translocated in
the nucleus after 16 h of hypoxia. Nu-
clei were counterstained with To-
Pro-3 iodide. The confocal scanning
fluorescence micrographs shown are
representative of most of the cells an-
alyzed (blue, nucleus; green, HIF-1
and p-STAT3).
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Hypoxia-induced phosphorylation of STAT3 is associated with
induction of VEGF
The role of hypoxia in controlling the activation of STAT3 in
tumor cells is not fully understood. Soluble factors like IL-6, IL-
10, and VEGF are known to induce activation of STAT3 through
JAK/STAT3 pathway (36), and furthermore, autocrine and para-
crine IL-6 has been shown to activate STAT3 via IL-6/JAK path-
way (37). Therefore, we investigated the role of these mediators in
activating JAK/STAT3 pathway under hypoxic conditions. As de-
picted in Fig. 4A, 24-h hypoxic conditioning (1% PO2) of IGR-
Heu tumor cells does not alter their production of IL-6 and IL-10.
However, a 16-fold increase in the production of VEGF under
hypoxia was observed.
To determine the role of VEGF in modulating the hypoxic ac-
tivation of STAT3, we incubated IGR-Heu tumor cells with dif-
ferent concentrations of anti-VEGF (Avastin) under normoxia
(21% PO2) and hypoxia (1% PO2) for 24 h. Using Western blot
analysis, we found that the neutralization of VEGF by Avastin
under hypoxic stress resulted in a dramatic inhibition of p-STAT3.
This VEGF-mediated p-STAT3 inhibition was also associated with an
inhibition of p-JAK2 (Fig. 4B). These observations indicate that
VEGF is involved in the control of hypoxic induction of p-STAT3
through an autocrine mechanism involving JAK/STAT3 pathway.
To find out the potential involvement of hypoxia-induced VEGF
in modulating the tumor cell susceptibility to CTL-mediated lysis
via p-STAT3, we incubated IGR-Heu tumor cells for 24 h with 25
g/ml Avastin or an isotype control Ab human IgG1 under nor-
moxia (21% PO2) and hypoxia (1% PO2). Data depicted in Fig. 4C
indicate a remarkable increase in CTL-mediated killing of anti-
VEGF (Avastin)-treated cells as compared with control cells. This
finding further strengthens the notion that the activation of STAT3
via VEGF-JAK/STAT3 autocrine loop plays an essential part in
the acquisition of tumor cell resistance to CTL-induced killing
under hypoxic conditions.
FIGURE 4. Involvement of VEGF in STAT3 activation under hypoxia and relationship with JAK/STAT3 pathway. A, IGR-Heu tumor cells were kept
under normoxia (21% PO2) and hypoxia (1% PO2) for 24 h. ELISA was performed for quantification of IL-6, IL-10, and VEGF by Quantikine Human
immunoassay R&D Systems. Bars, SD. The results shown are representative of two independent experiments. B, IGR-Heu tumor cells were incubated for
24 h with 25, 50, and 100 g/ml Avastin (Genentech) or an isotype control Ab (human IgG1; Sigma-Aldrich) in reduced serum conditions (0.5% FBS)
under (21% PO2) and hypoxia (1% PO2). Whole-cell lysates (30 g) were subjected to SDS-PAGE, blotted, and probed with Abs, as indicated. Actin was
used as the loading control. C, Attenuation of IGR-Heu tumor cells resistance to CTL (Heu171)-mediated lysis under hypoxic conditions following
treatment with anti-VEGF (Avastin). IGR-Heu tumor cells were incubated for 24 h with 25 g/ml Avastin or an isotype control Ab (human IgG1;
Sigma-Aldric h) under normoxia (21% PO2) and hypoxia (1% PO2). Cytotoxicity was determined by a conventional 4-h 51Cr release assay. Heu171
(TIL-derived T cell clone) was used as effectors. Bars, SD.
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Silencing of STAT3 in hypoxic tumor cells resulted in HIF-1
inhibition
To further assess the putative hypoxia-induced functional interac-
tion between HIF-1 and STAT3 in the regulation of IGR-Heu
susceptibility to CTL-mediated killing, transfection of hypoxic
IGR-Heu with siRNA-targeting STAT3 was performed. The inhi-
bition of STAT3 in hypoxic tumor cells was confirmed by Western
blot analysis, showing that an efficient and specific knockdown of
the levels of STAT3 protein was obtained. In contrast, luciferase
siRNA (siRNA-Luc), used as a control, had no effect on STAT3
protein levels (Fig. 5A).
Because STAT3 has been reported to modulate the stability and
the activity of HIF-1 in tumor cells (16), we assessed whether
such an interplay exists in NSCLC. Results of confocal micros-
copy depicted in Fig. 5B indicate that the induction of HIF-1 in
NSCLC hypoxic cells was dramatically inhibited in STAT3
siRNA-treated cells as compared with the control cells transfected
with siRNA-Luc. These results were further confirmed by Western
blot analysis (Fig. 5C), indicating a significant inhibition (77%) of
HIF-1 after gene silencing of STAT3 as revealed by densitometry
(Fig. 5D).
Pharmacological inhibition of STAT3 phosphorylation in
hypoxic tumor cells resulted in the inhibition of HIF-1
induction under hypoxic stress
Although STAT3 has been reported to modulate the stability and
activity of HIF-1 in tumor cells (16), the relationship between
hypoxic induction of HIF-1 and STAT3 activation remains to be
elucidated. For this purpose, we used CCB-I, known to specifically
inhibit STAT3 activation in various human cancer cell lines and,
more importantly, to inhibit the tumor growth in mice models (38).
Western blot analysis indicate that the CCB-I treatment of IGR-
Heu tumor cells resulted in an inhibition of p-STAT3 in a dose-
dependent manner under hypoxic conditions (Fig. 5E). As depicted
in the figure, the inhibition of P-STAT3 was accompanied by an
inhibition of HIF-1 induction by the hypoxic stress
RNAi-mediated knockdown of STAT3 increased hypoxic target
susceptibility to CTL-induced killing
To gain insight into the potential role of STAT3 in the regulation
of hypoxic target cell susceptibility to CTL-mediated lysis, the
ability of CTL to kill STAT3-siRNA-transfected IGR-Heu cells
treated with hypoxia was evaluated. Interestingly, as shown in
FIGURE 5. Gene silencing of
STAT3 and pharmacological inhibi-
tion of p-STAT3 resulted in HIF-1
inhibition. A, Knockdown of STAT3
expression. IGR-Heu tumor cells
were transfected with siRNA STAT3
or control siRNA-luciferase. Seventy-
two hours after transfection, whole-
cell lysates (30 g) were subjected to
SDS-PAGE, blotted, and probed with
Abs, as indicated. Actin was used as
the loading control. B, Confocal mi-
croscopy analysis of localization of
HIF-1. IGR-Heu tumor cells were
placed in normoxia (21% PO2) and
hypoxia (1% PO2), followed by im-
munofluorescence staining with Abs
recognizing HIF-1. Nuclei were
counterstained with To-Pro-3 iodide.
The confocal scanning fluorescence
micrographs shown are representative
of most of the cells analyzed (blue,
nucleus; green, HIF-1). C, Western
blots analysis of HIF-1 following
the knockdown of STAT3 by siRNA.
Actin was used as a loading control.
D, Densitometry analysis of HIF-1
inhibition using Image J. E, CCB-I-
mediated inhibition of p-STAT3 un-
der hypoxic stress is associated with
inhibition of HIF-1. IGR-Heu tumor
cells were incubated under normoxia
(21% PO2) and hypoxia (1% PO2)
(medium, a volume equivalent of
DMSO and along with 30 M CCB-I)
for 6 h. Afterward, whole-cell lysates
(30 g) were subjected to SDS-
PAGE, blotted, and probed with Abs,
as indicated. Actin was used as a load-
ing control.
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Fig. 6A, a remarkable increase at all the E:T ratios tested in CTL-
induced killing of STAT3-siRNA IGR-Heu-transfected cells as
compared with control cells was observed. These data strengthen
the notion that activation of STAT3 plays an essential part in the
acquisition of tumor cell resistance to CTL-induced killing under
hypoxic conditions. Because hypoxia is known to induce AKT
phosphorylation, we wished to examine its status in hypoxic IGR-
Heu cells as well as its putative involvement in STAT3-induced
inhibition of tumor cell susceptibility to CTL-induced lysis. Re-
sults shown in Fig. 6B indicate that hypoxic treatment resulted in
the simultaneous phosphorylation of STAT3 and AKT in IGR-Heu
cells, suggesting a role of AKT in the resistance of hypoxic IGR-
Heu to CTL. As shown in Fig. 6C, knocking down of STAT3 in
hypoxic cells resulted in down-regulation of p-AKT phosphoryla-
tion. As shown in Fig. 6D, a significant decrease (40%) in the
induction of p-AKT following STAT3 knockdown was observed.
Gene silencing of HIF-1 resulted in restoration of IGR-Heu
tumor cells susceptibility to CTL-mediated killing under hypoxic
stress.
To delineate the role of HIF-1 in the regulation of tumor cell
susceptibility to CTL mediated lysis under hypoxic conditions,
siRNA mediated knock down of HIF-1 under hypoxic conditions
was performed. As shown in Fig. 7A, a strong inhibition of HIF-1
induction (90%) under hypoxic stress was observed. Using three
different siRNA sequences, when these cells were tested for their
susceptibility to CTL induced killing, a remarkable restoration of
cell lysis was obtained (Fig. 7B). This point to a role of HIF-1 in
the negative regulation of hypoxic tumor targets susceptibility to
lysis by the autologous CTL.
Microarray expression profiles of tumor cells in response to
hypoxia: relationship with STAT3
To further investigate the role of HIF-1 and STAT3 in controlling
tumor cell susceptibility to lysis by CTL, we performed a global
analysis using DNA Microarray (Agilent Human Whole Genome
Microarray: 44,000 spots) under two different conditions, hypoxia
vs normoxia (Hypo Normo) and siRNA STAT3 vs siRNA-Luc
(STAT3 CT). Of 44,000 probe sets, for Hypo Normo, 4138 probe
sets were differentially expressed with a 2-fold change: 1582 probe
sets were down-regulated and 2556 up-regulated. For (STAT3
CT), we found 354 probe sets that were differentially expressed
with a 2-fold change: 88 probe sets were down-regulated and 266
up-regulated. These results are summarized in Fig. 8A and point to
a potential role of both hypoxia-induced HIF-1 and hypoxia-ac-
tivated STAT3 in modulating the tumor behavior.
To identify the molecular processes/potential clusters associated
with the modulation of tumor cell susceptibility to CTL-mediated
lysis, the differentially expressed probe sets were analyzed by Ro-
setta resolver software. This analysis indicates that the majority of
genes differentially expressed under hypoxic conditions belong to
five major groups, namely metabolism, apoptosis, cell cycle, cell
adhesion, and transcriptional regulation. Similarly, under siRNA
STAT3 inhibition condition, the overall profile showed a similar
gene ontology distribution. These results further strengthen the
role of STAT3 in modulating the hypoxic response (Fig. 8B). In
addition, as shown in Fig. 8A, under (STAT3 CT), the number of
differentially expressed genes was reduced and using pathway
analysis softwares Rosetta and GenMapp/Mapfinder; these genes
were found to be dispersed among a number of pathways and not
FIGURE 6. Gene silencing of STAT3 results in res-
toration of IGR-Heu tumor cells susceptibility to CTL
(Heu171)-mediated lysis. A, Role of STAT3 in Heu171
TIL clone-mediated lysis toward autologous IGR-Heu
tumor cells. IGR-Heu tumor cells electroporated with
siRNA STAT3 or siRNA-luciferase in normoxia (21%
PO2) and hypoxia (1% PO2) for 16 h. Cytotoxicity was
determined by a conventional 4-h 51Cr release assay at
different ratios. Heu171 (TIL-derived T cell clone) was
used as effectors. Bars, SD. B, IGR-Heu tumor cells
were kept in normoxia (21% PO2) and hypoxia (1%
PO2). After 16 h of incubation, whole-cell lysates (30
g) were subjected to SDS-PAGE, blotted, and probed
with Abs, as indicated. Actin was used as the loading
control. C, Western blots analysis after the knockdown
of STAT3 by SiRNA. D, Densitometry analysis of P-
AKT inhibition after gene silencing of STAT3. The im-
ages were analyzed by Image J.
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linked to a single pathway. We further proceeded by making a list
of genes that had changed significantly under hypoxia (up or
down) and linked it with the expression of the same genes under
STAT3 inhibition. These combined results (mHypxmSTAT) indi-
cate that there is a reversal (partial or full) of the expression when
STAT3 is inhibited under hypoxia and returning to a normoxic
profile. The most prominent changes are listed in Table I with
some of the genes in this list related to cell death: AATK, MAF,
MAPK4, and MYCT1. Further analysis of the molecular pathways
resulted in the identification of an additional list of genes that are
known to play a role in regulation of resistance/apoptosis: DFFB,
TRIB3, ERN1, BCLAF1, and NALP1. It is interesting to mention
here that in the list of differential expressed genes there were also
several genes linked to NF-B signaling.
Taken together, the microarray analysis suggests that hypoxia-
induced HIF-1 and p-STAT3 may act coordinately to mediate
hypoxia-induced alteration of tumor susceptibility to CTL-medi-
ated lysis.
Discussion
The efficacy of antitumor CTL critically depends on functional
processing and presentation of tumor Ags by the malignant cells
but also on their susceptibility to CTL-induced lysis. The identi-
fication of tumor-associated Ags and their epitopes recognized by
autologous T cells has lead to their broad use as immunogens to
induce or augment tumor-associated Ag-specific immune re-
sponses in vaccination strategies (23, 39–42). However, the un-
derstanding of tumor-host interactions remains elusive despite this
identification. In fact, tumor rejection in patients does not always
follow successful induction of tumor-specific immune responses
by cancer vaccine immunotherapy (4). Even if a strong and sus-
tained cytotoxic response is induced, complex issues such as tumor
evasion and selection of tumor-resistant variants remain. In this
respect, solid tumors with disorganized, insufficient blood supply
contain hypoxic cells that are resistant to classical cytotoxic treat-
ments (43). The results of the present studies provide the first
demonstration that tumor cells, through their adaptation to hypoxic
stress, impede CTL cytotoxic activity independently of their po-
tential to trigger CTL reactivity. However, our data differ from
earlier report of MacDonald and Koch (44). This discrepancy may
lie in the fact that the reported data were collected using mice
system, CTL generated in mixed leukocyte cultures, and hypoxic
chambers, whereas we respectively used human Ag-specific CTL
clone and hypoxic station. These observations are consistent with
the notion that hypoxia-induced adaptive changes contribute to
alterations that lend toward a surviving phenotype. Thus, it is con-
ceivable to imagine that tumors frequently develop this specific
strategy to shift the balance from immune surveillance to toler-
ance. In this context, the various strategies aimed at the induction
of antitumor cytotoxic responses should consider the crucial role
of tumor hypoxia as an additional antitumor mechanism of tumor
escape that is partly involved in resistance of tumor cells to Ag-
specific cytotoxicity.
FIGURE 7. Restoration of IGR-Heu tumor cells susceptibility to CTL
(Heu171)-mediated lysis following RNAi-mediated gene silencing of
HIF-1 under hypoxic conditions. A, Gene silencing of HIF-1 under hy-
poxic conditions. IGR-Heu tumor cells were transfected with siRNA
HIF-1 or control siRNA-luciferase. Seventy-two hours after transfection,
whole-cell lysates (30 g) were subjected to SDS-PAGE, blotted, and
probed with Abs, as indicated. Actin was used as the loading control. B,
Role of HIF-1 in modulating tumor cell susceptibility to Heu171-CTL
clone-mediated lysis. IGR-Heu tumor cells electroporated with three dif-
ferent siRNA HIF-1 or siRNA-luciferase in hypoxia (1% PO2) for 16 h.
Cytotoxicity was determined by a conventional 4-h 51Cr release assay at
different ratios. Heu171 (CTL clone) was used as effectors. Bars SD.
FIGURE 8. Differential gene expression under 1% PO2 hypoxic and
siRNA STAT3 conditions. A, IGR-Heu tumor cells were kept under nor-
moxia (21% PO2) and hypoxia (1% PO2) for 24 h. Total RNA was isolated,
and DNA microarray analysis was performed using an Agilent Human
Whole Genome Microarray. B, Gene ontology identification (GOID) clas-
sification based distribution of probe sets 2-fold change under hypoxic
and siRNA STAT3 conditions. Rosetta resolver software was used for
analysis.
3518 HYPOXIA-MEDIATED INHIBITION OF SPECIFIC TUMOR CELL LYSIS
 o
n
 A
pril 2, 2012
w
w
w
.jimmunol.org
D
ow
nloaded from
 
To get more insights into the mechanism associated with alter-
ation of tumor susceptibility to CTL-mediated lysis under hypoxic
conditions, we asked whether hypoxia resulted in reshaping im-
munogenicity of tumor cells that may contribute to lose or avoid
recognition. We found that hypoxic tumor treatment did not result
in alteration of CTL reactivity as measured by TNF secretion and
granzyme B polarization, indicating that tumor-induced priming of
the autologous CTL clone was not most likely affected after ex-
posure to hypoxia. We further investigated the influence of hyp-
oxia on cell morphology since disruption of the cytoskeletal net-
work by hypoxia has been reported in diverse tissues (45). We did
not detect any influence of hypoxia on tumor cell morphological
change.
It is well established that hypoxia-induced gene transcription
promotes characteristic tumor adaptations, including resistance to
cytotoxic treatments. However, the mechanisms underlying this
resistance still need a deeper understanding. Although increasing
evidence supports a link between hypoxia and resistance to apo-
ptosis (46), the mechanism by which the hypoxic stress inhibits
apoptosis is not well understood and remains unclear. In this re-
gard, it has been suggested that alterations in the Bcl-2 family of
proapoptotic and antiapoptotic proteins may play a role in this
process (47). In addition, HIF-1-mediated increase in glucose
uptake has been also reported to play an important role in confer-
ring apoptosis resistance and that its effect is mediated in part via
Mcl-1 gene expression (48). To gain a better understanding of the
influence of hypoxia on non-small lung cancer cells’ resistance to
CTL, we asked whether it interferes with the expression of p53,
survivin, AKT, and STAT3 pathways. Under our experimental
conditions, we failed to observe any p53 and survivin induction in
hypoxic NSCLC, suggesting that the expression of HIF-1 and
these proteins may be coupled during the hypoxia response de-
pending on the cell type tested and confirming the existence of a
cell-specific effect of hypoxia (49). In the present study, we
Table I. List of genes that gave a reversal (partial or full) of expression under STAT3 inhibitiona
Primary
Sequence Name Accession No. MeanHYP MeanSTAT mHypxmSTAT
AATKb NM_001080395 8.085192508c 0.419208371d 3.389380384
ABLIM3 NM_014945 6.649144582 0.426638997 2.836784373
ADH1A NM_000667 0.167966415 2.019030276 0.339129278
ADH1A NM_000667 0.231080138 2.226025826 0.514390355
ANGPTL4 NM_139314 31.45983155 0.307092850 9.661089326
BNC2 NM_017637 2.349535188 0.479137192 1.125749692
C16orf78 NM_144602 0.501471398 2.068901367 1.037494861
CALB2 NM_001740 33.55977682 0.412261363 13.83539933
CD72 NM_001782 4.753225996 0.403382591 1.917368619
CNN1 NM_001299 2.143496155 0.405801693 0.869834369
EBI3 NM_005755 17.33144061 0.393332038 6.817010850
EFNA1 NM_004428 12.93814775 0.481075561 6.224226688
FGF21 NM_019113 3.191536311 0.328079978 1.047079163
FGG NM_000509 4.171329662 0.275914383 1.150929851
GLT1D1 NM_144669 7.621011279 0.399096116 3.041515999
HCG4 NR_002139 3.418579404 0.387191733 1.323645684
HMGCLL1 NM_019036 2.456706141 0.408455845 1.003455983
HTR3A NM_213621 4.450853706 0.434079395 1.932023882
IL21R NM_181078 7.608334185 0.180035020 1.369766595
JAK3 BC028068 2.418664759 0.444393028 1.074837756
KCNMB4 NM_014505 4.107457716 0.493705933 2.027876243
LCN2 NM_005564 2.432430479 0.317610668 0.772565868
LY96 NM_015364 8.183074746 0.382420550 3.129375943
MAFb AF055376 3.373622120c 0.488526477d 1.648103730
MAPK4b X59727 60.05014398c 0.414925830d 24.91635583
MYCT1b NM_025107 3.398289596c 0.483077899d 1.641638598
NNMT NM_006169 28.66610466 0.342793814 9.826563336
OR51E2 NM_030774 0.073586722 2.456032870 0.180731407
PECAM1 NM_000442 10.68675702 0.437580990 4.676321721
PLA2G3 NM_015715 3.960428765 0.449291227 1.779385898
PTGS1 NM_000962 5.496247103 0.435281377 2.392414008
SOCS3 NM_003955 30.13365930 0.354334745 10.67740248
SRPX2 NM_014467 4.621833783 0.416867169 1.926690763
STAT3 NM_213662 2.128718329 0.248762483 0.529545258
TNFRSF11A AB209762 2.400841610 0.487085993 1.169416319
TNS1 NM_022648 9.331115713 0.482862705 4.505647770
TNXB NM_032470 11.10529609 0.429757704 4.772586553
TSKS NM_021733 5.177481996 0.324157290 1.678318533
BCLAF1b NM_014739 0.503805042d 1.283749270c 0.632957814
DFFBb NM_004402 0.430407334d 1.201755655c 0.518365789
ERN1b AK055561 2.047796458c 0.965524773c 1.908652475
NALP1NLRP1b NM_033004 0.557328993d 1.288832253c 0.708904005
TRIB3b NM_021158 2.175000632c 0.783258470d 1.704318640
a Using GenMAPP2 analysis, a list of genes was created that gave a reversal under STAT3 inhibition. MeanHYP, mean
hypoxia in absolute numbers; MeanSTAT, mean STAT inhibition; and meanHYPXSTAT, product meanHYP  meanSTAT
should give indication on the expression between normoxic cells and hypoxic cells with STAT inhibition.
b Genes related to cell death.
c Genes up-regulated.
d Genes down-regulated.
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demonstrate that culture of IGR-Heu cells under hypoxic condi-
tions resulted in a dramatic induction of STAT3 tyrosine phos-
phorylation. Moreover, confocal microscopy analysis revealed that
the hypoxic cells exhibited an optimal and simultaneous accumu-
lation of HIF-1 and STAT3 in the nucleus. To further delineate
the putative interplay between STAT3 and HIF-1 in hypoxia-
induced alteration of tumor susceptibility to CTL-mediated cell
lysis, we performed experiments to block STAT3 under hypoxic
conditions using RNAi. We found that such knockdown resulted in
an inhibition of HIF-1 induction. This suggests that STAT3 is an
essential component of HIF-1 pathway under hypoxic conditions
and fits with a recent report indicating that hypoxia-phosphory-
lated STAT3 up-regulates HIF-1 stability through delaying pro-
tein degradation and accelerating protein synthesis in human renal
cell carcinoma (16, 50).
To further elaborate the existing relationship between hypoxia-
induced HIF-1 and activated STAT3, using CCB-I, a known in-
hibitor of STAT3 phosphorylation, we observed that both STAT3
phosphorylation and HIF-1 induction was inhibited in hypoxic
tumor cells. These results shown in Fig. 5 strengthen the existing
of an interplay between HIF-1 and p-STAT3 during the regula-
tion of specific tumor lysis under hypoxic conditions.
It is also important to note that STAT3 activation has been as-
sociated with cytokine-induced proliferation, antiapoptosis, and
transformation. We also showed that knockdown of STAT3 in
hypoxic IGR-Heu cells resulted in a significant inhibition of AKT
phosphorylation (40% inhibition) and significant restoration of tu-
mor susceptibility to CTL, indicating that the attenuation of the
resistance of hypoxic cells to CTL-induced cell death may be as-
sociated at least in part with inhibition of AKT activation in these
cells (Fig. 6D). This is also in agreement with our unpublished data
indicating that wortmannin, an AKT inhibitor; sensitized tumor
cells to CTL-mediated lysis under hypoxic conditions. It should be
noted that activated STAT3 in cancer cells does not just function
as a mediator of intracellular signaling but also affects cell-cell
interaction. In this respect, it is now well established that that
STAT3 modulates the cross-talk between tumor and immune cells
(36, 51). Very recently, a novel small molecule inhibitor of STAT3
has been reported to reverse immune tolerance in malignant gli-
oma patients (52). It would be of interest to investigate the use of
such an inhibitor to attenuate hypoxic tumor resistance to CTL-
mediated cytotoxicity.
More interestingly, we have shown that VEGF neutralization
resulted in the attenuation of hypoxic tumor target resistance to
CTL-mediated killing. We have also demonstrated that STAT3
phosphorylation can be stimulated by autocrine signaling through
VEGF, suggesting that tumor microenvironment through hypoxia-
induced VEGF may play a key role in the induction of active form
of stat3. In this regard, it is very likely that stat3 activation is
associated with the regulation of target gene expression potentially
involved in the alteration of hypoxic tumor target-specific killing.
Therefore, understanding how VEGF and other soluble factors
may lead to STAT3 activation via the tumor microenvironment
may provide a more effective cancer treatment strategy for hypoxic
tumors with elevated p-STAT3 levels. This also suggests that re-
duction of VEGF release, a main immunosuppressive factor, in
tumor microenvironment may favor induction of a stronger anti-
tumor CTL response against tumors expressing VEGFR. Our stud-
ies are in agreement with reports suggesting that inhibition of
VEGF may be a valuable adjuvant in the immunotherapy of cancer
(53) and indicating a synergy between tumor immunotherapy and
antiangiogenic therapy (54).
The results presented here provide evidence that hypoxia inhib-
its tumor-specific lysis and suggest that it induces cellular adap-
tation that compromise the effectiveness of killer cells. Using mi-
croarray analysis, we further demonstrate that hypoxia induces
transcriptional changes that may promote cell survival and resis-
tance to specific lysis. Cluster analysis of data reveals several pos-
sible pathways affected by hypoxia, including apoptosis, cell cycle,
metabolism, cell adhesion and transcriptional regulation. Addition-
ally, STAT3 inhibition under hypoxia affected the expression of
genes belonging to the same or related pathways and resulted in a
partial reversal of the differentially expressed genes under hypoxia.
This point to the potential role of STAT3 in tumor adaptation
induced by hypoxia. This emphasizes that a better understanding
of the tumor behavior and its interplay with the killer cells in the
context of the complexity and plasticity of a hypoxic microenvi-
ronment will be a critical determinant in a rational approach to
tumor immunotherapy. Although resistance of tumor targets to
killer cells is likely to be regulated by multiple factors (5), the data
we present herein suggest that hypoxic microenvironment is an
important determinant involved in the control of target sensitivity
to CTL-mediated lysis. Therefore, the possibility that novel ap-
proaches targeting HIF-1 and STAT3 with potent small molecule
drugs, being actively developed, may provide an exciting novel
approach for cancer immunotherapy.
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B. Article 2: “Blocking hypoxia-induced autophagy in tumors restores 
cytotoxic T-cell activity and promotes regression” 
Tumor growth and spread depends as much on the host response as on the biological 
characteristics of the tumor itself and on the influence of the tumor microenvironment. 
Evidences indicate that cancer cells which remain viable in hypoxia often possess an 
increased survival potential and an aggressive growth [346]. Cytolytic T lymphocytes (CTLs) 
are important effector cells during tumor rejection [340]. Tumor cells develop resistance to 
CTL-mediated cytotoxis (resistance to perforin, granzyme-B or defect in death receptor 
expression or signalling) [343]. Hypoxia has been shown to render tumor targets resistant to 
CTL mediated lysis by signaling pathways involving HIF-1α and activation of STAT3 [347]. 
Autophagy is a protective mechanism involved in cell homeostasis and protection [348] under 
stress conditions. Moreover, autophagy is involved in regulating adaptive immune responses 
and tolerance induction [349]. Autophagy is also associated with tumor cell resistance to 
different apoptotic inducers [350] [351]. Recently, a relationship between tumor hypoxia and 
autophagy has been described [84] to promote cell survival [85]. The relationship between 
hypoxic stress, autophagy and specific cell-mediated cytotoxicity remains unknown. The 
present study demonstrates that hypoxia-induced resistance of lung tumor to CTL-mediated 
lysis is associated with autophagy induction in target cells. In turn this correlates with STAT3 
phosphorylation on tyrosine 705 residue (pSTAT3) and HIF-1α accumulation. Inhibition of 
autophagy by siRNA targeting of either beclin1 or Atg5 resulted in impairment of pSTAT3 
(via inhibition Src kinase) and restoration of hypoxic tumor cell susceptibility to CTL-
mediated lysis. Autophagy-induced pSTAT3 and pSrc regulation appeared to involve the 
Ubiquitin Proteasome System (UPS) and p62/SQSTM1. In vivo experiments using B16F10 
melanoma tumor cells indicated that depletion of beclin1 resulted in an inhibition of B16F10 
tumor growth and increased tumor apoptosis. Moreover, in vivo inhibition of autophagy by 
hydroxychloroquine (HCQ) in B16F10 tumor bearing mice and mice vaccinated with TRP2 
peptide dramatically increased tumor growth inhibition. Collectively, the current study 
establishes a novel functional link between hypoxia-induced autophagy and the regulation of 
antigen specific T cell lysis and points to a major role of autophagy in the control of in vivo 
tumor growth.  
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Blocking Hypoxia-Induced Autophagy in Tumors Restores
Cytotoxic T-Cell Activity and Promotes Regression
Muhammad Zaeem Noman1, Bassam Janji2, Bozena Kaminska3, Kris Van Moer2, Sandrine Pierson2,
Piotr Przanowski3, Stephanie Buart1, Guy Berchem2, Pedro Romero4, Fathia Mami-Chouaib1, and Salem Chouaib1
Abstract
The relationship between hypoxic stress, autophagy, and specific cell-mediated cytotoxicity remains un-
known. This study shows that hypoxia-induced resistance of lung tumor to cytolytic T lymphocyte (CTL)–
mediated lysis is associated with autophagy induction in target cells. In turn, this correlates with STAT3
phosphorylation on tyrosine 705 residue (pSTAT3) and HIF-1a accumulation. Inhibition of autophagy by siRNA
targeting of either beclin1 or Atg5 resulted in impairment of pSTAT3 and restoration of hypoxic tumor cell
susceptibility to CTL-mediated lysis. Furthermore, inhibition of pSTAT3 in hypoxic Atg5 or beclin1-targeted
tumor cells was found to be associated with the inhibition Src kinase (pSrc). Autophagy-induced pSTAT3 and
pSrc regulation seemed to involve the ubiquitin proteasome system and p62/SQSTM1. In vivo experiments using
B16-F10 melanoma tumor cells indicated that depletion of beclin1 resulted in an inhibition of B16-F10 tumor
growth and increased tumor apoptosis. Moreover, in vivo inhibition of autophagy by hydroxychloroquine in
B16-F10 tumor-bearing mice and mice vaccinated with tyrosinase-related protein-2 peptide dramatically
increased tumor growth inhibition. Collectively, this study establishes a novel functional link between
hypoxia-induced autophagy and the regulation of antigen-specific T-cell lysis and points to a major role of
autophagy in the control of in vivo tumor growth. Cancer Res; 71(18); 5976–86. 2011 AACR.
Introduction
Tumor growth and spread depend as much on the host
response as on the biologic characteristics of the tumor itself
and on the influence of the tumor microenvironment. Hypoxic
microenvironment plays a role in shifting the normal balance
towardmalignancy. Evidence indicates that cancer cells which
remain viable in hypoxia often possess an increased survival
potential and an aggressive growth (1). A better understanding
of the hypoxic tumor context could improve the prospect of
developing effective cancer immunotherapy.
Cytolytic T lymphocytes (CTL) are important effector cells
during tumor rejection (2). Currently, most cancer immu-
notherapy approaches involve the generation of CTLs
against tumor-associated antigens (TAA) through vaccina-
tion strategies that induce or optimize TAA-specific immune
responses. However, tumor rejection does not always follow
successful induction of tumor-specific immune responses
(3). Numerous studies have shown a paradoxical coexistence
of cancer cells with TAA-specific T cells in an immune-
competent host. Moreover, tumor cells themselves play a
crucial role in controlling the antitumor immune response
(4) allowing them to maintain their functional disorder and
evade destruction by CTLs. Clearly, a strong and sustained
CTL response is insufficient for successful elimination of
tumors. Tumor growth is influenced by tumor cell recogni-
tion by specific CTLs and tumor susceptibility to T cell–
mediated target cell death. In addition to chemo- and radio-
resistance, tumor cells also develop resistance to CTL-
mediated cytotoxicity (resistance to perforin, granzyme-B,
or defect in death receptor expression or signaling) leading
to tumor cell survival and proliferation (5). In addition,
resistance of tumor cells to cell-mediated cytotoxicity
involves several strategies including cross-talk with the
tumor microenvironment (6). Therefore, a better under-
standing of how the tumor microenvironment contributes
to the resistance of tumors to killer cells is critically impor-
tant for improved immune intervention. In this regard,
hypoxic areas within tumors results from morphologically
and functionally inappropriate neovascularization leading to
the expression of genes involved in proliferation, glycolysis,
and angiogenesis (7). Tumor cells evade adaptive immunity
under hypoxia (8), and the adaptation to hypoxia results in
an aggressive and metastatic cancer phenotype associated
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with a poor treatment outcome (9). In addition, hypoxia
favors the emergence of tumor phenotypes that are resistant
to therapy approaches (10). Signaling pathways involving
hypoxia-inducible factor HIF-1a (11) and hypoxia-depen-
dent activation of STAT3 (12) have been well elucidated (13).
These hypoxia-dependent signaling pathways contribute to
malignant transformation (14) and progression by transac-
tivating host target genes involved in tumor proliferation,
survival, self-renewal, invasion, and angiogenesis (15).
Autophagy, initially described as a mechanism involved in
cell homeostasis and protection (16), has been also proposed
to mediate tumor progression and promotion of cancer cell
death (17). Moreover, autophagy has been involved in regu-
lating adaptive immune responses and tolerance induction
(18). Autophagy is also associated with tumor cell resistance to
different apoptotic inducers (19, 20) and can modulate dif-
ferent stages of cancer development. Recently, a relationship
between tumor hypoxia and autophagy has been described
(21) to promote cell survival (22).
This study aims to examine the involvement of hypoxia-
induced autophagy in the regulation of tumor cell lysis by
specific CTLs. We show that hypoxia-induced autophagy
promotes tumor cell resistance to specific lysis by a mecha-
nism dependent on STAT3 phosphorylation. We also show
that autophagy and the proteasome pathway cooperate to
regulate STAT3 activation in hypoxic tumor cells. Simulta-
neous stimulation of immune system and inhibition of auto-
phagy in vivo significantly inhibited tumor growth. These data
uncover a key role of autophagy in the regulation of antitumor
immunity.
Materials and Methods
Tumor cells and CTLs culture
IGR-Heu lung carcinoma cell line and Heu171 cell clone
were derived and maintained in culture as described (23). B16-
F10 melanoma cell line was purchased from American Type
Culture Collection. Cells were transfected with LC3 cDNA
fused with GFP (provided by Dr. Mizushima, Tokyo, Japan). To
detect ubiquitination, cells were transfected with Hemagglu-
tinin (HA)-tagged ubiquitin vector (pMT123), provided by Dr.
Matthias Treier (EMBL, Germany) using Lipofectamine 2000
(Invitrogen). Unless otherwise indicated the induction of HIF-
1a in cells was done in a hypoxia workstation (Invivo2 400,
Ruskinn), as previously described (23).
Reagents and antibodies
Reagents include protease inhibitors and anti-HA (12CA5;
Roche); bicinchoninic acid protein assay reagent (Pierce);
CHAPS, E64d, pepstatin, PP2, 3-methyladenine (3-MA), cobalt
chloride (CoCl2), and hydroxychloroquine (HCQ) sulfate
(Sigma); and bortezomib (Velcade; Millennium Pharmaceuti-
cals). Antibodies include the following: mouse anti-HIF-1a
and -p62 (BD-Transduction Laboratories); rabbit anti-LC3B,
-pSTAT3, -Src, -pSrc, -Beclin1, -Atg5, and mouse anti-STAT3
(Cell signaling, Bioke); mouse anti-actin (clone c-11) and
-Beclin1 (clone G-11; Santa Cruz Biotechnology); mouse
anti-Bcl2 (clone 124), and rabbit anti-ubiquitin (Dako).
Cytotoxicity assay
Cytotoxic activity of CTL clone (Heu171) was measured by a
conventional 4-hour Cr51 release assay and percent-specific
cytotoxicity was calculated as described (23).
RNA interference and generation of short hairpin RNA
Atg5 and Beclin tumor cells
Cells were transfected by electroporation with 50 nmol/L
siRNA of human and mouse BECN1 (beclin1), p62 or Atg5
(Qiagen), or Luciferase (Invitrogen) as previously described
(23). Atg5 short hairpin RNA (shRNA) expressing cells were
generated by infection with commercial human APG5 shRNA
lentiviral particles (Santa Cruz Biotechnology) according to
manufacturer's protocol. Details for the generation of shRNA
Beclin B16-F10 cells are available upon request.
Western blot and immunoprecipitation
Western blotting was done as previously reported (23).
Immunoprecipitation was done on 1 mg of total protein
using Dynabeads protein G (Invitrogen) according to the
manufacture's protocol.
Live cell imaging and confocal microscopy
Time-lapse videomicroscopywas doneusingAxiovert 200M
microscope (CarlZeissMicroImaging).Cellswereculturedwith
150 mmol/L CoCl2 to mimic hypoxia condition over a period of
24 hours. Frames were taken with 40 oil objective lense in
intervals of 1 frame/3minutes. Cells were analyzedwith a Zeiss
laser scanning confocalmicroscope LSM-510Meta (Carl Zeiss).
In vivo experiments
C57BL/6 mice (Charles River Laboratories) were housed at
the Institut Gustave Roussy animal facility and treated in
accordance with institutional animal guidelines. Six to 7-
week-old mice (n ¼ 10 per group) were inoculated s.c. with
3  105 B16-F10 cells. Tumor volume was measured using a
caliper every other day and estimated as follows: Volume
(cm3) ¼ (width)2  length  0.5.
TRP-2 180–188 peptide vaccination and HCQ treatment
Lyophilized TRP-2(180-188) peptide (SVYDFFVWL; Proteo-
genix) was diluted in dimethyl sulfoxide and stored at 20C.
Synthetic CpG ODN 1826 (TCCATGACGTTCCTGACGTT;
Oligofactory) was dissolved in sterile PBS. TRP-2(180-188)
peptide vaccination was done by s.c. injection of 50 mg CpG
ODN and 50 mg TRP-2(180-188) emulsified in 100 mL of IFA on
the left side of back. The vaccination was boosted at day 4
and day 12. Daily HCQ treatment [30 mg/kg administered
intraperitoneally (i.p.)] was started at day 8 for 10 days.
Immunohistochemical analysis
B16-F10–engrafted tumors were fixed in 4% PFA, and par-
affin sections were stained with hematoxylin-eosin-saffranin.
Apoptotic cells were quantified using in situ cell death detec-
tion kit (Roche) based on the terminal deoxynucleotidyl trans-
ferase–mediated dUTP nick end labeling (TUNEL) method as
previously described (24). Hypoxic tumor areas were detected
after injection of mice with pimonidazole (60 mg/kg i.p.
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hypoxyprobe-1; Chemicon) 60 minutes before killing. Frozen,
acetone-fixed sections were stained using anti-cleaved LC3B
(Abgent), anti-pimonidazole (Chemicon) andMouse CD31 (BD
biosciences) antibodies.
Statistics
Data were analyzed with GraphPad Prism. Student t test
was used for single comparisons. Data were considered sta-
tistically significant when P < 0.005.
Results
Hypoxic stress-induced impairment of tumor
susceptibility to CTL-mediated lysis is associated
with the induction of autophagy
We have previously reported (23) that hypoxic stress-
induced HIF-1a is associated with a decrease in CTL-
mediated tumor cell lysis (Fig. 1A) and correlated with an
increase in pSTAT3 (Fig. 1B). To investigate whether hyp-
oxia-dependent impairment of target cell susceptibility to
CTL-mediated lysis is associated with autophagy activation,
we analyzed the expression of p62/SQSTM1 and the lipi-
dated form of microtubule-associated protein light chain 3
(LC3-II). Figure 1C shows a time-dependent decrease in p62/
SQSTM1 expression in hypoxic cells which correlated with
an accumulation of LC3-II only in hypoxic cells treated with
lysosomal protease inhibitors E64 and pepstatin (Fig. 1D)
reflecting the activation of autophagy under hypoxia. This
was further confirmed by time-lapse video microscopy
(Supplementary Data S1A and B) using GFP-LC3 expressing
IGR-Heu cells (Supplementary Data S2). Representative
images from time-lapse experiments showed a time-depen-
dent increase of autophagosomes per cell under hypoxia
(Fig. 1E, top and bottom). The molecular mechanism
Figure 1. Hypoxia decreases
susceptibility of IGR-Heu cells to
CTL-mediated lysis and induces
autophagy. A, cells were
incubated in normoxia (21% pO2)
or hypoxia (1% pO2) for 16 hours.
Cytotoxicity was determined at
different effector–tumor (E:T) cell
ratios. Tumor-infiltrating
lymphocyte (TIL)–derived T-cell
clone Heu 171 cells were used as
effectors. A statistically significant
difference (indicated by asterisks)
in specific lysis was observed
between normoxic and hypoxic
tumor cells. (*, P < 0.05;
**, P < 0.005; and ***, P < 0.0005).
B, cells were cultured under
normoxia (N) and 16 hours of
hypoxia (H). Immunoblot analysis
was done on 40 mg of total protein
extracts using HIF1-a, pSTAT3,
STAT3 antibodies. b-Actin was
used as a loading control. C, time-
dependent expression of p62/
SQSMT1 under normoxia (N) and
hypoxia at 1, 4, and 16 hours by
immunoblot using specific
antibody. Hypoxia was generated
by adding 150 mmol/L CoCl2 to the
culture medium. D, time-
dependent expression of LC3 by
immunoblot. Cells were grown as
described in C in the absence (top)
or presence (middle) of lysosomal
protease inhibitors E64d/
pepstatin. E, top, representative
images from time-lapse video
microscopy experiments showing
the presence of autophagosomes
in hypoxic as compared with
normoxic GFP-LC3 expressing
IGR-Heu cells. Bar, 10 mm.
Bottom, quantification of the
number of autophagosomes of the
top images. Hypoxia was
generated as described in C.
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involved in the activation of autophagy was next investigat-
ed. Results shown in Supplementary Data S3A reveal a lower
amount of Bcl-2 coimmunoprecipitated with Beclin1 in
hypoxic as compared with normoxic cells suggesting that
the activation of autophagy involves a disruption of the
autophagy inhibitory complex of Beclin 1/Bcl-2. BNIP3
and BNIP3L seem to be involved in displacing Beclin1 from
Bcl-2 under hypoxia (21) because the expression of BNIP3
and BNIP3L was increased in hypoxic as compared with
normoxic cells (Supplementary Data S3B and C). Silencing
BNIP3 and BNIP3L inhibited autophagosome formation in
hypoxic IGR-Heu cells (Supplementary Data S3D). Collec-
tively, our results show that hypoxic stress–induced
impairment of tumor susceptibility to CTL-mediated lysis
is associated with the induction of autophagy in IGR-Heu
cells by a mechanism involving BNIP3/BNIP3L.
Targeting autophagy restores IGR-Heu tumor cell
susceptibility to CTL-mediated lysis
To investigate whether the inhibition of hypoxia-induced
autophagy is able to restore tumor cell susceptibility to CTL-
mediated lysis, we targeted autophagy genes Atg5 and Beclin1
by siRNA (Fig. 2A). As shown in Fig. 2B, there was a remarkable
reversal of hypoxia-induced inhibition of CTL-mediated killing
in autophagy defective cells. Interestingly, CTL-induced killing
of autophagy defective cells was observed at all effector–target
(E:T) ratios tested, compared with control cells. These data
suggest that hypoxia-induced autophagy plays an important
role in the acquisition of tumor cell resistance to T cell
receptor–dependent killing.
Figure 2. Targeting autophagy restores IGR-Heu tumor cell susceptibility
to CTL-mediated lysis. A, expression of Atg5 and Beclin1 by immunoblot in
normoxic (pO2 21%) and hypoxic (pO2 1%) cells transfected with Atg5,
Beclin1 (BECN1), or luciferase (Luc) siRNA. B, CTL-mediated cytotoxicity
of IGR-Heu tumor cells at different E:T ratios. Data represent 3
independent experiments with SD. Statistically significant differences
(indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; and
***, P < 0.0005).
Figure 3. Targeting autophagy
inhibits hypoxia-induced pSTAT3.
A, expression of pSTAT3 by
immunoblot in IGR-Heu cells
transfected with siRNA targeting
autophagy genes and cultured
under normoxia (pO2 21%) and
hypoxia (pO2 1%). B, expression
of pSTAT3 in IGR-Heu cells
untreated () or treated (þ) with
autophagy inhibitors HCQ (60
mmol/L) or 3 MA (1 mmol/L) and
cultured under normoxia (N) or
hypoxia for 16 hours. Hypoxia was
generated as described in Fig. 1C.
C, accumulation of hypoxia-
dependent autophagosomes
shown by confocal microscopy in
hypoxic GFP-LC3 expressing
IGR-Heu cells treated with HCQ
(60 mmol/L). Nuclei were stained
with 40,6-diamidino-2-
phenylindole. Bar, 10 mm.
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Hypoxia-induced pSTAT3 is regulated by autophagy in
IGR-Heu cells
Because hypoxia-dependent impairment of IGR-Heu cell
susceptibility to CTL-mediated lysis correlated with HIF-1a
and pSTAT3 induction (23), we investigated whether the
autophagic process operates upstream of hypoxia-dependent
induction of pSTAT3. Targeting Beclin1 or Atg5 under hypoxia
abrogates pSTAT3 expression without affecting STAT3
expression (Fig. 3A). Similar results were obtained using
autophagy inhibitors 3-MA and HCQ, which block the early
and late events of autophagy, respectively (Fig. 3B). Figure 3C
shows a strong accumulation of autophagosomes in hypoxic
cells treated with HCQ, thus showing the effectiveness of the
HCQ concentration used in blocking the autophagic flux.
These results show that hypoxia-induced autophagy regulates
the induction of pSTAT3.
Figure 4. Autophagy and ubiquitin
proteasome system cooperate to
regulate pSTAT3 in hypoxic IGR-
Heu cells. A, expression of pSrc by
immunoblot in normoxic (N) and
hypoxic cells transfected with
Luciferase (Luc), Beclin1 (BECN1)
or Atg5 siRNA. B, expression of
pSrc and pSTAT3 by immunoblot
in normoxic (N) and hypoxic cells
untreated () or treated with Src
kinase inhibitor (PP2, 10 mmol/L).
C, immunoblot analysis of
ubiquitinated protein in hypoxic
cells untreated () or treated (þ)
with 3MA or Bz. D, expression of
pSrc and pSTAT3 in normoxic (N)
and hypoxic cells untreated () or
treated (þ) with Bz. Hypoxic cells
were transfected with Luc,
BECN1, or Atg5 siRNA.
E, immunoblot analysis of pSrc
and pSTAT3 polyubiquitination.
Left, immunoblot analysis of the
expression of HA-ubiquitin in
control (C) untransfected and
transfected cells cultured under
normoxia (N) or hypoxia (H).
Middle and right panels represent
immunoprecipitation experiments
using anti-HA antibody followed
by immunoblot using anti-pSrc
(middle) or anti-pSTAT3 (right).
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Impairment of pSTAT3 in autophagy defective cells is
related to Src kinase activity and involves the ubiquitin
proteasome system
We next investigated the involvement of the receptor-
associated–specific Janus kinases (JAK) and Src in the phos-
phorylation of STAT3 to get more insights into the mechan-
isms associated with hypoxia-induced pSTAT3 and to
elucidate the role of autophagy in this process. Our data show
that inhibition of autophagy in hypoxic cells does not affect
the phosphorylation of JAK2 (data not shown) but dramati-
cally decreased the tyrosine-416 phosphorylation of Src (pSrc).
It is noteworthy that pSrc expression is highly increased under
hypoxia (Fig. 4A). Figure 4B shows that inhibition of Src
activity in hypoxic cells by PP2 significantly inhibits hypox-
ia-induced pSTAT3. Together our data show that targeting
autophagy inhibits hypoxia-induced pSrc.
Analysis of the ubiquitination profile of proteins in auto-
phagy-defective cells cultured under hypoxia shows that high-
molecular-weight proteins (up to 40 KDa) are highly ubiqui-
tinilated (Fig. 4C). The ubiquitination level is decreased in
autophagy-defective cells and dramatically reaccumulated in
cells treated with the proteasome inhibitor bortezomib,
highlighting the role of the ubiquitin proteasome system
(UPS) in the clearance of pSTAT3 and/or pSrc in autophagy
defective cells under hypoxia. This was supported by our data
(Fig. 4D) showing that inhibition of UPS by bortezomib in
autophagy-defective cells completely restores the expression
of pSTAT3 and partially that of pSrc.
Because UPS-dependent protein clearance implies their
ubiquitination, we analyzed the ubiquitination profile of
pSTAT3 and pSrc in autophagy defective cells expressing
HA-tag ubiquitin. As shown in Fig. 4E left panel, no HA-
ubiquitin was detected in untransfected cells, but equal and
high expression level of HA-ubiquitin was detected in trans-
fected cells cultured under normoxia and hypoxia. Immuno-
precipitation results (Fig. 4E, middle) clearly show the absence
of pSrc ubiquitination. However, a strong high-molecular-
weight smear was detected with anti-pSTAT3 antibody in
hypoxic cells most likely corresponding to a polyubiquitinated
form of pSTAT3 (Fig. 4E, right). Together, these results indi-
cate that autophagy and UPS cooperate to regulate pSTAT3 in
hypoxic tumor cells.
P62/SQSTM1 is required for autophagy-dependent
pSTAT3 degradation
P62/SQSTM1 (p62) is a multifunctional protein acting as an
adaptor between ubiquitylated protein aggregates and auto-
phagy (25). p62 degradation by autophagy represents another
way for cancer cells to survive under hypoxia (26). We targeted
p62 in autophagy-competent and -defective cells and analyzed
the expression of pSTAT3 and pSrc. Figure 5A shows that
targeting p62 in autophagy-defective cells induces a reaccu-
mulation of pSTAT3 and pSrc under hypoxia. siRNA p62 alone
did not affect the expression of pSTAT3 and pSrc in auto-
phagy-competent cells (Fig. 5A). These results suggest that p62
is required for autophagy-dependent pSTAT3 degradation and
could play a role as a cargo for pSTAT3 or pSrc degradation.
Immunoprecipitation experiments on normoxic and hypoxic
Figure 5. Involvement of p62 in autophagy-dependent degradation of
hypoxia-induced pSTAT3. A, expression of pSTAT3 and pSrc by
immunoblot in normoxic (N) and hypoxic cells untransfected () or
transfected with Atg5 siRNA and Beclin1 and/or p62 siRNAs. Luc siRNA
was used as control. B, immunoprecipitation (IP) of pSTAT3 and p62 in
normoxic (N) or hypoxic (H) cells using p62 antibody onwhole-cell lysate (1
mg). C, nuclear and cytoplasmic (cyto) expression of pSTAT3, pSrc, and
p62 by immunoblot in cells under normoxia (N) and different duration of
hypoxia (H).
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cells using anti-p62–specific antibody (Fig. 5B) provided com-
pelling evidence for a direct interaction between p62 and
pSTAT3 under hypoxia, suggesting that p62 interacts with
pSTAT3 to trigger its degradation. These results are supported
by data in Fig. 5C showing that under hypoxia pSTAT3, pSrc,
and a fraction of p62 are present in the nuclear compartment.
Autophagy is activated in B16-F10 hypoxic tumor areas
To determine whether autophagy was induced in hypoxic
zones of tumors, we analyzed the colocalization of LC3
(autophagy marker) in the hypoxic zones (stained with
pimonidazole) of the B16-F10 tumors established in
C57BL/6 mice. B16-F10 melanoma cells are able to activate
autophagy under hypoxia (Supplementary Data S4A and B).
Figure 6A (I) shows the presence of hypoxic areas (green),
and Fig. 6A (II and III) show a colocalization of LC3 (blue
staining in II and red staining in III) in hypoxic areas (green),
suggesting that autophagy was strongly induced in hypoxic
zones of the tumor. Moreover, Fig. 6A (IV) shows a cyto-
plasmic expression of LC3 in the entire hypoxic zone with
strongest expression seen in extreme hypoxic areas. The
impact of Beclin1 silencing on B16-F10–engrafted tumor
progression was next evaluated. Figure 6B shows that the
inhibition of autophagy in beclin1 silenced B16-F10–
engrafted tumors resulted in a significant decrease in tumor
growth. TUNEL staining clearly shows the presence of
apoptotic foci and an increase of the number of TUNEL-
positive nuclei in autophagy-defective tumors as compared
with control (Fig. 6C). These data strongly suggest a role for
autophagy in mediating hypoxia tolerance.
In vivo inhibition of autophagy potentiates the
antitumor effect of tyrosinase-related protein-2 peptide
vaccination
Vaccination with peptide from the melanocyte differenti-
ation antigen tyrosinase-related protein-2 (TRP2) in combi-
nation with oligodeoxynucleotides containing unmethylated
CpG motifs (CpG ODN) as adjuvant has been reported to be
efficient in the induction of tumor cell–specific CTLs (27).
We hypothesized that autophagy blockade in combination
with TRP2 peptide vaccination would result in a potent
antitumor effect. B16-F10–engrafted tumors were treated
with different doses of HCQ (30 mg/kg) and vaccinated with
TRP2 peptide antigen. A significant decrease in tumor
Figure 6. Autophagy is primarily
detected in hypoxic areas of the
tumor and its blockade decreases
tumor growth. A, confocal
microscopy analysis of LC3,
hypoxic area, blood vessels, and
nuclei in B16-F10 melanoma-
engrafted tumor sections. Merged
images show hypoxic area of
tumor (I) and colocalization of LC3
in hypoxic area (II and III). IV
(higher magnification 400)
shows a strong cytoplasmic LC3
staining within severe hypoxic
regions.
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growth was observed as compared with control mice
(Fig. 7A). A similar effect on the inhibition of tumor growth
with 60 mg/kg HCQ was observed (data not shown). Strik-
ingly, the combination of TRP2 peptide vaccination and
HCQ treatment resulted in complete abrogation of tumor
growth (Fig. 7A). These results were further confirmed by
TUNEL staining, which showed an increase in the number of
TUNEL-stained positive nuclei following HCQ treatment and
vaccination (Fig. 7B and C). Moreover, a dramatic increase
(20-fold) in TUNEL-positive nuclei was observed in tumors
after the combined treatment.
Discussion
Hypoxia is a common feature of solid tumors and a major
limiting factor in successful cancer treatment (7). Previously,
we showed that hypoxia impairs tumor susceptibility to CTL-
mediated cell lysis by a mechanism involving cooperation
between HIF-1a and pSTAT3 (23). Given the role of autophagy
in induction of the adaptive immune system (18) and cellular
survival under hypoxia (28), we sought to determine the
molecular basis of the hypoxia/autophagy interaction and
its interference with tumor cell survival and growth. Here,
Figure 6. (Continued ) B, growth
curve of control (B16-F10) or
Beclin1-deficient (B16-F10
shRNA-Beclin1) engrafted tumor
in C57BL/6 mice (n ¼ 10). Data
(mean  SEM) represent 3
independent experiments.
Statistically significant differences
(indicated by asterisks) are shown.
(*, P < 0.05; **, P < 0.005; and
***, P < 0.0005). C, TUNEL staining
of apoptotic cell death in tumors
from mice shown in B. (a) and (b)
show the apoptotic foci, and (c)
and (d) show TUNEL-positive
nuclei in indicated tumors. Boxes
represent an enlarged region of
apoptotic cells. Images represent
2 independent experiments using
samples isolated from 3 individual
mice. Statistically significant
differences (indicated by
asterisks) are shown
(*, P < 0.05; **, P < 0.005;
and ***, P < 0.0005).
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we show that hypoxia-induced autophagy acts as a tumor cell
resistance mechanism to specific T cell–mediated lysis. Tar-
geting autophagy was sufficient to significantly restore tumor
cell susceptibility to CTL-mediated lysis. We show for the first
time that autophagy is a protective cell survival mechanism
against CTL-mediated lysis under hypoxia.
Figure 7. Autophagy inhibition by
HCQ potentiates the antitumor
effects of TRP-2(180–188) peptide
vaccination. A, growth curve of
melanoma-engrafted tumor in the
following group of C57BL/6 mice
(n ¼ 10): control unvaccinated
mice treated with PBS; vaccinated
mice treated with PBS (PBS þ
TRP2); unvaccinated mice treated
with 30 mg/kg HCQ (30 mg/kg
HCQ) and vaccinatedmice treated
with 30 mg/kg HCQ (30 mg/kg
HCQ þ TRP2). Data (mean 
SEM) are representative of 3
independent experiments.
Statistically significant differences
(indicated by asterisks) are shown
(*, P < 0.05, **, P < 0.005; and
***, P < 0.0005). B, TUNEL staining
of apoptotic cell death in tumor
from mice shown in A. (a) and (b)
show apoptotic foci (100) and (c)
to (f) show, with enlarged region,
TUNEL-positive nuclei (200)
within the indicated tumors.
Images are representative of 2
independent experiments using
samples isolated from 3 individual
mice. C, representative results of
TUNEL-positive nuclei
quantification from 2 independent
experiments using samples
isolated from 3 individual mice.
Statistically significant differences
(indicated by asterisks) are shown
(*, P < 0.05; **, P < 0.005; and
***, P < 0.0005).
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It has been suggested that the unfolded protein response
enhances the capacity of hypoxic tumor cells to activate
autophagy by PKR-like endoplasmic reticulum kinase
(PERK) and ATF4-dependent upregulation of Atg5 and
LC3 mRNA (20). This mechanism seems unlikely to be
involved in the induction of autophagy in hypoxic IGR-
Heu cells because there is no evidence for the activation
of PERK and ATF4 and for the upregulation of Atg5 and LC3
mRNA (data not shown). However, we show (Supplementary
Data S1) that hypoxia induces autophagy by BNIP3/BNIP3L-
dependent displacement of the autophagy-inhibitory com-
plex Beclin1/Bcl-2 (21).
We attempted to investigate the role of autophagy in the
regulation of tumor susceptibility to CTL-mediated lysis by
blocking autophagy. Although much still remains to be
learned mechanistically, our data show that autophagy inhi-
bition compromised the hypoxia-dependent induction of
pSTAT3. Consistent with the clearance function of autophagy,
it is difficult to reconcile the idea that the autophagy machin-
ery plays a role in a specific stabilization of pSTAT3 and/or
pSrc. Indeed, it is nowwell documented that there is cross-talk
between the UPS and autophagy (25, 29). On the basis of our
results, we believe that the decreased level of pSTAT3 in
hypoxic and autophagy-defective IGR-Heu cells is related to
its degradation by UPS. This was supported by our data
showing that hypoxia induces a polyubiquitination of pSTAT3
and our results showing that inhibition of UPS by bortezomib
accumulates pSTAT3 in hypoxic and autophagy-defective
IGR-Heu cells. It is noteworthy that a UPS-dependent degra-
dation of phospho-p53 (30) and phospho-PKC-d (31) has been
previously described. The interplay between autophagy and
UPS is mainly mediated by the adaptor protein p62/SQSTM1,
which plays a role as a cargo for targeting proteins to
proteasomes degradation and autophagy (32). Because p62
is an autophagic substrate, an accumulation of this protein
was observed in autophagy-deficient cells. In this regard, it has
been recently reported that an excess of p62 inhibits the
clearance of ubiquitinated proteins destined for proteasomal
degradation by delaying their delivery (32). Our results show
discrepancy with this mechanism as we show that the accu-
mulation of p62 in autophagy-defective cells correlates with a
decrease, rather than an accumulation, of pSTAT3 in hypoxic
IGR-Heu cells, and targeting p62 in autophagy-defective cells
reaccumulates pSTAT3. Although additional work needs to be
done to clarify this discrepancy, one possible reason is that
degradation of p62 by autophagy in IGR-Heu cells under
hypoxia could represent a feedback mechanism to restrict
further autophagy and excessive destruction of proteins under
hypoxia. Such a feedback mechanism has been recently de-
scribed (26).
Vaccine approaches have proven effective in enhancing
antitumor immunity against tumor cells expressing targeted
antigens in vitro (33). However, clinical and animal studies
have shown little success in the inhibition of tumor growth
by vaccines (34). One of the most important factors that
could be responsible for this failure is the hypoxia-depen-
dent activation of prosurvival pathways. Inhibition of auto-
phagy has been reported to sensitize tumor cells to cytotoxic
treatments including antitumoral agents and irradiation
(35). In light of our in vitro observations, we asked whether
targeting of hypoxia-induced autophagy could influence in
vivo tumor growth. To address this issue, we used the
transplantable murine melanoma B16-F10 cell line that
expresses different TAA, including TRP2 (36). Our data
showed that autophagy is primarily localized to tumor
hypoxic regions as previously reported in other tumor
models (20). We also show that targeting beclin1 reduced
tumor growth, which correlated with an increase in TUNEL
staining. In addition, we observed a significant decrease of
tumor growth in mice treated with the autophagy inhibitor
HCQ, used at a concentration that had no effect on cell
proliferation (data not shown). These observations are in
agreement with recent reports indicating that inhibition of
autophagy by HCQ inhibits in vitro cell growth and in vivo
tumor growth via induction of apoptosis (37, 38). Our results
are also supported by several studies showing that inhibition
of autophagy promotes cancer cell death (39) and potenti-
ates anticancer treatments (19, 40, 41). HCQ has been used in
vitro for the inhibition of autophagy in several tumor models
including melanoma (42) and is currently being tested in
different ongoing phase II studies (43, 44)
Finally, with regard to potential therapeutic treatment, we
show that the combination of TRP2 peptide vaccination with
HCQ treatment results in a strong inhibition of tumor
growth. These observations further establish the significance
of hypoxia in inducing autophagy, demonstrate that it is an
adverse prognostic factor, and confirm its critical role not
only in radio- and chemoresistance but also in immune
effector cell resistance. A better understanding of the hyp-
oxic tumor context is likely to improve the prospect of
developing effective cancer immunotherapy. Together, our
results show that targeting autophagy could have significant
therapeutical implications for tumor progression and extend
the notion that simultaneously boosting the immune system
and targeting of autophagy could enhance the therapeutic
efficacy of cancer vaccines and may prove beneficial in
cancer immunotherapy.
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A major challenge in formulating aneffective immunotherapy is to
overcome the mechanisms of tumor
escape from immunosurveillance. We
showed that hypoxia-induced autophagy
impairs cytotoxic T-lymphocyte (CTL)-
mediated tumor cell lysis by regulating
phospho-STAT3 in target cells. Autophagy
inhibition in hypoxic cells decreases phos-
pho-STAT3 and restores CTL-mediated
tumor cell killing by a mechanism invol-
ving the ubiquitin proteasome system and
p62/SQSTM1. Simultaneously boosting
the CTL-response, using a TRP-peptide
vaccination strategy, and targeting auto-
phagy in hypoxic tumors, improves the
efficacy of cancer vaccines and promotes
tumor regression in vivo. Overall, in
addition to its immunosuppressive effect,
the hypoxic microenvironment also con-
tributes to immunoresistance and can be
detrimental to antitumor effector cell
functions.
Despite considerable progress made in the
identification of new strategies based on
boosting the antigen-specific antitumor
responses, the immunotherapy approaches
that are currently used in the clinic
have only a limited success. The tumor
escape from immunosurveillance repre-
sents the last series of hurdles to be
overcome in formulating a more effective
cancer immunotherapy.
In this regard, the hypoxic tumor
microenvironment has attracted much
attention from immunologists as a
major contributor in tumor escape from
immunosurveillance. Indeed, several lines
of evidence documented that immune
effector cells recruited to the hypoxic
tumor site exhibit distinct functions
compared with those present in normoxic
areas. Subsequently, their antitumor
activities are largely attenuated. In addi-
tion, immune cells in the tumor micro-
environment not only fail to exert their
antitumor effector functions, but they are
co-opted to promote tumor growth. In
this report, we discuss a new insight into
how tumor cells escape from (CTL)
specific lysis under the conditions of the
hypoxic tumor microenvironment.
Using a human non-small cell lung
carcinoma (NSCLC) cell line (IGR-Heu)
and the autologous CTL clones, we have
previously shown that hypoxic tumor
cells are less susceptible to specific T cell
receptor (TCR)-dependent lysis. Con-
sistent with the fact that hypoxia can
inhibit T cell-mediated immune response,
we showed that impairment of tumor cell
susceptibility to CTL-mediated lysis under
conditions of hypoxia is neither related to
an alteration of the effector immune
response, nor to a defect in the interaction
between effector cells and target cells.
However, this impairment was associated
with the hypoxia-dependent phosphoryla-
tion of STAT3 (pSTAT3) at the Tyr705
residue in the target cells by a mechanism
involving, at least in part, vascular
endothelial growth factor (VEGF). This
study predicts that, despite an apparently
intact cytolytic potential of CTL, tumor
cells escape CTL-mediated lysis under
hypoxic conditions by activating a hypoxia
inducible factor (HIF)-1a-dependent
intrinsic signaling pathway leading to
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STAT3 phosphorylation. Overall, this
study highlights pSTAT3 in tumor targets
as a key determinant in the regulation of
CTL-mediated tumor cell lysis under
hypoxia. We have extended our previous
findings by showing that STAT3 phos-
phorylation depends on Src kinase phos-
phorylation at the Tyr416 residue (pSrc).
Indeed, pSrc inhibition by PP2 dramati-
cally decreases pSTAT3 without affecting
total STAT3 expression. Consistent with
the role of autophagy as a cell protective
mechanism in response to oxidative stress,
we showed that hypoxia leads to auto-
phagy induction in tumor cells and that
the pSTAT3 level is tightly regulated
by autophagy. Targeting autophagy with
BECN1 or ATG5 siRNA significantly
decreases hypoxia-dependent induction of
pSTAT3 and restores CTL-mediated lysis
of tumor cells. This could allow the
prediction that autophagy induction under
hypoxia plays a role in pSTAT3 stabiliza-
tion in tumor cells. Given the role of
autophagy as a protein degradation system,
however, it is difficult to reconcile the idea
that the autophagy machinery plays a role
in the stabilization of pSTAT3 under
hypoxia. The mechanism responsible for
the decrease in pSTAT3 level in auto-
phagy-defective hypoxic tumor cells was,
therefore, extensively addressed by focus-
ing on the crosstalk mediated through the
cargo receptor/adaptor protein p62/
SQSTM1 between the ubiquitin-protea-
some system (UPS) and autophagy. Using
genetic and pharmacological approaches to
inhibit p62/SQSTM1 and the UPS in
either autophagy competent or defective
tumor cells, our results unraveled the
mechanism by which hypoxia-induced
autophagy regulates the level of pSTAT3
(Fig. 1). Indeed, hypoxia-dependent
induction of HIF-1a has two effects in
target cells: by an as yet undefined
mechanism, but still under investigation,
HIF-1a induces pSrc, which subsequently
phosphorylates STAT3 at the Tyr705
residue. HIF-1a also induces autophagy
by a mechanism involving the upregulated
expression of BNIP3/BNIP3L and the
dissociation of the BECN1-BCL2 com-
plex. Autophagy activation results in
degradation of the p62/SQSTM1 protein,
responsible for the targeting of pSTAT3 to
the UPS. In keeping with the fact that
p62/SQSTM1 is the receptor/adaptor
protein for pSTAT3 targeting to the
UPS, its degradation by autophagy leads
to pSTAT3 accumulation. In autophagy-
defective cells, p62/SQSTM1 is no longer
degraded and its accumulation accelerates
the process of pSTAT3 targeting for
degradation by the UPS.
In light of our in vitro observation, we
investigated whether targeting hypoxia-
induced autophagy could affect CTL-
mediated tumor cell lysis in vivo. To
address this issue, we used the autophagy
inhibitor hydroxychloroquine (HCQ) in
combination with a tyrosinase-related pro-
tein-2 (TRP2) peptide-based vaccination
strategy. TRP2 combined with oligo-
deoxynucleotides containing unmethylated
CpG motifs (CpG ODN) vaccination has
been previously reported to be efficient in
the induction of tumor cell-specific CTLs.
Using a transplantable murine melanoma
B16-F10 cell line we first provided evidence
that autophagy is primarily detected in
hypoxic areas of the tumor. Inhibition of
autophagy in B16-F10 engrafted tumors
results in a significant decrease in tumor
growth by inducing apoptosis, as revealed
by TUNEL staining. These results strongly
argue for a role of autophagy in mediating
hypoxia tolerance to the immune system.
More interestingly, we showed a significant
decrease in tumor growth of the vaccinated
and HCQ-treated group of mice as com-
pared with control and to either treatment
alone. Although subcutaneous tumor
implantation models have their limits,
it would be interesting to perform
Figure 1. Model of pSTAT3 regulation by hypoxia-induced autophagy in tumor cells. Hypoxic stress
leads to the accumulation of HIF-1a. By an as yet undefined mechanism, HIF-1a increases the level
of phospho-Src, which subsequently phosphorylates STAT3 at the Tyr705 residue. As HIF-target gene
products, BNIP3 and BNIP3L are transcriptionally upregulated and compete with the BECN1-BCL2
complex. This competition releases BECN1 from the complex and then activates the autophagic
machinery by recruiting several autophagic proteins including ATG5. As an autophagic substrate,
p62/SQSTM1 is degraded in the autophagosomes following their fusion with lysosomes. In view
of the fact that p62/SQSTM1 is involved in targeting pSTAT3 to the UPS, its degradation leads
to the accumulation of pSTAT3 in cells. In autophagy-defective cells, p62/SQSTM1 is no longer
degraded, and its accumulation accelerates the UPS-dependent degradation of pSTAT3.
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simultaneous boosting of the immune
system and inhibition of autophagy in
spontaneous animal tumor models.
Transgenic mouse models of spontaneous
oncogene-driven tumors that are deficient
in autophagy could be useful to explore
the impact of the hypoxic tumor micro-
environment and autophagy inhibition
on the antitumor immune responses.
Nevertheless, our results strongly argue that
in vivo inhibition of autophagy potentiates
the antitumor effect of a TRP2-based
vaccine. It would be interesting to investi-
gate whether the inhibition of autophagy
will affect other parameters of the anti-
tumor T cell activity in vivo and in vitro
(i.e., cytokine production, proliferation,
activation, etc.). Several other important
mediators of immune tolerance such as
the number of the myeloid-derived
suppressor cells (MDSCs) and the tumor-
specific T regulatory cells (Tregs) should
also be studied.
It has become increasingly clear that the
tumor microenvironment plays a crucial
role in the control of immune protection
and contains many overlapping mecha-
nisms, which ultimately lead to tumor
evasion of antigen-specific immuno-
therapy. Obviously, tumors have evolved
to utilize hypoxic stress to their own
advantage by activating key biochemical
and cellular pathways that are important
for progression, namely survival and
metastasis. In this regard, we provided
evidence that hypoxia-induced autophagy
plays a determinant role in tumor evasion
of specific CTL-mediated lysis. Further-
more, our findings establish, for the first
time, that simultaneously boosting the
immune system and inhibiting autophagy
can enhance the therapeutic efficacy of
antigen-based cancer vaccines. This study
highlights autophagy inhibition in hypoxic
tumors as a cutting-edge approach to
improve cancer immunotherapy and paves
the way to formulate more effective cancer
vaccine-based therapy. While several clini-
cal trials using the autophagy inhibitor
hydroxychloroquine in combination with
several chemotherapy drugs are currently
in progress, trials combining peptide
vaccination with autophagy inhibitors
could be an innovative strategy in cancer
immunotherapy. Integrating clinical and
lab findings will be crucial to understand
the complex role of hypoxia-induced
autophagy in modulating host tumor
immunity.
Acknowledgments
This work was supported by grants from
the ARC (Association pour la Recherche
sur le Cancer), Ligue contre le Cancer,
INCA (Institut National du Cancer),
FNR (Fonds National de la Recherche,
Luxembourg) and the Luxembourg
Ministry of Culture, Higher Education
and Research.
www.landesbioscience.com Autophagy 3
107 
 
C. Article 3: “Hypoxia-inducible miR-210 regulates the susceptibility of 
tumor cells to lysis by cytotoxic T cells” 
Although hypoxia has been reported to play a major role in the acquisition of tumor resistance 
to cell death [83, 346, 352], the molecular mechanisms that enable the survival of hypoxic 
cancer cells have not been fully elucidated. Recently, evidence has shown that aberrantly 
expressed microRNAs (miRNAs or miRs) are highly associated with tumour development, 
progression, and specific clinical phenotypes such as disease progression or recurrence [353]. 
Furthermore, a set of hypoxia-regulated microRNAs (HRMs) were identified that suggest a 
link between a tumor-specific stress factor and control of gene expression [354]. One 
particular miRNA, miR-210, has been frequently reported as the master regulator of tumor 
hypoxic response [355]; however, a significant number of additional miRNAs have also been 
linked to the cellular response to hypoxia [356]. Although the role of miR-210 in 
tumorigenesis, angiogenesis, mitochondrial metabolism, cell survival and DNA repair has 
been well characterized [355], its role in the immune response remains unknown. Of 
particular interest is its role in the regulation of tumor susceptibility to antigen specific killer 
cells. 
Hypoxia in the tumor microenvironment plays a central role in the evolution of immune 
escape mechanisms by tumor cells. In this study, we report the definition of miR-210 as a 
microRNA regulated by hypoxia in lung cancer and melanoma, documenting its involvement 
in blunting the susceptibility of tumor cells to lysis by antigen-specific cytotoxic T 
lymphocytes (CTL). miR-210 was induced in hypoxic zones of human tumor tissues. Its 
attenuation in hypoxic cells significantly restored susceptibility to autologous CTL-mediated 
lysis, independent of tumor cell recognition and CTL reactivity. A comprehensive approach 
using transcriptome analysis, argonaute protein immunoprecipitation and luciferase reporter 
assay revealed that the genes PTPN1, HOXA1and TP53I11 were miR-210 target genes 
regulated in hypoxic cells. In support of their primary importance in mediating the 
immunosuppressive effects of miR-210, coordinate silencing of PTPN1, HOXA1 and 
TP53I11 dramatically decreased tumor cell susceptibility to CTL-mediated lysis. Our findings 
show how miR-210 induction links hypoxia to immune escape from CTL-mediated lysis, by 
providing a mechanistic understanding of how this miRNA mediates immunosuppression in 
oxygen-deprived regions of tumors where cancer stem-like cells and metastatic cellular 
behaviors are known to evolve. 
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7 Abstract
8 Hypoxia in the tumormicroenvironment plays a central role in the evolution of immune escapemechanisms by
9 tumor cells. In this study, we report the deﬁnition of miR-210 as amiRNA regulated by hypoxia in lung cancer and
10 melanoma, documenting its involvement in blunting the susceptibility of tumor cells to lysis by antigen-speciﬁc
11 cytotoxic T lymphocytes (CTL). miR-210 was induced in hypoxic zones of human tumor tissues. Its attenuation in
12 hypoxic cells signiﬁcantly restored susceptibility to autologous CTL-mediated lysis, independent of tumor cell
13 recognition and CTL reactivity. A comprehensive approach using transcriptome analysis, argonaute protein
14 immunoprecipitation, and luciferase reporter assay revealed that the genes PTPN1, HOXA1, and TP53I11 were
15 miR-210 target genes regulated in hypoxic cells. In support of their primary importance in mediating the
16 immunosuppressive effects of miR-210, coordinate silencing of PTPN1, HOXA1, and TP53I11 dramatically
17 decreased tumor cell susceptibility to CTL-mediated lysis. Our ﬁndings show how miR-210 induction links
18 hypoxia to immune escape from CTL-mediated lysis, by providing a mechanistic understanding of how this
19 miRNA mediates immunosuppression in oxygen-deprived regions of tumors where cancer stem-like cells and
20 metastatic cellular behaviors are known to evolve. Cancer Res; 1–13. 2012 AACR.
21
22
23
24 Introduction
25 Cytotoxic T lymphocytes (CTL) are important effector cells
26 in tumor rejection and play a crucial role in host defense
27 against malignancies in both mouse and human (1, 2). Cur-
28 rently, most cancer immunotherapy approaches involve the
29 generation of CTLs against tumor-associated antigens (TAA)
30 through vaccination strategies that induce or optimize TAA-
31 speciﬁc immune responses (3). However, tumor rejection does
32 not always follow successful induction of tumor-speciﬁc
33 immune responses (4). Numerous studies have shown a par-
34 adoxical coexistence of cancer cells with TAA-speciﬁc T cells in
35 immune-competent hosts. Moreover, tumor cells themselves
36 play a crucial role in controlling the antitumor immune
37 response (5), allowing them to maintain their functional
38 disorder and evade destruction by CTLs. In this regard, it has
39 been suggested that tumor cell growth in vivo is not only
40 inﬂuenced by CTL-tumor cell recognition (6) and tumor
41 susceptibility to cell-mediated death, but also by the complex
43and highly dynamic tumor microenvironment, providing very
44important clues to tumor development and progression (7).
45Hypoxia, a common feature of solid tumors and one of the
46hallmarks of the tumor microenvironment, is known to favor
47tumor survival and progression (8, 9). Although hypoxia has
48been reported to play a major role in the acquisition of tumor
49resistance to cell death (10, 11), themolecularmechanisms that
50enable the survival of hypoxic cancer cells have not been fully
51elucidated. Recently, attention has been focused on the
52mechanisms by which hypoxic tumor cells alter their tran-
53scriptional proﬁles to modulate glycolysis, proliferation, sur-
54vival, and invasion, allowing them to persist under the condi-
55tions of hypoxic stress (12, 13).
56Emerging evidence has shown that aberrantly expressed
57miRNAs Q2are highly associated with tumor development, pro-
58gression, and speciﬁc clinical phenotypes such as disease
59progression or recurrence (14). Recently, a set of hypoxia-
60regulated miRNAs (HRM) were identiﬁed that suggest a link
61between a tumor-speciﬁc stress factor and control of gene
62expression (15, 16). One particular miRNA, miR-210, has been
63frequently reported as the master regulator of tumor hypoxic
64response (17); however, a signiﬁcant number of additional
65miRNAs have also been linked to the cellular response to
66hypoxia (18). Although the role of miR-210 in tumorigenesis,
67angiogenesis, mitochondrial metabolism, cell survival, and
68DNA repair has been well characterized (17), its role in the
69immune response remains unknown. Of particular interest is
70its role in the regulation of tumor susceptibility to antigen-
71speciﬁc killer cells.
72We have previously reported that hypoxic induction of
73HIF1a and pSTAT3 (19) and autophagy (20) modulates tumor
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76 cell susceptibility to CTL-mediated lysis. In this study, we
77 conducted miRNA proﬁling to improve our understanding of
78 tumor cell resistance to CTL-mediated cell lysis under hypoxic
79 stress. We provide evidence that hypoxia-induced miR-210
80 regulates tumor cell susceptibility to CTL-mediated cell lysis
81 by a mechanism involving its downstream targets PTPN1,
82 HOXA1, and TP53I11.
83 Materials and Methods
84 Culture of tumor cells and CTLs
85 The human IGR-Heu NSCLC (non–small cell lung carcino-
86 ma) cell line and its autologous TIL clone Heu171 were derived
87 and maintained in culture as described (21). The human
88 melanoma cell line NA-8 and CTL clones R11, R18P1, and
89 R2C9 were provided by Dr. Pedro Romero (Ludwig Center for
90 Cancer Research, Lausanne, Switzerland). Human NSCLC tis-
91 sues were obtained from Dr Fathia Mami-Chouaib (INSERM
92 U753, IGR, France).
93 Reagents and antibodies
94 SDS was obtained from Sigma. Mouse anti-HIF-1a from BD
95 Transduction Laboratories; rabbit anti-PTPN1, anti-pSTAT3,
96 anti-PIM1, and mouse anti-STAT3 from Cell signaling; and
97 rabbit anti-TP53I11, mouse anti-Actin-HRP, and goat-anti-
98 HOXA1 from Abcam.
99 Hypoxic conditioning of tumor cells
100 Hypoxic treatment was conducted in a hypoxia chamber as
101 previously described (19).
102 51Cr cytotoxicity assay
103 The cytotoxic activity of the CTL clone (Heu171) was mea-
104 sured by a conventional 4-hour 51Cr release assay (22).
105 Tumor necrosis factor and interferon production assay
106 TNF-b and IFN-g production by the CTL clones Heu 171
107 (cocultured with IGR-Heu) and R2C9 (cocultured with NA-8)
108 were measured as described (19).
109 Flow cytometry analysis
110 Flow cytometry analysis was conducted by using a FACS-
111 Calibur ﬂow cytometer (19).
112 Gene silencing by RNA interference
113 Predesigned siRNA (HIF-1a, PTPN1, HOXA1, and TP53I11)
114 were obtained from Ambion and transfected as described
115 earlier (19).
116 miR-210 blockade and overexpression
117 Transfections were conducted with anti-miR-210 (miR
118 inhibitor, Ambion) and pre-miR-210 (miR precursor, Ambion)
119 under hypoxic and normoxic conditions, respectively. siPORT
120 NeoFx Transfection Agent (NeoFx; Ambion) was used for
121 transfection according to manufacturer's instructions. Anti-
122 miR-CT (miR negative control, Ambion) and pre-miR-CT (miR
123 positive control, Ambion) were used as controls under hypoxic
124 and normoxic conditions, respectively.
126RNA isolation and SYBR-GREEN qRT-PCR
127Total RNA was extracted from the samples with TRIzol
128solution (Invitrogen). DNase I-treated 1 mg of total RNA was
129converted into cDNA by using TaqMan Reverse transcrip-
130tion reagent (Applied Biosystems) and mRNA levels were
131quantiﬁed by SYBR-GREEN qPCR method (Applied Biosys-
132tems). Relative expression was calculated by using the
133comparative Ct Q3method (2-DCt). Primer sequences are avail-
134able upon request.
135MicroRNA (miR) isolation and detection and microRNA
136microarray experiment
137For extraction of miRs, TRIzol (Invitrogen) was used. DNase
138I-treated total RNA (8 ng) was subjected to qRT-PCR analysis
139using TaqMan miR Reverse Transcription Kit (Applied Bio-
140systems). MiR-210 was detected and quantiﬁed by using
141speciﬁc miRNA primers from Ambion. Expression levels of
142mature miRNAs were evaluated using comparative Ct method
143(2-DCt). Transcript levels of RNU44 were used as endogenous
144control. miRNA microarray analysis was conducted using
145Agilent human miRNA microarray. Rosetta resolver software
146was used for analysis. The microarray data related to this
147paper have been submitted to the Array Express data repos-
148itory at the European Bioinformatics Institute (http://www.
149ebi.ac.uk/arrayexpress/) under the accession number E-
150MTAB-1157.
151Western blot analysis
152Western blotting was conducted as previously reported (20).
153Immunoprecipitation of FLAG/HA Ago2-containing
154RISC—argonaute 2 ribonucleoprotein
155immunoprecipitation
156IGR-Heu cells were transfected with pIRESneo-FLAG/HA
157Ago2 (Addgene plasmid 10821; ref. 23) by using Lipofectamine
1582000 Transfection Reagent (Invitrogen). Immunoprecipitation
159was conducted as described (24). B2M, glyceraldehyde-3 phos-
160phate dehydrogenase (GAPDH) and 18S (shown to be RISC-
161associated but not miR-210 targets) were used for
162normalization.
163Luciferase reporter assay for miR-210 target gene
164validation
165The 30 UTRs of PTPN1, HOXA1, and TP53I11 were cloned
166into a pSI-CHECK-2 vector by PCR ampliﬁcation of geno-
167mic DNA. Primer sequences are available upon request.
168IGR-Heu cells were cotransfected with 800 ng pSI-CHECK-2
169and 10 nmol/L of pre-miR in 24-well plates with Lipofec-
170tamine 2000 (Invitrogen) in OPTIMEM (Invitrogen) medi-
171um. After 48 hours, ﬁreﬂy and Renilla luciferase activities
172were measured using the Dual-Luciferase Reporter assay
173(Promega).
174Immunohistochemical staining for CA-IX expression
175Hypoxic zones were detected by CA-IX staining on human
176NSCLC sections. Immunohistochemistry was conducted as
177previously described (25).
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180 Locked nucleic acid-based in situ detection ofmiR-210 in
181 human NSCLC tissues
182 HumanNSCLC sections were ﬁxed in 4% paraformaldehyde.
183 miRNA ISH Optimization Kit 2 (FFPE; Exiqon) was used for
184 miR-210 staining as per manufacturer's protocol.
185 Statistics
186 Datawere analyzed with GraphPad Prism. Student t test was
187 used for single comparisons. Data were considered statistically
188 signiﬁcant when P was less than 0.005.
189 Results
190 miR-210 is the miRNA predominantly induced by
191 hypoxia in NSLCC and melanoma cells
192 To identify the miRs that are induced by hypoxia in non–
193 small cell lung cancer (NSCLC) and melanoma, we conducted
194 miRNA expression proﬁling using human NSCLC (IGR-Heu)
195 and humanmelanoma (NA-8) cell lines following incubation of
196 these cells under conditions of normoxia (21% O2) or hypoxia
197 (1% O2) for 6, 16, or 24 hours (Fig. 1A–D). Several miRs that
198 exhibited more than a 2-fold change under hypoxia were
199 identiﬁed in both cell lines. Twenty-six miRs were upregulated
200 in IGR-Heu cells and 9 miRs were upregulated in NA-8 cells at
201 one or more time points under hypoxia as compared with
202 normoxia (Supplementary data S1). Among these putative
203 hypoxia-induced miRs, miR-210 was highly upregulated in
204 IGR-Heu cells (Fig. 1A) and NA-8 cells (Fig. 1C). Volcano plot
205 analysis further conﬁrmed that miR-210 was the most highly
206 (more than 10-fold change) and signiﬁcantly (adjusted P value
207 < 0.05) upregulated miR under hypoxia in IGR-Heu cells (Fig.
208 1B) and NA-8 cells (Fig. 1D).
209 Expression ofmiR-210 in hypoxic zones of humanNSCLC
210 tissues
211 To determine whether miR-210 is selectively expressed in
212 the hypoxic zones of human NSCLC tissues, we ﬁrst selected
213 human NSCLC tissues on the basis of a well-established
214 hypoxia marker (CA-IX; carbonic anhydrase-9; ref. 13) expres-
215 sion by immunohistochemistry (data not shown). We identi-
216 ﬁed 12 CA-IX–positive tissues out of 31 NSCLC specimens. We
217 next conducted miR-210 staining by in situ hybridization on
218 serial sections. As shown in Fig. 2A and B, miR-210–positive
219 staining was observed in the hypoxic zones (CA-IX–positive
220 staining) of tumor areas. While 23% of the tumor areas
221 were positively stained for CA-IX, 19% of the tumor areas were
222 positive for miR-210. As depicted in Fig. 2C, an overlap of
223 CA-IX and miR-210 staining was observed: 68% of the CA-IX–
224 positive cells were also positive for miR-210. Moreover, using
225 ImageJ JACoP analysis, a positive Pearson correlation coefﬁ-
226 cient between miR-210 expression (r ¼ 0.685) and CA-IX
227 positivity was found. These ﬁndings clearly indicate in vivo
228 miR-210 expression in the hypoxic zones of NSCLC tissues.
229 miR-210 upregulation in melanoma and NSCLCCQ5 under
230 hypoxia is HIF-1a–dependent
231 We next measured the expression levels of miR-210 in
232 hypoxic IGR-Heu and NA-8 tumor cells. As shown in Fig. 3A,
234hypoxia resulted in the signiﬁcant induction of miR-210
235after 6 hours (4-fold), 16 hours (6-fold), and 24 hours (10-
236fold) in IGR-Heu cells. Similarly, Fig. 3B shows that miR-210
237was upregulated in NA-8 cells as early as 6 hours (2-fold), 16
238hours (4-fold) and 24 hours (6-fold) of hypoxia induction.
239Similar results were obtained by using a panel of 5 human
240NSCLC and 5 human melanoma cell lines (Supplementary
241data S2). We further show that siRNA-mediated knock-
242down of HIF-1a with 3 different siRNAs efﬁciently silenced
243HIF-1a and completely inhibited miR-210 induction in
244IGR-Heu cells under hypoxia (Fig. 3C). Same results were
245obtained using NA-8 cells (Fig. 3D). Collectively, these
246results indicate that hypoxia-induced miR-210 is HIF-
2471a–dependent.
248Hypoxia-induced miR-210 regulates tumor cell
249susceptibility to CTL-mediated lysis
250To investigate the potential role of hypoxia-induced miR-
251210 in regulating the hypoxic tumor cell susceptibility to CTL-
252mediated lysis, IGR-Heu and NA-8 tumor cells were trans-
253fected with anti-miR-210 (miR-210 inhibitor) or anti-miR-CT
254(miR-control inhibitor) and cultured under hypoxia. Trans-
255fection of these cells with anti-miR-210 resulted in the abro-
256gation of miR-210 expression in both IGR-Heu (Fig. 3E) and
257NA-8 (Fig. 3F) cell lines as compared with anti-miR-CT (miR-
258control inhibitor).
259We next examined the susceptibility of IGR-Heu and NA-8
260tumor cells in which miR-210 expression had been abrogated
261to CTL-mediated lysis under hypoxic conditions. Interesting-
262ly, as shown in Fig. 3G, there was a signiﬁcant and remarkable
263restoration of tumor cell susceptibility to CTL-mediated lysis
264in hypoxic IGR-Heu cells transfected with anti-miR-210 as
265compared with anti-miR-CT. More interestingly, this restora-
266tion of susceptibility to CTL-induced killing in miR-210 abro-
267gated IGR-Heu tumor cells (anti-miR-210–transfected cells)
268was observed at all effector:target ratios (E:T) tested in
269comparison with control cells. Similarly, data depicted
270in Fig. 3H clearly show that hypoxic NA-8 cells transfected
271with anti-miR-210 were more susceptible to CTL-mediated
272lysis as compared with cells transfected with anti-miR-CT.
273Similar results were obtained for NA-8 cells with 2 different
274CTL clones (Supplementary data S3). These data strongly
275indicate that hypoxia-induced miR-210 plays an important
276role in the acquisition of tumor cell resistance to CTL-medi-
277ated lysis.
278miR-210 in hypoxic cells does not alter tumor cell
279recognition and CTL reactivity
280We next examined the inﬂuence of miR-210 on MHC class I
281molecule expression. As shown in Table 1, no difference in
282staining with HLA class I-speciﬁc antibody and HLA-A2–
283speciﬁc antibody was observed in hypoxic IGR-Heu cells
284transfected with miR-210 inhibitor (anti-miR-210) as com-
285pared with cells transfected with anti-miR-CT. Similarly, no
286difference was observed in normoxic IGR-Heu cells transfected
287with miR-210 precursor (pre-miR-210) as compared with miR-
288control precursor (pre-miR-CT). Similar results were obtained
289for NA-8 cells (Table 1). Next, we analyzed the reactivity of the
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Figure1. HypoxicQ4 stress on tumor cells results in the upregulation ofmiRNA-210 (miR-210). A, heatmapof the hypoxia regulatedmiRNAs in IGR-Heu cells. Red
signiﬁes upregulation, whereas green signiﬁes downregulation. B, volcano plot of miRNA expression (Log2 fold change) and adjusted P values for IGR-Heu
under hypoxia 1% O2. C, miR-210 is signiﬁcantly upregulated in NA-8 tumor cells. Heat map of the hypoxia regulated miRNAs in NA-8 cells. Red signiﬁes
upregulation, whereas green signiﬁes downregulation. D, volcano plot ofmiRNA expression (Log2 fold change) and adjustedP values for NA-8 under hypoxia
(1% O2). Data shown are representative of 2 independent experiments.
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292 CTL clone to hypoxic autologous targets with abrogated miR-
293 210.We observed no difference in TNF-a and IFN-g production
294 by the autologous T-cell clone in response to stimulation with
295 IGR-Heu cells (Fig. 4A and C) and NA-8 cells (Fig. 4B and D)
297with abrogated (anti-miR-210) or overexpressed miR-210 (pre-
298miR-210). These results clearly show that miR-210 does not
299alter tumor cell recognition and CTL priming in IGR-Heu and
300NA-8 tumor cells.
Figure 2. Hypoxia induced miR-210
staining in human NSCLC tissues
colocalizes with CA-IX. Human
NSCLC biopsies were stained for
CA-IX expression by
immunohistochemistry and miR-210
expression by in situ hybridization.
(A) and (B) are representative images
of CA-IX/miR-210 staining on serial
sections of specimen (IGR-2220). C,
Venn diagram representation of the
staining analysis of CA-IX and miR-
210 showing overlap on serial
sections of specimen (IGR 2220).
Colocalization analysis was
conducted by using JACoP Plug-in
in ImageJ software. Arrows
represent areas positively stained for
CA-IX and miR-210. Magniﬁcation:
50.
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Figure 3. Hypoxia induced miR-210
is HIF-1a–dependent in IGR-Heu
cells and targeting miR-210 by
anti-miR-210 under hypoxia
resulted in the restoration of tumor
cell susceptibility to CTL-mediated
lysis. A, miR-210 expression was
monitored by TaqMan qRT-PCR in
IGR-Heu with or without exposure
to 1% O2 hypoxia at indicated
times. B, miR-210 expression was
monitored by TaqMan qRT-PCR in
NA-8 with or without exposure to
1% O2 hypoxia at indicated times.
Expression levels of RNU44 were
used as endogenous control. C,
expression of miR-210 in IGR-Heu
tumor cells transfected with
different siRNAs targeting either
HIF-1a or Luciferase (Luc) and
cultured under hypoxic conditions
(1%O2) for 24 hours. D, expression
of miR-210 in NA-8 cells
transfected with different siRNAs
targeting either HIF-1a or
Luciferase (Luc) and cultured under
hypoxic conditions (1% O2) for 24
hours. E, TaqMan qRT-PCR
showing successful knockdown of
hypoxia-induced miR-210 in IGR-
Heu tumor cells and in (F) NA-8
cells. G, CTL-mediated lysis of
IGR-Heu tumor cells at different E:T
ratios. Heu 171 cells were used as
effectors. Data represents 3
independent experiments with SD.
Statistically signiﬁcant difference
(indicated by asterisks) are shown
(,P < 0.05; , P < 0.005; and ,P
< 0.0005). H, CTL-mediated lysis of
NA-8 cells at different E:T ratios.
R2C9 TIL clone was used as
effector.
Table 1. Anti-miR-210 and pre-miR-210 does not affect tumor cell recognition in IGR-Heu and NA-8 tumor
cells
(NSCLC) IGR-Heu (Melanoma) NA-8
HLA Class I HLA-A2 HLA Class I HLA-A2
Conditions 21%O2 1%O2 21%O2 1%O2 21%O2 1%O2 21%O2 1%O2
Medium 99.9% (8444) 99.8% (9083) 99.5% (6151) 99.8% (6150) 99.91% (635.62) 99.96% (590.09) 99.92% (113.19) 99.91% (84.71)
Pre-miR-CT 99.8% (8222) 99.4% (6121) 99.90% (625.25) 99.90% (109.85)
Pre-miR-210 97.5% (7745) 99.5% (5609) 99.87% (580.02) 99.91% (105.78)
Anti-miR-CT 99.9% (7560) 99.7% (5365) 99.97% (580.12) 99.89% (87.89)
Anti-miR-210 99.9% (7599) 99.3% (5988) 99.98% (595.56) 99.90% (90.55)
NOTE:Analysis of surface expressionofMHCclass-I in IGR-HeuandNA-8 tumor cells under different conditions.HLAclass I andHLA-
A2 surface expression was detected by using W632 and MA2.1 antibodies respectively. Isotypic control mAb (IgG) was used.
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303miR-210 has no effect on hypoxia-induced transcription
304factors (HIF1a, HIF2a, and pSTAT3) in IGR-Heu cells
305It has been well established that HIF1a, HIF2a, and pSTAT3
306are the main mediators of hypoxia-induced responses in
307tumors (19, 20). We next wondered whether miR-210 is able
308to regulate these hypoxia-induced factors (HIF1a, HIF2a, and
309pSTAT3) in IGR-Heu cells. We observed that both HIF1a and
310pSTAT3 were increased under hypoxic conditions (6, 16, 24, 48,
311and 72 hours of 1%O2). However, abrogation or overexpression
312of miR-210 (anti-miR-210 in hypoxic IGR-Heu cells and pre-
313miR-210 in normoxic cells) had no effect on HIF-1a and
314pSTAT3 protein levels. We also quantiﬁed, using the same
315experimental conditions, changes inmRNAexpression levels of
316HIF1a, HIF2a, VEGF, and GLUT, no difference was observed
317(Supplementary data S4).
318Identiﬁcation of miR-210 candidate target genes in IGR-
319Heu tumor cells
320Wenext conducted a comprehensive transcriptome analysis
321using RNA from IGR-Heu cells transfected with anti-miR-210
322or anti-miR-CT under hypoxia. We selected a panel of 44 genes
323(validated miR-210 targets) from a miRNA database, miRTar-
324Base (http://mirtarbase.mbc.nctu.edu.tw/), which has the larg-
325est number of validated miRNA-target interactions (MTI).
326We selected 11 genes that meet the following criteria:
3271. Signiﬁcantly downregulated under hypoxia as compared
328to normoxia.
3292. Signiﬁcantly upregulated when hypoxic IGR-Heu cells
330were transfected with anti-miR-210 as compared to
331transfected with anti-miR-CT.
3323. Signiﬁcantly downregulated when transfected with pre-
333miR-210 under normoxic conditions (Supplementary
334data S5).
335
336As shown in Fig. 5A and B, the expression levels of ISCU,
337E2F3, FGFRL1, NPTX1, PTPN1, HOXA1, TP53I11, RAD52, and
338EFNA3 were, respectively, increased or downregulated follow-
339ing anti-miR-210 and pre-miR-210 transfection in IGR-Heu
340cells.
341We selected 3 of these 11 identiﬁed genes (PTPN1, HOXA1,
342and TP53I11) based on their involvement in tumor cell death
343and apoptosis. These identiﬁed target genes were further
344validated by Western blot analysis. Figure 5C clearly shows
345that the protein level of PTPN1 was signiﬁcantly decreased by
346pre-miR-210 as compared with pre-miR-CT under normoxia,
347and signiﬁcantly increased when IGR-Heu cells were trans-
348fected by anti-miR-210 as compared with anti-miR-CT under
349hypoxia. Similar results were obtained for HOXA1 (Fig. 5D) and
350TP53I11 (Fig. 5E). PIM1 was used as control (Fig. 5F). Taken
351together, these results point to the regulationofPTPN1,HOXA1,
352and TP53I11 at both mRNA and protein levels by miR-210.
353Validation of PTPN1, HOXA1, and TP53I11 as miR-210
354target genes
355To validate the identiﬁed targets, we inserted miR-210
356binding sites sequence from the 30 UTR of PTPN1, HOXA1,
357and TP53I11 mRNA (Fig. 6A) into the 30 UTR of pSI-check2
Figure 4. Anti-miR-210 and pre-miR-210 does not affect CTL priming in
IGR-Heu and NA-8 tumor cells. A–D, TNF-a and IFN-g production by the
CTL clones Heu 171 (cocultured with IGR-Heu) and R2C9 (cocultured
with NA-8) for 24 hours under different conditions. Data represents 3
independent experiments with SD.
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360 vector and conducted luciferase reporter assays. We show that
361 pre-miR-210 signiﬁcantly reduced the luciferase activities of
362 PTPN1, HOXA1, and TP53I11 reporters by 65% to 40% and 25%,
363 respectively, as compared with pre-miR-CT (Fig. 6B). In con-
364 trast, pSI-check2 (empty vector control) and PIM1 reporter
365 luciferase activities were not repressed by pre-miR-210, con-
366 ﬁrming that PTPN1, HOXA1, and TP53I11 target sites directly
367 mediates repression of the luciferase activity through seed-
368 speciﬁc binding. In addition, we used a biochemical assay
369 based on the immunoprecipitation of RNA-induced silencing
370 complexes (RISC) enriched for miR-210 and its targets. To
371 accomplish this, IGR-Heu cells were stably transfected with
372 pIRESneo-FLAG/HA Ago2 and cultured under normoxic or
373 hypoxic conditions for 24 hours. miR-210 was selectively
374 enriched in Ago2-HA immunoprecipitates under hypoxia as
375 compared with normoxia, suggesting that the argonaute pro-
376 tein immunoprecipitation (miRNP-IP) worked efﬁciently (Sup-
377 plementary data S6). To further validate this, IGR-Heu cells
378 stably expressing pIRESneo-FLAG/HA Ago2 were transfected
379 with pre-miR-210 or pre-miR-CT and cultured under nor-
381moxia. First, we showed that ISCU and EFNA3, 2 well-estab-
382lished miR-210 targets (24), were signiﬁcantly enriched in
383normoxic pre-miR-210-Ago2-HA immunoprecipitates (Fig.
3846C). Furthermore, as shown in Fig. 6C, PTPN1, HOXA1, and
385TP53I11 were selectively and signiﬁcantly increased in the
386immunoprecipitates of the IGR-Heu cells transfected with
387pre-miR-210 as compared with pre-miR-CT. It is worth noting
388that B2M, GAPDH, and PIM1 remain unchanged (Fig. 6D).
389These results clearly show that PTPN1, HOXA1, and TP53I11
390are validated targets of miR-210 in IGR-Heu cells.
391miR-210 modulates IGR-Heu tumor target cell
392susceptibility to CTL-mediated lysis by targeting PTPN1,
393HOXA1, and TP53I11
394We next asked whether miR-210 confers resistance in hyp-
395oxic tumor targets to CTL-mediated lysis by degrading its
396target genes (PTPN1, HOXA1, and TP53I11). Using a 51Cr
397cytotoxicity assay and target gene silencing, we show that
398siRNA-mediated silencing of PTPN1 resulted in a signiﬁcant
399decrease in the IGR-Heu tumor cell susceptibility to CTL-
Figure 5. Conﬁrmation of a panel of
mirtarbase (MTI-miRNA target
identiﬁcation) database-identiﬁed
targets in IGR-Heu tumor cells. A,
IGR-Heu tumor cells were
transfected with anti-miR-210 or
anti-miR-CT used as a control and
cultured under hypoxia (1% O2) for
24 hours. ISCU, E2F3, FGFRL1,
NPTX1, PIM1, PTPN1, HOXA1,
TP53I11, RAD52, and EFNA3
expression was monitored by
SYBR-GREEN qRT-PCR. B, IGR-
Heu tumor cells were transfected
with pre-miR-210 or pre-miR-CT
used as a control and cultured
under normoxia (21% O2) for 24
hours. ISCU, E2F3, FGFRL1,
NPTX1, PIM1, PTPN1, HOXA1,
TP53I11, RAD52, and EFNA3
expression was monitored by
SYBR-GREEN RT-qPCR.
Expression level of 18S was used
as endogenous control.
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402 mediated lysis (Fig. 7A). However, siRNA silencing of HOXA1
403 (Fig. 7B) or TP53I11 (Fig. 7C) had no effect on tumor cell
404 susceptibility to CTL-mediated lysis. Surprisingly, as depicted
405 in Fig. 7D, siRNA silencing of all 3 genes (PTPN1, HOXA1, and
406 TP53I11) resulted in a dramatic decrease in target suscepti-
407 bility to CTL-mediated lysis. Taken together, these results
408 strongly show that miR-210 is able to confer resistance in
409 hypoxic target cells by degrading PTPN1, HOXA1, and TP53I11.
410 Discussion
411 Tumors have evolved to use hypoxic stress to their own
412 advantage by activating key biochemical and cellular pathways
413 that are important in angiogenesis, cell-cycle regulation, cell
414 survival, progression, survival, metastasis, and resistance to
415 apoptosis (9–11, 19). Tumor resistance remains a crucial issue
416 in immunotherapy, as it limits the effectiveness of cancer
417 immunotherapy (5, 6). It has become clear that a hypoxic
418 tumor microenvironment plays a determining role in neutral-
419 izing the immune system of the host and negatively impacting
420 the outcome of therapy (26). We observed a signiﬁcant miRNA
421 dysregulation between normoxic and hypoxic melanoma and
422 NSCLC cells (Supplementary data S1). This is in agreement
423 with the concept that tumors may adapt to hypoxic stress in
425different ways depending on their genetic background and
426phenotypic characteristics (10).
427To our knowledge, this is the ﬁrst time we showed that miR-
428210 is expressed in the hypoxic zones of NSCLC tissues and in
429hypoxic melanoma tumor cells. Our results support the claim
430that induction of miR-210 is the most important hypoxia-
431induced miR in different cancer types (17, 27). miR-210 is also
432generally recognized as a robust HIF1 target (16, 28) and an in
433vivo marker of tumor hypoxia (29, 30). The increased expres-
434sion of miR-210 correlates with a poor prognosis in patients
435with breast and pancreatic cancer (31, 32). Zhang and collea-
436gues provided evidence indicating that miR-210 levels are high
437in tumors and correlate with their metastatic behavior, sug-
438gesting a potential oncogenic role for miR-210 (33, 34).
439Although the role ofmiR-210 in tumorigenesis, angiogenesis,
440mitochondrial metabolism, cell survival, and DNA repair has
441been well characterized (17), its role in the immune response is
442less well understood, in particular, its role in the regulation of
443tumor cell susceptibility to antigen-speciﬁc killer T cells. We
444showed for the ﬁrst time that expression of miR-210 under
445hypoxic conditions correlates with the alteration of tumor
446susceptibility to CTLs by a mechanism independent of target
447recognition and alteration of CTL reactivity. Mandelboim and
448colleagues have shown that several humanmiRNAs are able to
Figure 5. (Continued ) C–F, IGR-Heu tumor cells were transfected with either anti-miR-210 or anti-miR-CT and cultured under hypoxia (1%O2) or transfected
with pre-miR-210 or pre-miR-CT and cultured under normoxia (21% O2) for 24 hours. Western blot analysis and densitometry analysis were conducted to
show PTPN1 (C), HOXA1 (D), and TP53I11 (E) protein levels, which were signiﬁcantly regulated by miR-210. F, PIM1 is used as a control. Data represents 3
independent experiments with SD. Statistically signiﬁcant difference (indicated by asterisks) are shown (, P < 0.05; , P < 0.005, and , P < 0.0005).
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451 regulate stress-induced immune responses mediated by the
452 NKG2D receptor (35). It has been recently reported that
453 frequent loss of miR-34a/miR-34c expression helps metastatic
455melanoma cells to escape the tumor immune surveillance by
456enhancing ULBP2 expression (36). Similarly, a report of Udea
457and colleagues indicate that dicer-regulatedmiR-222 andmiR-
Figure 6. Conﬁrmation of the identiﬁed miR-210 target genes. A, schematic view of miR-210 complementary sites (CS) in the 30 UTR of PTPN1, HOXA1, and
TP53I11 genes (predicted by miRanda). B, IGR-Heu cells were cotransfected with 10 nmol/L Pre-miR-CT or Pre-miR-210 and different pSI-Check-2
constructs. After 48 hours, cells were harvested and luciferase activities analyzed. All Renilla luciferase activities were normalized to the ﬁreﬂy luciferase
activity. pSI-PTPN1, pSI-HOXA1, pSI-TP53I11, and pSI-PIM1correspond to distinct fragments of PTPN1, HOXA1, TP53I11, andPIM130UTRcontainingmiR-
210 putative binding sites, respectively. pSI-check2was used as an empty vector control. C, IGR-Heu cells stably expressing pIRESneo-FLAG/HAAgo2were
cotransfectedwithpre-miR-210or pre-miR-CTandculturedunder normoxia (21%O2) for 24hours. Anti-HAantibodywasused to immunoprecipitate themiR-
210/HA-Ago2–containing complexes. Anti-IgG antibody was used as IP-CT (immunoprecipitation control). RNA was puriﬁed and speciﬁc mRNAs were
measured by SYBR GREEN qRT-PCR. D, B2M, GAPDH, and PIM1 did not display any signiﬁcant differences and thus were used for normalization. Data
represents 3 independent experiments with SD. Statistically signiﬁcant difference (indicated by asterisks) are shown (,P < 0.05; , P < 0.005; and
, P < 0.0005).
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460 339 promote resistance of cancer cells to CTLs by down
461 regulating ICAM and subsequently affecting immune regula-
462 tion (37).
463 To get more insight into how miR-210 confers resistance to
464 hypoxic tumor targets to CTL-mediated lysis, we conducted a
465 comprehensive transcriptome analysis to identify miR-210
466 target genes. Among these genes, E2F3, FGFRL1, and RAD52
467 have already been reported as validated targets of miR-210
468 involved in cell-cycle regulation and DNA repair (17, 38).
469 However, we observed no effect on cell-cycle regulation when
470 IGR-Heu cells were transfected with either anti-miR-210 or
471 pre-miR-210 (data not shown). We showed that the expression
472 levels of PTPN1, HOXA1, and TP53I11, were respectively upre-
473 gulated or downregulated following anti-miR-210 or pre-miR-
474 210 transfection in IGR-Heu cells. We also found that simul-
475 taneously silencing PTPN1, HOXA1, and TP53I11 resulted in a
476 dramatic decrease in target susceptibility to CTL-mediated
477 lysis. Among these 3 genes, PTPN1 has been shown to play a
478 role in immune regulation. PTPN1 is a negative regulator of
479 cytokine receptors and receptor tyrosine kinases in lympho-
480 hematopoietic cells (39). Knockdown of endogenous PTPN1
481 expression increases production of TNF-a, IL-6, and IFN-b in
482 TLR-triggered macrophages (40). PTPN1 has been shown to
483 function as a critical negative regulator of inﬂammatory
484 responses (41). In addition, PTPN1 and TP53I11 have been
485 reported to be involved in the regulation of cell survival and
486 apoptosis (42–46). HOXA1 has been shown to be involved in
487 cell proliferation and tumor initiation (30). It would be ofmajor
489interest to determine how these genes interfere with CTL-
490induced hypoxic tumor cell death.
491In conclusion, we provide evidence that hypoxia-induced
492miR-210 regulates tumor cell susceptibility to CTL-mediated
493lysis by a mechanism involving its downstream targets PTPN1,
494HOXA1, and TP53I11. Taken together, our studies show that
495miR-210 is mechanistically linked to the regulation of the
496antigen-speciﬁc tumor cell lysis and suggest that in addition
497to its potential as a prognostic biomarker, miR-210 may have
498therapeutic applications in the ﬁeld of cancer immunotherapy.
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DISCUSSION AND CONCLUSIONS 
A. Hypoxia-mediated inhibition of specific tumor cell lysis  
The efficacy of antitumor CTL critically depends on functional processing and presentation of 
tumor antigens by the malignant cells but also on their susceptibility to CTL-induced lysis. 
Tumor rejection in patients does not always follow successful induction of tumor-specific 
immune responses by cancer vaccine immunotherapy [342]. Even, if a strong and sustained 
cytotoxic response is induced, complex issues such as tumor evasion and selection of tumor 
resistant variants remain. In this respect solid tumor with disorganized, insufficient blood 
supply contains hypoxic cells that are resistant to classical cytotoxic treatments [357]. 
Hypoxia-induced HIF-1α is associated with a decrease in CTL-mediated tumor cell lysis 
Our results provided the first demonstration that tumor cells, through their adaptation to 
hypoxic stress, impede CTL cytotoxic activity independently of their potential to trigger CTL 
reactivity.  However, our data differ from earlier report of MacDonald [358]. This 
discrepancy may lie in the fact that the reported data were collected using mice system, CTLs 
generated in mixed leukocyte cultures  and hypoxic chambers whereas we respectively used 
human antigen specific CTL clone and hypoxic station. These observations are consistent 
with the notion that hypoxia-induced adaptive changes contribute to alterations that lend 
towards a surviving phenotype. Thus, it is conceivable to imagine that tumors frequently 
develop this specific strategy to shift the balance from immune surveillance to tolerance. In 
this context, the various strategies aimed at the induction of antitumor cytotoxic responses 
should consider the crucial role of tumor hypoxia as an additional antitumor mechanism of 
tumor escape that is partly involved in resistance of tumor cells to antigen specific 
cytotoxicity.  
Hypoxia confers resistance to CTL-mediated lysis by STAT3 and AKT phosphorylation  
It is well established that hypoxia-induced gene transcription promotes characteristic tumor 
adaptations, including resistance to cytotoxic treatments [2]. However, the mechanisms 
underlying this resistance still need deeper understanding. Although increasing evidence 
supports a link between hypoxia and resistance to apoptosis [359], the mechanism by which 
the hypoxic stress inhibits apoptosis is not well understood and remains unclear. In this regard 
it has been suggested that alterations in the Bcl-2 family of pro-apoptotic and anti-apoptotic 
proteins may play a role in this process [83]. In addition HIF-1α mediated increase in glucose 
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uptake has been also reported to play an important role in conferring apoptosis resistance and 
that its effect is mediated in part via Mcl-1 gene expression [360]. To gain a better 
understanding of the influence of hypoxia on non-small lung cancer cells resistance to CTLs, 
we asked whether it interferes with the expression of p53, survivin, AKT, and STAT3 
pathways. Under our experimental conditions, we failed to observe any p53 and survivin 
induction in hypoxic NSCLC suggesting that the expression of HIF-1α and these proteins may 
be coupled during the hypoxia response depending on the cell type tested and confirming the 
existence of a cell specific effect of hypoxia [361]. We observed that culture of IGR-Heu cells 
under hypoxic conditions resulted in a dramatic induction of STAT3 tyrosine phosphorylation 
and that SiRNA knock down of STAT3 resulted in an inhibition of HIF-1α induction. This 
suggests that STAT3 is an essential component of HIF-1 pathway under hypoxic conditions 
and fits with a recent report indicating that hypoxia-phosphorylated STAT3 up-regulates HIF-
1α stability through delaying protein degradation and accelerating protein synthesis in human 
renal cell carcinoma [345, 362].  
It is also important to note that STAT3 activation has been associated with cytokine-induced 
proliferation, anti-apoptosis, and transformation [363]. It should be noted that activated 
STAT3 in cancer cells does not just function as a mediator of intracellular signalling but also 
affects cell-cell interaction. In this respect it is now well established that that STAT3 
modulates the cross talk between tumor and immune cells [295, 364]. Very recently a novel 
small molecule inhibitor of STAT3 has been reported to reverse immune tolerance in 
malignant glioma patients [365]. It would be of interest to investigate the use of such an 
inhibitor to attenuate hypoxic tumor resistance to CTL-mediated cytotoxicity.  
VEGF is involved in STAT3 phosphorylation under hypoxia in tumor cells  
More interestingly, we have shown that VEGF neutralization resulted in the attenuation of 
hypoxic tumor target resistance to CTL-mediated killing and that hypoxia induced STAT3 
phosphorylation can be stimulated by autocrine signalling through VEGF.  In this regard, it is 
very likely that stat3 activation is associated with the regulation of target gene expression 
potentially involved in the alteration of hypoxic tumor target specific killing. Therefore, 
understanding how VEGF and other soluble factors may lead to STAT3 activation via the 
tumor microenvironment may provide a more effective cancer treatment strategy for hypoxic 
tumors with elevated p-STAT3 levels. This also suggests that reduction of VEGF release, a 
main immunosuppressive factor, in tumor microenvironment may favour induction of a 
stronger anti-tumor CTL response against tumors expressing VEGF receptors. Our studies are 
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in agreement with reports suggesting that inhibition of VEGF may be a valuable adjuvant in 
the immunotherapy of cancer [366] and indicating a synergy between tumor immunotherapy 
and anti-angiogenic therapy [367]. 
Our data provide evidence that hypoxia inhibits tumor specific lysis and suggest that it 
induces cellular adaptation that compromise the effectiveness of killer cells and point to the 
potential role of STAT3 in tumor adaptation induced by hypoxia. In this regard, better 
understanding of the tumor behaviour and its interplay with the killer cells in the context of 
the complexity and plasticity of a hypoxic microenvironment will be a critical determinant in 
a rational approach to tumor immunotherapy. Although resistance of tumor targets to killer 
cells is likely to be regulated by multiple factors [343], the data we present herein suggest that 
hypoxic microenvironment is an important determinant involved in the control of target 
sensitivity to CTL-mediated lysis. Therefore the possibility that novel approaches targeting 
HIF-1α and STAT3 with potent small molecule drugs, being actively developed, may provide 
an exciting novel approach for cancer immunotherapy. 
B. Autophagy and hypoxia-induced immune resistance 
Hypoxia is a common feature of solid tumors and a major limiting factor in successful cancer 
treatment [160]. Given the role of autophagy in induction of the adaptive immune system 
[349] and cellular survival under hypoxia [368], we sought to determine the molecular basis 
of the hypoxia/autophagy interaction and its interference with tumor cell survival and growth.  
Targeting hypoxia induced autophagy restores IGR-Heu tumor cell susceptibility to CTL-
mediated lysis 
We demonstrate that hypoxia-induced autophagy acts as a tumor cell resistance mechanism to 
specific T-cell-mediated lysis. Targeting autophagy was sufficient to significantly restore 
tumor cell susceptibility to CTL-mediated lysis. It has been suggested that the unfolded 
protein response (UPR) enhances the capacity of hypoxic tumor cells to activate autophagy by 
PERK and ATF4-dependent upregulation of Atg5 and LC3 mRNA [351]. This mechanism 
seems to be unlikely involved in the induction of autophagy in hypoxic IGR-Heu cells 
because there is no evidence for the activation of PERK and ATF4 and for the upregulation of 
Atg5 and LC3 mRNA. However, we demonstrate that hypoxia induces autophagy by 
BNIP3/BNIP3L-dependent displacement of the autophagy inhibitory complex Beclin1/Bcl-2 
[84].  
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Autophagy and ubiquitin proteasome system cooperate to regulate STAT3 phosphorylation 
in hypoxic IGR Heu cells. 
We attempted to investigate the role of autophagy in the regulation of tumor susceptibility to 
CTL-mediated lysis by blocking autophagy. While much still remains to be learned 
mechanistically, our data demonstrate that autophagy inhibition compromised the hypoxia-
dependent induction of pSTAT3. Consistent with the clearance function of autophagy, it is 
difficult to reconcile the idea that the autophagy machinery plays a role in a specific 
stabilization of pSTAT3 and/or pSrc. Indeed, it is now well documented that there is a 
crosstalk between the UPS and autophagy [369]. Based on our results we believe that the 
decreased level of pSTAT3 in hypoxic and autophagy defective IGR-Heu cells is related to its 
degradation by UPS. This was supported by our data demonstrating that hypoxia induces a 
polyubiquitination of pSTAT3 and our results showing that inhibition of UPS by bortezomib 
accumulates pSTAT3 in hypoxic and autophagy-defective IGR-Heu cells. It is noteworthy 
that a UPS-dependent degradation of phospho-p53 [370] and phospho-PKC-delta [371] has 
been previously described. The interplay between autophagy and UPS is mainly mediated by 
the adaptor protein p62/SQSTM1 which plays a role as a cargo for targeting proteins to 
proteasomes degradation and autophagy [372]. Because p62 is an autophagic substrate, an 
accumulation of this protein was observed in autophagy deficient cells. In this regard, it has 
been recently reported that an excess of p62 inhibits the clearance of ubiquitinated proteins 
destined for proteasomal degradation by delaying their delivery [372]. Our results show 
discrepancy with this mechanism as we show that the accumulation of p62 in autophagy 
defective cells correlates with a decrease, rather an accumulation, of pSTAT3 in hypoxic 
IGR-Heu cells, and targeting p62 in autophagy-defective cells reaccumulates pSTAT3. While 
additional work needs to be performed to clarify this discrepancy, one possible reason is that, 
degradation of p62 by autophagy in IGR-Heu cells under hypoxia could represent a feedback 
mechanism to restrict further autophagy and excessive destruction of proteins under hypoxia. 
Such a feedback mechanism has been recently described [373]. 
In vivo inhibition of autophagy potentiates the antitumor effect of tyrosinase-related 
protein-2 peptide vaccination 
Vaccine approaches have proven effective in enhancing antitumor immunity against tumor 
cells expressing targeted antigens in vitro [374]. However, clinical and animal studies have 
shown little success in the inhibition of tumor growth by vaccines [375]. One of the most 
important factors that could be responsible for this failure is the hypoxia-dependent activation 
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of prosurvival pathways. Inhibition of autophagy has been reported to sensitize tumor cells to 
cytotoxic treatments including anti-tumoral agents and irradiation [376]. In light of our in 
vitro observations, we asked whether targeting of hypoxia-induced autophagy could influence 
in vivo tumor growth. To address this issue, we used the transplantable murine melanoma 
B16-F10 cell line that expresses different tumor-associated antigens TAA, including TRP2. 
Our data showed that autophagy is primarily localized to tumor hypoxic regions as previously 
reported in other tumor models [351]. We also show that targeting autophagy reduced tumor 
growth which correlated with an increase in apoptosis. These observations are in agreement 
with recent reports indicating that inhibition of autophagy by HCQ inhibits in vitro cell 
growth and in vivo tumor growth via induction of apoptosis [377, 378]. Our results are also 
supported by several studies showing that inhibition of autophagy promotes cancer cell death 
[379] and potentiates anti-cancer treatments [350] [380]. HCQ has been used in vitro for the 
inhibition of autophagy in several tumor models including melanoma [381] and is currently 
being tested in different ongoing Phase II studies [382].  
Finally with regards to potential therapeutic treatment, we show that the combination of TRP2 
peptide vaccination with HCQ treatment results in a strong inhibition of tumor growth. These 
observations further establish the significance of hypoxia in inducing autophagy, demonstrate 
that it is an adverse prognostic factor and confirm its critical role not only in radio- and 
chemoresistance but also in immune effector cell-resistance. A better understanding of the 
hypoxic tumor context is likely to improve the prospect of developing effective cancer 
immunotherapy. Together, our results show that targeting autophagy could have significant 
therapeutical implications for tumor progression and extend the notion that simultaneously 
boosting the immune system and targeting of autophagy could enhance the therapeutic 
efficacy of cancer vaccines and may prove beneficial in cancer immunotherapy.  
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PERSPECTIVES 
Cancer vaccines are expected to augment already established anti-tumor immune responses 
and to induce de novo immunity or reverse tolerance. Even, if a strong and sustained 
cytotoxic response is induced, complex issues remain such as tumor evasion, tolerance and 
selection of tumor resistant variants [374, 375] [270]. The hypoxia’s critical role in 
radioresistance, chemoresistance, tumor stemness and its significance as an adverse prognosis 
factor have been well established [2].  In addition, a direct link between tumor hypoxia and 
tolerance through the recruitment of regulatory cells has been established [339]. Hypoxia is 
therefore attracting a particular attention in the field of tumor immune biology since hypoxic 
stress impact angiogenesis, tumor progression and immune tolerance. Important questions 
remain to answer as how hypoxia favors the emergence of a resistant phenotype? Whether 
such phenotype is resistant to anti-tumor immune effectors? And how peripheral immune 
tolerance and hypoxic programs are closely connected and cooperate under hypoxic 
conditions to sustain tumor growth?  
Hypoxia-mediated inhibition of specific tumor cell lysis  
Although we have clearly shown that the concomitant hypoxic induction of pSTAT3 and HIF-
1α are functionally linked to the alteration of NSCLC target susceptibility to CTL-mediated 
killing, the mechanisms underlying this resistance still need a deeper understanding and a 
number of issues need to be further investigated.   
We have already observed that hypoxic tumor targets are resistant to Granzyme B, it would be 
interesting to investigate the molecular mechanisms underlying this resistance, more 
importantly the activation of caspases (caspase3 and caspase8), p53 accumulation, the pro-
apoptotic genes (IAPs, survivin, Mcl-1, Bcl-xL and Bcl2 family members) and various 
regulators of mitochondrial apoptotic pathway? It would be of great interest to investigate the 
effect of in-vivo inhibition of tumor hypoxia on the antitumor cytotoxic response (quality and 
quantity of tumor infiltra-CD8, Treg and MDSC) after vaccination under the conditions of 
hypoxia inhibition. 
Considering the eminent functions of STAT3 and HIF-1α in the tumor microenvironment, 
their targeting by potent small molecules, being actively developed, may provide an exciting 
novel approach for cancer immunotherapy. 
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Autophagy and hypoxia-induced immune resistance 
We have shown that hypoxia-induced autophagy impairs CTL-mediated tumor cell lysis by 
regulating phospho-STAT3 in target cells. More interestingly, simultaneous boosting of the 
CTL-response (TRP2-peptide vaccination) and targeting autophagy in hypoxic tumors, 
improved the efficacy of cancer vaccines by promoting tumor regression in vivo.  
Transgenic mouse models of spontaneous oncogene-driven tumors that are deficient in 
autophagy could be useful to explore the impact of the hypoxic tumor microenvironment and 
autophagy inhibition on the antitumor immune responses. Very recently, Michaud et al. have 
shown that in mice, chemotherapy-induced autophagy causes can stimulate antitumor immune 
responses [383]. It would be interesting to study whether the inhibition of autophagy directly 
by autophagy inhibitors like hydroxychloroquine (HCQ) or indirectly by targeting hypoxia 
(HIF-1α inhibitors) will affect other parameters of the anti-tumor immunity like CD8 T 
lymphocyte activity in vivo and in vitro (i.e., cytokine production, proliferation, activation, 
etc.). Several other important mediators of immune tolerance like MDSC and T regulatory 
cells (recruitment, function and differentiation) should also be studied. Autophagy inhibition 
in hypoxic tumors can be used as a cutting-edge approach to improve cancer immunotherapy 
and to formulate more effective cancer vaccine-based therapy.   
micoRNA-210 (miR-210) and hypoxia-induced immune resistance   
Although we provide evidence that hypoxia-induced miR-210 regulates tumor cell 
susceptibility to CTL-mediated lysis by a mechanism involving its downstream targets PTPN, 
HOXA1, and TP53I11, a number of important questions remains unanswered. It is still 
unclear how the simultaneous inhibition of these PTPN, HOXA1, and TP53I11 results in 
resistance to CTL-mediated killing. Do these genes differentially regulate the activation of 
caspases (caspase3 and caspase8), p53 accumulation, the pro-apoptotic genes (IAPs, survivin, 
Mcl-1, Bcl-xL and Bcl-2 family members) and various regulators of mitochondrial apoptotic 
pathway?  
We strongly believe that by modulating tumor hypoxia (inhibition of HIF-1α, P-STAT3 and 
autophagy or miR-210), we will be able to inhibit tumor growth, reverse immunosuppressive 
microenvironment (by decreasing T reg, MDSC and favouring CD8 T lymphocyte 
infiltration) and modulate anti-tumor immune response (by increasing anti-tumor CD8 
effector response) to achieve their killing activity.  
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Hypoxia-Dependent Inhibition of Tumor Cell Susceptibility to
CTL-Mediated Lysis Involves NANOG Induction in Target
Cells
Meriem Hasmim,* Muhammad Zaeem Noman,* Jessica Lauriol,† Houssem Benlalam,*
Aude Mallavialle,‡ Filippo Rosselli,x Fathia Mami-Chouaib,* Catherine Alcaide-Loridan,†
and Salem Chouaib*
Hypoxia is a major feature of the solid tumor microenvironment and is known to be associated with tumor progression and poor
clinical outcome. Recently, we reported that hypoxia protects human non-small cell lung tumor cells from specific lysis by stabilizing
hypoxia-inducible factor-1a and inducing STAT3 phosphorylation. In this study, we show that NANOG, a transcription factor
associated with stem cell self renewal, is a new mediator of hypoxia-induced resistance to specific lysis. Our data indicate that
under hypoxic conditions, NANOG is induced at both transcriptional and translational levels. Knockdown of the NANOG gene in
hypoxic tumor cells is able to significantly attenuate hypoxia-induced tumor resistance to CTL-dependent killing. Such knock-
down correlates with an increase of target cell death and an inhibition of hypoxia-induced delay of DNA replication in these cells.
Interestingly, NANOG depletion results in inhibition of STAT3 phosphorylation and nuclear translocation. To our knowledge, this
study is the first to show that hypoxia-induced NANOG plays a critical role in tumor cell response to hypoxia and promotes tumor
cell resistance to Ag-specific lysis. The Journal of Immunology, 2011, 187: 4031–4039.
T
he tumor microenvironment is an integral part of tumor
physiology, structure, and function, playing a critical role
in tumor cell survival and growth and contributing to cell
transformation and tumor development. Indeed, it is well estab-
lished that a disrupted relationship between tumoral and stromal
cells is essential for tumor cell growth, progression, and de-
velopment (1), suggesting that an improved understanding of this
interaction may provide new and valuable clinical targets for
controlling tumor progression.
Tissue oxygenation is an important component of the micro-
environment and can acutely alter cell behavior through the direct
regulation of genes involved in cell survival, apoptosis, glucose
metabolism, and angiogenesis (2). Evidence indicates that hyp-
oxia, defined as oxygen deprivation, is an important feature of the
microenvironment of a wide range of solid tumors. Its critical role
in radio- and chemoresistance and its significance as an adverse
prognosis factor have been well established during the last deca-
des (2). Hypoxia has been shown to induce the loss of differen-
tiation markers of several tumor types while increasing the ex-
pression of embryonic markers such as the transcription factors
NANOG, octamer-binding transcription factor (OCT) 4, SOX2,
and the Notch ligand (3, 4). This reprogramming of non-stem
cancer cells toward a cancer stem phenotype is associated with
increased tumorigenic capacity (4).
At a cellular level, hypoxia evokes a complexmolecular response
mainly characterized by changes in gene expression that are me-
diated by hypoxia-inducible factors (HIFs) (2). The HIFs are het-
erodimers that consist of a and b subunits. Three isoforms of the a
subunit are described: HIF-1a, HIF-2a, and HIF-3a (2). Under
hypoxic conditions, the a subunit is stabilized and activated and
binds the HIFb isoform, which is not regulated by oxygen levels
and is constitutively present in the nucleus (2). A broad range of
tumors respond to hypoxia by stabilizing the HIF-1a subunit (5).
In a previous study, we reported that tumor hypoxia decreases
tumor susceptibility to CTL-mediated lysis via HIF-1a stabi-
lization and STAT3 phosphorylation (6). Although it has been
reported that tumor stem cells were intrinsically susceptible to
immune effector cell cytotoxicity (7), the effects of hypoxia-
driven tumor dedifferentiation on the response to CTL-mediated
lysis have not been reported.
NANOG, a homeodomain-containing protein expressed in
embryonic cells, germ cells, and pluripotent stem cells, has the
ability when overexpressed to inhibit in vitro embryonic stem
cell differentiation and maintain their self-renewal capability
independently of the LIF/gp130/STAT3 pathway (8). In human
cancers, NANOG expression has been found in germ cell tumors
where NANOG functions are required, and it has been reported
to increase in several tumoral tissues (breast, prostate, kidney)
compared with matched benign tissues (9). Although accumulat-
ing evidence suggests that the protumoral functions of NANOG
rely on promoting tumor cell proliferation (9), stimulation of
STAT3 transcriptional activity has also been reported, leading to
tumor resistance to chemotherapy and improved cell survival (10).
In line with these reports, NANOG expression in head and neck
cancers has recently been associated with unfavorable clinical
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outcome (11). However, whether NANOG interferes with tumor
cell susceptibility to CTL-mediated cytotoxicity is not yet known.
The present study shows that hypoxia increases NANOG ex-
pression in non-small cell lung carcinoma cells and that this in-
duction contributes to hypoxia-induced tumor target resistance to
CTL-mediated lysis. Such induction is also associated with the
regulation of cell replication and of nuclear translocation of
STAT3. Our findings provide new insights into understanding the
role of hypoxia-induced NANOG in regulating the cellular re-
sponse to hypoxia and tumor target susceptibility to CTL-dependent
killing.
Materials and Methods
Culture of tumor cells and CTL
The IGR-Heu lung carcinoma cell line was derived and maintained in
culture as described previously (12). Briefly, the cells were grown in
DMEM/F12 medium supplemented with 10% heat-inactivated FCS, 1%
Ultroser G, 1% penicillin-streptomycin, and 1 mM sodium pyruvate (Life
Technologies, Cergy Pontoise, France). The Heu161 cytotoxic T cell clone
was derived from autologous tumor-infiltrating lymphocytes (13).
Reagents and Abs
Protease inhibitors and sodium orthovanadate were purchased from Roche
Molecular Biochemicals. Abs against CD133 and OCT4 were from Abcam.
Abs against NANOG were purchased from Santa Cruz Biotechnology (for
Western blotting) and R&D Systems (for confocal microscopy). Ab against
HIF-1a was from BD Transduction Laboratories. Abs against total STAT3,
phospho-STAT3 (STAT3Y705), total Src, and phosphor-Src (Y416) were
from Cell Signaling Technology. Abs against b-actin and GAPDH were
from Sigma-Aldrich.
Hypoxia treatment
For hypoxia treatment, cell cultures were incubated in a hypoxia chamber
(Invivo2 400 hypoxia workstation; Ruskinn) with a humidified atmosphere
containing 5% CO2, 01% O2, and 94% N2 at 37˚C (14). Cells were ex-
posed to these hypoxic conditions for 24, 48, and 72 h. Cells for protein
analysis were harvested while inside the hypoxia workstation and were not
reoxygenated before harvesting.
Flow cytometry analysis
Flow cytometry analysis was performed using a FACSCalibur flow cyto-
meter. Data were processed using CellQuest software (BD Biosciences).
Anti-HLA class I (W6/32) Ab was used as reported previously (15).
RNA extraction and quantitative real-time PCR
Total RNA was extracted using TRIzol (Sigma-Aldrich) following the
manufacturer’s instructions. For quantification of OCT4, NANOG, and
hairy and enhancer of split (HES) 1 expression, cDNA was synthesized
from 1 mg mRNA using an Applied Biosystems kit (N808-0234). Real-
time PCR analysis was performed using a LightCycler (Roche Applied
Science, Meylan, France) and the LightCycler-FastStart DNA Master
SYBR Green I mix (Roche Applied Science) according to the manu-
facturer’s instructions with an initial denaturation step at 95˚C for 10 min,
followed by 45 cycles at 95˚C for 10 s and annealing at specific temper-
ature for 10 s and at 72˚C for 10s. Primers used for NANOG, OCT4, and
HES1 amplification were: NANOG forward, 59-CAGCTGTGTGTACT-
CAATGATAGA-39, reverse, 59-ACACCATTGCTATTCTTCGGCCAG-39;
OCT4 forward, 59-ACATCAAAGCTCTGCAGAAAGAACT-39, reverse,
59-CTGAATACCTTCCCAAATAGAACCC-39; HES1 forward, 59-AGG-
CGGCACTTCTGGAAATG-39, reverse, 59-CGGTACTTCCCCAGCAC-
ACTT-39 (at a 63˚C annealing temperature). Specificity of PCR amplicons
was confirmed by melting curve analysis. Expressions of target genes were
normalized to that of RPL13. Relative expression of tested genes was
calculated using the target threshold cycle value (Ct) and the 22DCt
method. For each gene, values were averaged over three independent
measurements and the relative transcript level was calculated.
For quantification of apoptosis-related genes, reverse transcription was
performed using a high-capacity cDNA reverse transcription kit (Ambion).
Real-time PCR was done using Platinum SYBR Green qPCR SuperMix-
UDG w/ROX (Invitrogen) and an Applied Biosystems 7900HT Fast
real-time PCR system. Apoptosis-dedicated arrays were elaborated by the
PETC platform of INSERM Unite´ 576.
Western blotting
Adherent tumor cells were washed in 13 PBS and lysed in plates with lysis
buffer (62.5 mM Tris-HCl [pH 6.8], 2% w/v SDS, 10% glycerol, 1 mM
sodium orthovanadate, 2 mM PMSF, 25 mM leupeptin, 5 mM benzami-
dine, 1 mM pepstatin, 25 mM aprotinin). Lysates were sonicated on ice,
resolved by SDS-PAGE electrophoresis (60 mg/lane), and transferred onto
nitrocellulose membranes. After incubation in blocking buffer, the mem-
branes were probed overnight at 4˚C with the indicated Abs. The labeling
was visualized using peroxidase-conjugated secondary Abs and with an
ECL kit (Amersham International). Blots were scanned and processed by
Adobe Photoshop 7.0 software.
Cytotoxicity assay
Four-hour chromium release assays were performed as described previously
(6). Briefly, different E:T ratios were used on 1000 target cells per well
(round-bottom 96-well plates). After 4 h coculture, the supernatants were
transferred to LumaPlate-96 wells (PerkinElmer), dried down, and counted
on a Packard Instrument TopCount NXT. Percentage-specific cytotoxicity
was calculated conventionally as described earlier (6). All cytotoxicity
experiments with [51Cr] were performed under normoxic conditions.
TNF-b production assay
TNF-b release was measured as described previously (16). Briefly, TNF-b
was detected by measuring the cytotoxicity of the culture medium on the
TNF-sensitive WEHI-164c13 cells with an MTT colorimetric assay.
Confocal microscopy
Cells were plated in 8 well m-slide (Ibidi) and incubated for 24, 48, and
72 h at 37˚C and 01% partial pressure of O2 (pO2). Afterwards, cells were
washed twice in 13 PBS, fixed with 4% paraformaldehyde for 10 min,
permeabilized with 0.1% Triton X-100 for 10 min, and blocked for 45 min
with 0.1% Triton X-100, 10% FCS, and 1% BSA. After blocking, cells
were incubated overnight with diluted anti-STAT3Y705 and anti-NANOG
primary Abs, followed by incubation with Alexa 488 and Alexa 546
secondary Abs (Molecular Probes), respectively, in the dark for 1 h at room
temperature. Wells were covered with Fluoromount-G (SouthernBiotech,
Birmingham, AL) and analyzed the following day by a Zeiss laser scan-
ning confocal microscope (LSM-510; Zeiss, Jena, Germany). Z-projection
of slices was performed using LSM Image Examiner software (Zeiss).
Gene silencing
Gene silencing of NANOG was performed using sequence-specific small
interfering RNA (siRNA; Santa Cruz Biotechnology). Briefly, 8 3 106
cells were electroporated twice in 48 h in serum-free medium with 20 mM
siRNA in an EasyJect Plus electroporation system (EquiBio; 260 V, 450
mF) and then allowed to grow for 24, 48, and 72 h in hypoxia. siRNA
targeting luciferase was used as a negative control (59-GCAAGCUGACC-
CUGAAGUUCAU-39). Gene-specific targeting was evaluated by quanti-
tative real-time PCR (RT-qPCR) or Western blot.
Cell fractionation
For isolation of cytoplasmic and nuclear proteins, the ProteoJET cyto-
plasmic and nuclear protein extraction kit (Fermentas) was used following
the manufacturer’s instructions. Briefly, hypoxic or normoxic cells were
harvested after trypsinization and solubilized in lysis buffer with protease
inhibitors and DTT. After centrifugation, the cytoplasmic fraction was
isolated. Nuclear pellets were washed twice and then lysed in nuclear lysis
buffer added with protease inhibitors and DTT. Nuclear lysates were ob-
tained after centrifugation.
Cell cycle
Electroporated IGR-Heu cells were incubated in normoxia or hypoxia (01%
pO2) for 72 h. In the last 10 min, BrdU was added to the culture medium.
Then, cells were harvested and fixed in 80% ice-cold ethanol. For BrdU
detection, DNA was first denaturated in a pepsine buffer (0.5 mg/ml
pepsine, 2 N 30 mM HCl) for 20 min at 37˚C. Cell pellets were then
resuspended in 2 N HCl for 20 min at room temperature. After washing in
ice-cold 13 PBS, detection of replicating cells was performed by BrdU
staining. Cells were washed in BrdU detection buffer (0.5% FCS, 0.5%
Tween 20, 20 mM HEPES in 13 PBS) and BrdU was detected in the dark
using a specific primary Ab for 45 min followed by a FITC-conjugated
secondary Ab. To detect total DNA, cell pellets were resuspended in
a propidium iodide solution (25 mg/ml propidium iodide, 50 mg/ml RNase
A in 13 PBS) and incubated in the dark at room temperature for 30 min.
Cells were then analyzed by flow cytometry.
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Statistical analyses
Data were analyzed with GraphPad Prism. A Student t test was used for single
comparisons. A p value of ,0.05 was considered statistically significant.
Results
The resistance of hypoxic tumor cells to CTL is not associated
with the acquisition of a stem cell-like phenotype
As previously reported, data depicted in Fig. 1A show that expo-
sure of the lung tumor cell line IGR-Heu to hypoxic treatment
resulted in an inhibition of its susceptibility to autologous CTL-
mediated killing. We next examined the relationship between
hypoxia-induced resistance to specific lysis and the adoption of
a stem cell-like phenotype. Indeed, cancer stem cells have been
shown to resist cell death induced by apoptotic and chemo- or
radiotherapeutic agents (17). For this purpose, we first investigated
the influence of hypoxic stress on the expression of the cell surface
protein CD133 and the cytosolic enzyme aldehyde dehydrogenase
(ALDH) 1. These two markers are respectively associated with
lung cancer stem cell proliferation and chemoresistance (18–20).
FIGURE 1. Hypoxia-induced resistance to specific lysis is not associated with the acquisition of a dedifferentiated phenotype. A, IGR-Heu cells were
incubated in hypoxia (01% pO2) or normoxia for 48 h and CTL-mediated lysis was measured by a conventional 4-h
51Cr-release assay at different ratios.
Cells from the Heu161 tumor-infiltrating lymphocyte-derived T cell clone were used as effectors. Data show the percentage of IGR-Heu–specific lysis of
three independent experiments 6 SD. B, Expression level of CD133 was compared between IGR-Heu cells incubated in normoxia or hypoxia for the
indicated times. a, Cell surface expression was analyzed by cytometry and (b) total expression was evaluated by Western blot using a specific Ab. c,
Influence of hypoxia on ALDH1 expression in IGR-Heu cells was analyzed by Western blot in total cellular extracts. b-actin was used as a loading control.
Results are representative of three experiments with similar results. C, Influence of hypoxic stress on EMT induction in IGR-Heu cells. a, E-cadherin and
Snail expression levels following exposure to hypoxia for 24, 48, and 72 h were evaluated by Western blot using specific Abs. Equal protein loading was
assessed using b-actin. b, IGR-Heu cells incubated in hypoxia for the indicated times were stained by rhodamine-phalloidin to visualize cell morphology.
Images shown are representative of most of the analyzed cells. Experiments were carried out three times.
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Flow cytometry analysis indicated that hypoxia did not affect the
cell surface expression of CD133 (Fig. 1Ba). Most of the IGR-Heu
cells express CD133 constitutively, suggesting that CD133 may
not be an exhaustive marker for detection of stem cell-like tumor
cells. Total cellular extracts were analyzed by Western blot, and
expression levels of CD133 (Fig. 1Bb) and ALDH1 (Fig. 1Bc)
were not influenced by exposure to hypoxic stress. Because epi-
thelial to mesenchymal transition (EMT) has been reported to be
associated with both acquisition of an immature phenotype (21)
and hypoxic stress (22), we investigated the induction of EMT in
hypoxic IGR-Heu cells. The expression of the epithelial marker
E-cadherin and of the EMT activator Snail, which is also an
important regulator of E-cadherin expression (23), was analyzed.
Fig. 1Ca shows that the total expression of E-cadherin, as well as
surface E-cadherin expression (data not shown), remained un-
changed after 72 h exposure to hypoxia. In contrast, Snail ex-
pression was significantly decreased after 24 h hypoxia (Fig. 1Ca).
Because EMT is associated with morphological changes resulting
in a distinct elongated phenotype, cell morphology of hypoxic
IGR-Heu cells was therefore visualized by phalloidin staining.
Data shown in Fig. 1Cb indicate that hypoxia had no effect on
IGR-Heu morphology for up to 72 h. Phalloidin staining also
showed the absence of cell rounding, which is a morphological
feature associated with the acquisition of immature phenotypes
(24). These results indicate that hypoxia-induced tumor resistance
was not associated with the acquisition of a stem cell-like phe-
notype in IGR-Heu cells.
NANOG is selectively induced in hypoxic tumor cells
Although hypoxic stress did not result in phenotypic changes in
IGR-Heu cells, hypoxia-induced dedifferentiation may be asso-
ciated with altered expression of specific genes. Thus, to evaluate
the potential role of dedifferentiation genes in hypoxic tumor cells,
we selected OCT4 and NANOG genes, as well as HES1, a Notch
target gene, based on their increased expression under hypoxia
(4, 25, 26) as well as their reported role in the control of stem
cell self-renewal and multipotency (27–29). Using RT-qPCR, we
measured their respective mRNA levels under hypoxic conditions
and found that OCT4 and NANOG mRNAs but not HES1 mRNA
markedly increased following exposure to hypoxia for 24, 48, and
72 h (Fig. 2A). Whereas Western blot analysis did not reveal
OCT4 expression (data not shown), fitting with its marginal
mRNA levels under hypoxia, NANOG protein was induced up
to 72 h hypoxia (Fig. 2B). This was confirmed by confocal
FIGURE 2. Hypoxic stress leads to
selective induction of NANOG expres-
sion via HIF-1a. A, Hypoxia effects on
mRNA expression levels of OCT4,
NANOG, and HES-1 genes measured by
RT-qPCR. B, IGR-Heu tumor cells were
incubated in normoxia or hypoxia for
different intervals. After hypoxia expo-
sure, total cell lysates (60 mg) were
subjected to SDS-PAGE, blotted, and
probed with specific Abs against HIF-
1a, HIF-2a, and NANOG, as indicated.
b-actin was used as the loading control.
C and D, Western blot analysis of
NANOG expression levels under hypoxia
following specific inhibition of HIF-1a
(C) or HIF-2a (D) expression by siRNA.
Each experiment was repeated at least
three times. NE, non-electroporated; siH1,
anti–HIF1-a siRNA1; siH2, anti–HIF1-a
siRNA2; siLuc, anti-luciferase siRNA.
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microscopy analysis, which revealed increased staining of
NANOG along with the time of exposure to hypoxia (data not
shown). Fig. 2B also showed that the induction of NANOG un-
der hypoxia correlated with HIF-1a and HIF-2a stabilization. To
delineate the potential link between hypoxia-induced NANOG
and HIF-1a or HIF-2a, NANOG protein expression was analyzed
following HIF-1a or HIF-2a knockdown using specific siRNAs.
As shown in Fig. 2C, specific silencing of HIF-1a resulted in the
inhibition of hypoxia-induced NANOG after 24, 48, and 72 h of
hypoxic stress whereas HIF-2a silencing had no effect (Fig. 2D).
These results indicate that hypoxia-induced NANOG was de-
pendent on HIF-1a and raise the possibility that NANOG may
play a role in the acquisition of tumor cell resistance to CTL lysis
under hypoxic conditions.
Attenuation of hypoxia-induced tumor resistance to
CTL-mediated killing following NANOG knockdown
To delineate the role of NANOG induction in hypoxia-mediated
tumor cell resistance to specific lysis, we investigated the sus-
ceptibility of NANOG-targeted IGR-Heu cells using siRNA under
hypoxic conditions. The inhibition of NANOG in hypoxic tumor
cells was performed using specific siRNA and confirmed by RT-
qPCR, showing an efficient and specific inhibition of NANOG
mRNA expression after 72 h hypoxia, whereas luciferase siRNA
used as a control had no effect on NANOG mRNA level (Fig. 3A).
As shown in Fig. 3B, NANOG knockdown in hypoxic IGR-Heu
cells was associated with sensitization of IGR-Heu cells to CTL-
mediated lysis following 48 h exposure to hypoxia as compared
with control hypoxic cells. We also show that the targeting of
NANOG in hypoxic IGR-Heu cells was not associated with an
alteration in autologous CTL reactivity, as TNF-b secretion by
CTL was not affected (Fig. 3C). Moreover, such targeting did not
alter MHC class I expression in IGR-Heu cells (Fig. 3D). This is
consistent with the fact that attenuation of hypoxia-induced tumor
cell resistance following NANOG targeting was not due to an
alteration in CTL reactivity and target cell recognition.
NANOG targeting increases cell death and interferes with cell
cycle transition in hypoxic tumor cells
To investigate the molecular mechanisms associated with the
attenuation of target cell resistance to CTL following NANOG
targeting under hypoxic conditions, we analyzed the expression of
a series of antiapoptotic and proapoptotic genes using an apoptosis-
related array of 94 genes. NANOG knockdown in hypoxic tumor
FIGURE 3. NANOG knockdown
restores tumor cell susceptibility to
lysis by CTL in hypoxia. A, NANOG
expression was silenced using spe-
cific siRNA administered by elec-
troporation. Silencing efficiency was
assessed by RT-qPCR after 48 h
hypoxia. B, Role of NANOG in
CTL-mediated lysis toward autolo-
gous IGR-Heu tumor cells. IGR-Heu
tumor cells were electroporated with
NANOG or luciferase siRNAs and
kept in normoxia (21% pO2) and
hypoxia (01% pO2) for 48 h. Cyto-
toxicity was determined by a con-
ventional 4-h 51Cr-release assay at
different ratios. Heu161 CTL clone
cells were used as effectors. Data
show the percentage of IGR-Heu–
specific lysis of three independent
experiments 6 SD. C, TNF-b pro-
duction by the autologous T cell clone
in response to stimulation by non-
electroporated, control, and NANOG-
deficient IGR-Heu cells. CTL clone
Heu161 cells were cocultured in the
presence of IGR-Heu cells placed in
normoxia (21% pO2) versus hypoxia
(01% pO2) for 48h. The amount of
TNF-b produced by the CTL clone
was measured using the TNF-sensi-
tive WEHI-164c13 cells. Each bar is
the mean of three independent ex-
periments 6 SD. D, Comparative
analysis of surface expression of
HLA class I (W6/32) conducted on
control and NANOG-deficient IGR-
Heu tumor cells kept in hypoxia
(01% pO2) for 48 h. Isotypic control
of mAb was included (IgG). Results
are representative of three indepen-
dent experiments. NE, nonelectropo-
rated; siRNA Luc, luciferase siRNA.
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cells revealed an increase in the expression of proapoptotic and
antiapoptotic genes (Fig. 4A). However, NANOG depletion in
hypoxic cells resulted in a limited but consistent increase in both
apoptotic (sub-G1) and nonreplicating (S-BrdU-negative) cells,
suggesting that one of the roles of NANOG in hypoxia is to
sustain cell viability (Fig. 4B). Additionally, flow cytometry
analysis of BrdU-labeled cells revealed that hypoxia modified the
overall level of nucleotides incorporation (Fig. 4Bb). Indeed, we
FIGURE 4. NANOG knockdown increases cell death and restores BrdU incorporation in hypoxic tumor cells. A, Pro- and antiapoptotic gene transcript
quantification by qPCR using a 94 apoptosis dedicated array. Ba, Sub-G1 cell quantification by flow cytometry based on propidium iodide incorporation in
hypoxic control and NANOG knocked down IGR-Heu cells. A statistically significant difference in sub-G1 cell percentage between hypoxic control and
NANOG-targeted cells was observed. *p , 0.05. Bb, Cells were gated according to their DNA content, propidium iodide incorporation (x-axis), and their
capability to incorporate BrdU during S phase (y-axis). Red indicates cells in G0/G1 (lower left) and G2/M (lower right). Cells in blue indicate S-phase
BrdU-negative cells, that is, cells showing an S-phase DNA content but unable to replicate their DNA and incorporate BrdU. Green and purple identify
replicating S-phase cells. The gated BrdU-positive cells were arbitrarily separated in two fractions as a function of their capability to incoporate BrdU.
Green indicates cells with low replication capabilities, as a consequence of the accumulation of slowing DNA replication forks, the decrease in the number
of active DNA replication forks, or both. Purple represents the fraction of cells able to replicate their DNA at a normal rate. Numeric values correspond to
the percentage of gated cells that have incorporated BrdU at a normal and a low level. They are indicated with the corresponding color. Results are
representative of two independent experiments.
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noticed the appearance of a cell subpopulation characterized by
lower BrdU incorporation. This subpopulation represented the
majority of S-phase cells in hypoxic conditions. Importantly,
NANOG depletion restored a cell cycle profile similar to that
observed in normoxic conditions. These results indicate that
NANOG knockdown in hypoxic tumor cells correlates with in-
creased replication levels, an event associated to and responsible
for DNA damage and apoptosis (30).
Regulation of STAT3 phosphorylation and nuclear
translocation by NANOG
We have recently shown that hypoxia-induced resistance of IGR-
Heu cells to specific lysis was critically dependent on STAT3
phosphorylation (6). Additionally, a functional cooperation be-
tween STAT3 and NANOG for gene transcription has been
reported in cancer drug resistance (10). Therefore, we asked
whether a functional interaction exists between NANOG and
FIGURE 5. NANOG knock down inhibits hypoxia-induced STAT3 phoshorylation and its nuclear translocation. A, Western blot analysis of the influence
of NANOG silencing on STAT3 and Src phosphorylation during hypoxic stress. After 48 h exposure to hypoxia, 60 mg total protein extracts were run with
b-actin used as the loading control. B, Luciferase siRNA- and siRNA-NANOG–electroporated IGR-Heu cells were kept in hypoxia for 24, 48, and 72 h and
cell lysates were fractionated in cytoplamsic and nuclear fractions following the manufacturer’s instructions. GAPDH was used for technical control and, as
expected, it was respectively found mainly in the cytosol for both luciferase siRNA- and siRNA-NANOG–electroporated IGR-Heu cells. Equal loading was
confirmed by b-actin blotting. C, Confocal microscopy analysis of pSTAT3-Y705 staining in NANOG-deficient IGR-Heu tumor cells kept in normoxia
(21% pO2) versus hypoxia (01% pO2), followed by immunofluorescence staining with pSTAT3-Y705–specific Ab. Nuclei were counterstained with To-Pro-
3 iodide. Rainbow panel indicates staining intensity (blue to red correspond, respectively, from low to high intensity). The confocal scanning fluorescence
micrographs shown are representative of most of the cells analyzed (blue, nucleus; green, pSTAT3-Y705). Experiments were performed at least three times.
Scale bars, 20 mm. siRNA Luc, luciferase siRNA.
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STAT3 upon hypoxic stress. Fig. 5A indicates that silencing of
hypoxia-induced NANOG resulted in an inhibition of STAT3
phosphorylation on Tyr705, a crucial event for STAT3 dimerization
and translocation to the nucleus (31). We next examined in hyp-
oxic NANOG-downregulated cells the phosphorylation state of
JAK2 and Src, two kinases involved in STAT3 phosphorylation
(32) (33). Results indicate that NANOG downregulation under
48 h hypoxia resulted in selective inhibition of Src (Fig. 5A) but
had no effect on JAK phosphorylation (data not shown).
Phosphorylation of STAT3-Y705 is crucial for STAT3 trans-
location to the nucleus (31). However, unphosphorylated nuclear
forms of STAT3 have already been described (34). Therefore we
investigated the role of NANOG on STAT3 nuclear translocation
in hypoxic IGR-Heu cells using siRNA-targeting NANOG. Fig.
5B indicates that knocking down NANOG in hypoxic NANOG-
targeted IGR-Heu cells suppressed STAT3 phosphorylation and its
subsequent translocation into the nucleus after 24, 48, and 72 h
of hypoxic stress. In contrast, in control hypoxic cells, phos-
phorylated STAT3 was induced and located in nuclear fractions. It
also shows that in NANOG-targeted and control cells, hypoxia-
induced NANOG did not translocate to the nucleus but remained
in the cytoplasm (Fig. 5B). Confocal microscopy analysis indi-
cated a constant decrease of pSTAT3-Y705 nuclear staining in
siRNA-NANOG–treated IGR-Heu cells under 24, 48, and 72 h
hypoxia compared with control cells (Fig. 5C). This further points
to the role of NANOG in STAT3 phosphorylation on Y705.
Discussion
It is well established that microenvironmental factors, in parti-
cular hypoxia, act to shift the normal balance toward malignancy.
Accumulating evidence indicates that cancer cells that remain
viable in hypoxic conditions often possess an increased survival
potential and tend to grow particularly aggressively. Hypoxia in-
duces tumor progression through multiple mechanisms, including
several transcriptional programs (2). In this study we show, in hu-
man non-small cell lung carcinoma cells, that hypoxic stress se-
lectively induces the stem cell marker NANOG, which is involved
in the hypoxia-mediated resistance to specific lysis. Hypoxia-
induced NANOG has the ability to control the expression of a
series of proapoptotic genes, to regulate cell replication, and to
contribute to STAT3 and Src phosphorylation.
The selective increase in NANOG expression under hypoxia was
not associated with alteration of CD133 or ALDH1 expression,
two reported markers for lung cancer stem cells (20). Additionally,
IGR-Heu cells did not lose their epithelial features under hypoxia,
as Snail expression was decreased and E-cadherin level remained
unchanged in IGR-Heu hypoxic cells. Whether Snail decrease is
due to transcriptional repression or increased degradation fol-
lowing hypoxic stress is currently under investigation. Nonethe-
less, this suggests that in our experimental system, tumor cells did
not undergo a phenotypic dedifferentiation but indeed displayed
increased expression of NANOG, a transcription factor associated
with stemness. NANOG induction in hypoxia has been recently
reported (4, 35, 36), suggesting its putative involvement in cell
adaptation to hypoxic stress. In this regard, it has been shown that
NANOG possesses proangiogenic activities by controlling vas-
cular endothelial growth receptor-2 expression in endothelial cells
(37). Although induction of this transcription factor under hyp-
oxia is usually described to be dependent on HIF-2 in cancer stem
cells (38, 39) and embryonic stem cells (35), our results clearly
indicate that only HIF-1a selectively regulates NANOG induction
in our experimental model.
To determine the functional relevance of NANOG in hypoxic
tumor resistance to CTL-mediated lysis, we targeted NANOG and
found that it resulted in the attenuation of target resistance to
CTL-mediated killing. How this transcription factor regulates tumor
susceptibility to lysis is not yet established. Nevertheless, our data
considering the relevance of NANOG induction following hypoxic
stress support the idea that NANOG is a significant mediator of the
adaptive cellular response to hypoxia. NANOG has been reported
to have antiapoptotic functions by inhibiting apoptosis in trans-
formed human stem cells (40) and choriocarcinoma cells (41).
NANOG targeting significantly increased the percentage of sub-
G1 dead cells, suggesting that hypoxia-induced NANOG has a
protective role on tumor cells. By analyzing cell cycle transition,
we show a decrease in BrdU incorporation under hypoxia. This
could be related to the activation of DNA repair processes sub-
sequent to DNA damage known to be induced by exposure to
hypoxia (42). Additionally, a major event in shifting cells form
normoxia to hypoxia is cell cycle arrest (43) (44). Interestingly,
our data show that NANOG knockdown restored BrdU incor-
poration in hypoxic cells, suggesting that NANOG, under con-
ditions of hypoxic stress, could be involved in the activation of
checkpoint signaling resulting in slowing down S phase. This is
supported by our finding that hypoxia induced p53 protein accu-
mulation and that this event was inhibited following NANOG
knocking down (data not shown). To further delineate the role
of NANOG in hypoxia, we explored the effect of NANOG on
hypoxia-induced STAT3 activation. Bourguignon et al. (10)
demonstrated functional cooperation of NANOG with activated
STAT3 in inducing expression of the chemoresistance gene
MDR1. Previously, we provided evidence indicating that STAT3
phosphorylation was a major event in the acquisition of hypoxic
tumor cell resistance to CTL-mediated killing (6). In the present
report, our data point to the potential role of NANOG in regulat-
ing STAT3 phosphorylation and its subsequent nuclear transloca-
tion. To our knowledge, this is the first demonstration involving a
functional interaction between NANOG and STAT3 in the regu-
lation of tumor cell susceptibility to CTL-dependent cytotoxicity.
More importantly, we showed that NANOG targeting resulted in
the inhibition of hypoxia-induced Src phosphorylation. Because
Src is known to be required for STAT3 phosphorylation (32, 33),
it is tempting to speculate that NANOG controls STAT3 phos-
phorylation by a mechanism involving Src phosphorylation under
hypoxia. This is in agreement with our recent observations show-
ing that chemical inhibition of Src phosphorylation in hypoxic
IGR-Heu cells was able to block hypoxia-induced STAT3 phos-
phorylation (45).
Along with inhibition of hypoxia-induced delay on cell repli-
cation levels, NANOG knockdown seems to allow hypoxic tumor
cells to gain a “normoxia-like” state that may shift CTL-resistant
hypoxic tumor cells to sensitive ones.
Collectively, these results point to a novel function of NANOG
and suggest the existence of a new relationship between stem cell
markers, hypoxia, and resistance to CTL-mediated lysis.
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Abstract. The tumor microenvironment is a com-
plex system playing an important role in tumor
development and progression. Besides tumor cells, the
tumor microenvironment harbours a variety of host-
derived cells, such as endothelial cells, ﬁbroblasts,
innate and adaptive immune cells, as well as extracellu-
lar matrix (ECM) ﬁbers, cytokines, and other mediators.
This review discusses the potential role of hypoxia and
endothelial cells within tumor microenvironment and
emphasizes their interaction with antigen speciﬁc killer
cells.
Key words: hypoxia, STAT3, HIF-1, endothelial cells, tumor
cells, CTLs
Introduction
Hypoxia is a common feature of solid tumors and one of
the hallmarks of tumor microenvironment [1]. In a solid
tumor microenvironment, a gradient of oxygen exists
which extends from well-oxygenated areas to hypoxic
areas and ﬁnally the necrotic areas where oxygen
concentration falls to zero [2].
Tumor cells adapt to hypoxic microenvironment by
the regulation of hypoxia inducible factor family of
transcription factors (HIF’s). This family is composed
of three members namely HIF-1, HIF-2 and HIF-3.
HIF-1 and HIF-2 has  and  subunits. HIF-1 is the
major player in mediating tumor hypoxic response
but HIF-2 is being implicated in participating in this
response. HIF-3 is only a negative regulator of HIF-1
and HIF-2. It is well established that intratumoral
hypoxia is the main inducer of HIF-1 but other
factors like genetic alteration (VHL mutations, etc) may
also contribute to the regulation of the stability of
HIF-1 [2]. A large body of clinical data shows a
positive correlation between increased hypoxic expres-
sion of HIF-1 and HIF-2 and patient’s mortality [3].
Both HIF-1 and HIF-2 have common target genes
as well as their respective target genes. The genes
induced by hypoxia dependent HIF-1 and HIF-2
play important roles in regulating different aspects of
tumor biology like angiogenesis, cell survival, chemo-
and radioresistance, proliferation, invasion and metas-
tasis, pH regulation and metabolism, resistance to
immune system and maintenance of cancer stem cells
[4, 5].
It is now well established that hypoxic tumor micro-
environment favours the emergence of tumor variants
with increased metastatic and invasive potential [6].
HIF-1 is believed to play a protective role under
hypoxic conditions [7, 8]. Since these tumor variants
are resistant to radiotherapy and chemotherapy, one
might postulate that the exposure to low-levels of
oxygen may lead to adaptive responses allowing tumor
cells to escape from immune surveillance. Fink et al.
reported inhibition of NK cytotoxicity toward liver
cell lines under hypoxic conditions [9]. Siemens et al.
have recently reported that hypoxia contributes to
tumor cell shedding of MIC (MHC class I chain-related
molecules) through a mechanism involving impaired
nitric oxide (NO) signalling [10].
An active and bi-directional molecular cross talk
between tumor cells and host cells has profound
implications for immunological recognition of tumor
cells and the formation of a microenvironment modu-
lating tumor progression [11, 12]. Several reports
[13] underscore the contribution of the microenvi-
ronment to tumor development and it has become
clear that tumors are not merely masses of neoplas-
tic cells, but instead, are complex tissues composed
of both non-cellular (matrix proteins) and cellular
components (tumor-associated ﬁbroblasts, capillary-
associated cells and inﬂammatory cells), in additiondo
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to the ever-evolving neoplastic cells. All of these com-
ponents might be involved in shaping the interactive
and migratory behavior of tumor-inﬁltrating T lym-
phocytes with and among tumor cells. In the context
of microenvironment complexity and plasticity, tumor
cells orchestrate the modiﬁcation of the microenvi-
ronment by attracting or activating many non-tumoral
cells, including blood and lymphatic endothelial cells,
ﬁbroblasts, bone marrow-derived cells, immune and
inﬂammatory cells [13]. It is now acknowledged that
tumor cells and their stroma co-evolve during tumorige-
nesis and progression. Besides, the critical importance
of the recruitment of endothelial cells by a tumor
to achieve tumor angiogenesis, leukocyte-endothelial
interactions within tumor microvasculature are criti-
cal for mounting a host immune response against tumor
tissue and for controlling tumor progression [14].
Recent evidences point at endothelial cell implication
in the indirect rejection of the tumor by the immune
system [15]. In fact, EC express the protein machinery
for antigen processing, including proteasome subunits,
TAP proteins, and both MHC classes I and II, and
can present endogenous peptides to activated T
cells. Several studies demonstrated the potential of
endothelial cells to cross-present exogenous antigens
from apoptotic tumor cells [16-18], or derived from
proteins secreted by surrounding cells or donated by
live cells interacting with the endothelium [19-21].
Recently, [22] it has been demonstrated that several
natural epitopes from an endogenous protein consti-
tutively expressed by endothelial cells, that is vascular
endothelial growth factor receptor-2 (VEGFR-2), were
presented in both HLA classes I and II [23].These obser-
vations clearly sustain the importance of endothelial
cells as “target” for the immune system.
Results
Inﬂuence of hypoxic stress on antitumor
cytotoxic response
Since hypoxia is a common feature of solid tumors and
one of the hallmarks of tumor microenvironment, it is
of interest to ﬁnd out whether hypoxia confers tumor
resistance to CTL-mediated killing. We have shown
[24] that indeed hypoxic exposure of target tumor cells
inhibits the CTL clone-induced autologous target cell
lysis. Interestingly the observed lysis inhibition was
not associated with an alteration of CTL reactivity and
tumor cell recognition indicating that tumor-induced
priming of the autologous CTL clone was not affected
after exposure to hypoxia.We further demonstrated that
HIF-1 induction and STAT3 activation are responsible
formediating hypoxia induced lysis inhibition [24].Our
results suggest a new role for hypoxia (HIF and STAT3)
in tumor resistance to the immune system. Here, we
discuss how these results add an important new facet
to our traditional view of hypoxia and cancer.
Role of hypoxia activated STAT3 in
modulating antitumor immune response
We show that hypoxia is directly implicated in the
acquisition of tumor cell resistance to CTL-mediated
lysis via HIF induction and STAT3 activation. Further-
more, STAT3 activation within tumor microenviron-
ment is known to be associated with cytokine-induced
proliferation, anti-apoptosis and transformation. More-
over, it is now well established that STAT3 modulates
the cross talk between tumor and immune cells
[25, 26]. More interestingly, we have shown that vas-
cular endothelial growth factor (VEGF) neutralization
resulted in the attenuation of hypoxic tumor target
resistance to CTL-mediated killing [24]. We have
also demonstrated that STAT3 phosphorylation can
be stimulated by autocrine signalling through VEGF
[24], suggesting that tumor microenvironment through
hypoxia-induced VEGF may play a key role in the
induction of active form of STAT3. In this regard, it
is very likely that STAT3 activation is associated with
the regulation of target gene expression potentially
involved in the alteration of hypoxic tumor target-
speciﬁc killing. Therefore, understanding how VEGF
and other soluble factors may lead to STAT3 activa-
tion via the tumor microenvironment may provide a
more effective cancer treatment strategy for hypoxic
tumors with elevated P-STAT3 levels. This also suggests
that reduction of VEGF release in tumor microenvi-
ronment may favour induction of a stronger antitumor
CTL response against tumors expressing VEGFR. Our
studies are in agreement with reports suggesting that
inhibition of VEGF may be a valuable adjuvant in the
immunotherapy of cancer [27] and indicating a synergy
between tumor immunotherapy and anti-angiogenic
therapy [28].
The consequence of hypoxic activation of STAT3
extends beyond its critical role in controlling cell sur-
vival and apoptosis. This emphasizes that a better
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understanding of the tumor behavior and its inter-
play with the killer cells inside a complex and
plastic hypoxic microenvironment will be a criti-
cal determinant for a rational approach of tumor
immunotherapy. Although resistance of tumor targets
to killer cells is likely to be regulated by multiple
factors [29], the data we present herein suggest that
hypoxic microenvironment is an important determi-
nant involved in the control of target sensitivity to
CTL-mediated lysis (ﬁgure 1). Therefore, the possibility
that novel approaches targeting HIF-1 and STAT3 with
potent small molecule drugs, being actively developed,
may provide an exciting novel approach for cancer
immunotherapy.
Endothelial cells targeted by
melanoma-speciﬁc cytotoxic T lymphocytes
The interaction of melanoma-derived endothelial cells
with autologous tumoral cells was investigated in the
presence of an autologous melanoma-speciﬁc T cell
clone. To better analyze these cellular interactions,
we set up a three-dimensional culture system (3D-
construct) based on collagen matrix containing these
cells derived from the same biopsy. This construct
presents many advantages in comparison to 2D-culture
environment:
• cell morphology and signalling are often more phy-
siological compared to routine 2D-cell culture;
• it permits rapid experimental manipulations and
hypotheses conﬁrmation;
• and permits a better real-time and/or ﬁxed imaging
by microscopy than in animals.
In fact, it allows CTL migration and killing of spe-
ciﬁc tumor cells and better reﬂects the cell-to-cell
and cell-to-matrix interactions occurring in an in vivo
tumor microenvironment. Thus, a 3D-construct con-
taining endothelial, tumor cells and autologous CTL
clonewas prepared and cellular interactionsweremon-
itored by live confocal microscopy. Eighteen hours
after co-culture, we observed that CTLs interacted and
killed tumor cells (about 70% of melanoma cells were
STAT3-P+ STAT3-P+ STAT3-P+ STAT3-P+
MDSC Immature DC CD8+T NK cell
Immune suppression/tolerance
Radioresistant
chemoresistant
NK resistant
CTL resistant
Hypoxia favours the selection
of  tumor resistant variants
HIF1α HIF1α
P-STAT3 P-STAT3
VEGF
Il6,IL10,VEGF
HYPOXIA
Figure 1. Role of hypoxia induced P-STAT3 in tumor immune suppression. Hypoxic tumor microenvironment is responsible for the
emergence of resistant variants. These hypoxic variants have increased HIF-1- and P-STAT3, which renders them resistant to chemo-
and radiotherapy and to the cytotoxic immune effectors NK and CTL. The increased VEGF secreted by tumor variants contributes to the
activation of STAT3. Hypoxia activated STAT3 in tumor variants promotes production of factors such as IL6, IL10 and most importantly
VEGF. VEGF in turn activates STAT3 in various immune cells, such as MDSC, immature dendritic cells, CD8+ T lymphocyte and NK cells
leading to the formation of an immunosuppressive network favouring tumor growth.
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Endothelial cell
Tumor cell
GJs
A B
Figure 2. Intercellular communication between endothelial and autologous tumor cells. A) Gap-junction formation (white) between
endothelial cell (green) and tumor cell (red). B) A three-dimensional collagen matrix containing a mix of endothelial cells (yellow),
tumor cells (red), and CD8 T cell clone (green). Confocal microscopy analysis of the 3D-construct, after 18 hours of live monitoring,
showed the lysis of tumor cells by the autologous CTL clone and that endothelial cells (yellow) became more rounded and lost their
elongated shape as well, illustrating the initiation of their killing by CTL clone.
killed) but, interestingly, we also observed the lysis
of endothelial cells (about 50%). To-Pro staining per-
formed 48hours after the beginning of the experiment
indicated that only the CTL clone was alive whereas
tumor and endothelial cells were lysed. Additional
data indicated that the lysis of endothelial cells by the
tumor speciﬁc clone required the presence of auto-
logous M4T melanoma cells and that endothelial cell
lysis was TCR/HLA peptide interaction dependent. To
get more insight into the mechanisms associated with
the EC recognition by CTLs, we investigated the classi-
cal antigen cross-presentation pathways in this process
by testing the uptake of tumor secreted molecules
and the phagocytosis of tumor cell fragments. We
demonstrated that our endothelial cells did not undergo
cell death subsequently to these two mechanisms,
indicating that the mechanism of antigenic peptide
cross-presentation by EC depended on another one
[30]. Recently, a new antigen cross-presentation path-
way via gap-junction (GJ) formation was published by
the group of Jacques Neefjes [44]. GJ allows inter-
cellular communications between adjacent cells per-
mitting a non-speciﬁc exchange of small cytoplasmic
molecules such as peptides. We then demonstrated
that endothelial cells and tumor cells form connexin
43-based GJ plaques (ﬁgure 2). These GJs are
functional and allows the transfer of peptides from
tumor to endothelial cells. In order to conﬁrm that
a peptide was indeed transferred from melanoma to
endothelial cells, we treated melanoma cells with
the proteasome inhibitor epoxomicin. When added in
the 3D-construct, epoxomycin inhibited the lysis of
melanoma cells but also of endothelial ones. These data
indicate that a peptide transfer indeed occurred from
melanoma to endothelial cells through GJs.
Conclusion
In this review, we addressed the recent advances in
our understanding of the contributions of hypoxia and
endothelial cells within tumor microenvironment, their
ability to actively perturb antitumor cytotoxic effector
cells. We also propose new therapeutic approach to
disrupt the immunosuppressive network orchestered by
the hypoxic tumor microenvironment.
We have shown that hypoxia is able to decrease tumor
target susceptibility to antigen speciﬁc cytotoxic T cells.
This resistancewasmediated by the induction ofHIF-1
and by the activation of STAT3 in tumor targets under
hypoxic conditions [24]. STAT3 propagates several
levels of cross talk between tumor and immune system
[26]. This dual role of STAT3 in tumor cells and immune
cells renders it a central and critical target for inhibi-
ting tumor growth. Recently, a novel small molecule
inhibitor of STAT3 has been reported to reverse immune
tolerance in malignant glioma patients [31]. More
recently sunitinib was shown to positively change the
immunosuppressive phenotype in RCC tumors [32] and
more interestingly Ozao-Choy et al. have shown that
sunitinib malate, a receptor tyrosine kinase inhibitor,
could reverse MDSC-mediated immune suppression
and modulate the tumor microenvironment by increa-
sing percentage and inﬁltration of CD8+ and CD4+ T
cells, thereby improving the efﬁcacy of immune-based
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therapies [33]. These ﬁndings suggest that sunitinib
can be used to reverse immune suppression and as a
potentially useful adjunct for enhancing the efﬁcacy of
immune-based cancer therapy for advanced malignan-
cies.
We have also shown that hypoxia activates STAT3
by autocrine signalling through HIF-1 induced VEGF
(ﬁgure 1) and VEGF neutralization resulted in the
attenuation of hypoxic tumor target resistance to CTL-
mediated killing. Therefore, understanding how VEGF
and other soluble factors may lead to STAT3 activa-
tion via the tumor microenvironment may provide a
more effective cancer treatment strategy for hypoxic
tumors with elevated P-STAT3 levels. This also suggests
that reduction of VEGF release in tumor microenviron-
ment might favour induction of a stronger antitumor
CTL response against tumors expressing VEGFR. Our
studies are in agreement with reports showing that
inhibition of VEGF may be a valuable adjuvant in the
immunotherapy of cancer [27] and indicating a synergy
between tumor immunotherapy and anti-angiogenic
therapy [28].
Our results points to a potential role of HIF-1 and
STAT3 in tumor adaptation to hypoxia. Therefore,
modulating hypoxic microenvironment either by
inhibiting HIF-1 or P-STAT3 would result in poten-
tiating the antitumor cytotoxic effector response.
In this regard, the possibility that novel approaches tar-
geting HIF-1 and STAT3 with potent small molecule
drugs, being actively developed, may provide an exci-
ting novel approach for cancer immunotherapy.
Recently, we provided evidence indicating that
endothelial cells cross-present tumor antigens and are
recognized and killed by melanoma-speciﬁc CTLs. It is
assumed that human endothelial cells do not express
CD80 and CD86 molecules [34], but they express con-
stitutively the co-stimulatory molecule inducible T cell
costimulator-ligand (ICOS-L) that mediate cytokines
secretion by T cells [35] after interaction with ECs. In
another hand, PD-L1 and PD-L2 expressed by ECs regu-
late negatively the cytokine secretion by CD4+ and
CD8+ cells. The capacity of ECs to stimulate or acti-
vate T cell is discussed. In fact, it was reported that
cross-presentation of exogenous or apoptotic antigens
by ECs to CD8+ T lymphocytes conducted them to tole-
rance [17, 21, 36]. Furthermore, it was shown that
ECs exclusively stimulate activated memory CD8+ T
lymphocytes to differentiate into EC-selective CTL, and
that any stimulation and proliferation was observed in
the case of naive CD8+ T cells [37, 38]. It is to note that
these observations were made in the context of murine
ECs and little is known about human ECs.
Although it is assumed that ECs are not a good “APC”,
it appears clearly that they can be “the origin” of slower
tumor progression. It has been previously suggested
that the antigen-presenting functions of endothelial
cells could contribute to lymphocyte homing [39, 40].
Also, it has been demonstrated that IFN- treated rat
microvascular endothelial cells are able to stimulate the
rejection of a rat heart that has been depleted of pas-
senger leukocytes [41]. Recently, it was demonstrated
that vaccination of endothelium inhibits angiogenesis
of colon cancer [42] and that injection of dendritic
cells pulsed with endothelium lysates was followed by
induction of immune response against tumor angioge-
nesis [43]. In addition to these previous observations,
we evidenced for the ﬁrst time that human ECs can be
recognized and killed by melanoma-speciﬁc cytotoxic
lymphocytes.We can then speculate that ECs in contact
with tumor cells can cross-present tumor-antigenic pep-
tide to CTL and that a close ECs/CTL interaction occurs
during tumor inﬁltration by T cells (following extrava-
sation) leading to the recognition of ECs and to the
destruction of microvascular vessels, thus suggesting a
potential “anti-angiogenic activity for CTL”.
Our results further strengthen the notion that many
aspects of tumor biology can only be explained by
a detailed understanding of the interaction between
tumor and its microenvironment. The development
of effective anticancer therapies must take into
consideration not only the tumor cells but also dif-
ferent components of tumor microenvironment. As
it has been clearly established that the outcome
of immunotherapy is mostly dependant on the host
tumor microenvironment, it would be interesting to
design anticancer treatment that may facilitate anti-
tumor effector response. It would be interesting to
try to enhance the effects of immunotherapy by
targeting tumor hypoxia (targeting HIF-1 or STAT3
or VEGF) while reverting the immunosuppressive
hypoxic tumor microenvironment. Further studies on
cellular and molecular mechanisms to contribute to
antitumor immune responses will be needed to over-
come immunological tolerance and promote tumor
rejection.
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ABSTRACT: Hypoxia, a common feature of solid tumors and one of the hallmarks of tumor microenviron-
ment, favors tumor survival and progression. Although hypoxia has been reported to play a major role in the 
acquisition of tumor resistance to cell death, the molecular mechanisms that control the survival of hypoxic 
cancer cells and the role of hypoxic stress in shaping the cross talk between immune cells and stroma com-
ponents are not fully elucidated. Recently, several lines of investigation are pointing to yet another ominous 
outcome of hypoxia in the tumor microenvironment involving suppression of antitumor immune effector cells 
and enhancement of tumor escape from immune surveillance. Although the identification of tumor-associated 
antigens provided a new arsenal of approaches to enhance antigen-specific response, the immunotherapy ap-
proaches that are currently used in the clinic have only limited success. In fact, tumor stroma components 
including hypoxia are engaged in an active molecular cross talk that has serious implications for immunological 
recognition of tumor in shaping the microenvironment. In this review, we will focus on the impact of hypoxia 
on the regulation of the antitumor response and the subsequent tumor progression. We will also in particular 
discuss data that indicate that manipulation of hypoxic stress may represent an innovative strategy for a better 
immunotherapy of cancer. 
Key woRdS: hypoxia, HIF-1α, antitumor response and tumor progression 
ABBReVIATIoNS: CSC: cancer stem cells; CTL: cytotoxic T lymphocyte; dC: dendritic cell; eMT: epithelial 
to mesenchymal transition; FIH-1: factor inhibiting HIF-1; HIF: hypoxia inducible factor; HRM: hypoxia-regulated 
micro-RNA; MdSC: myeloid derived suppressive cell; NF-κB: nuclear factor kappa-light-chain-enhancer of activated 
B cells; NK: natural killer; PHd2: prolyl hydroxylase domain protein 2; STAT-3: signal transducer and activator of 
transcription-3; TAM: tumor-associated macrophage; TGF-β: transforming growth factor beta; VHL: von Hippel-
Lindau tumor suppressor protein
I. InTROduCTIOn 
The term tumor hypoxia commonly refers to a 
condition in tumors where the oxygen pressure is 
less than 5–10 mm Hg.1 Hypoxia is a common 
feature of almost all of the solid tumors and one 
of the hallmarks of tumor microenvironment.2
Solid tumors contain areas of variable oxygen 
concentrations. Tumor cells closest to a perfused 
blood vessel have relatively high O2 concentrations, 
which decline as distance from the vessel increases. 
There are areas that are well oxygenated, poorly 
oxygenated, and finally necrotic in which cancer 
cells have died due to inadequate oxygenation2,3 
[Fig. 1(a)]. Accumulating evidence indicates that 
hypoxic zones in solid tumors have temporal 
fluctuations in oxygen concentration.4
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A. Hypoxia Inducible Factors (HIFs) and 
Tumor Cell Adaptation to Hypoxia
Tumor cells adapt to hypoxic microenvironment by 
the regulation of hypoxia inducible factor family of 
transcription factors (HIFs). This family is composed 
of three members, namely, HIF-1, HIF-2, and HIF-3. 
HIF-1 is a heterodimeric protein that is composed 
of a constitutively expressed HIF-1β subunit and an 
O2-regulated HIF-1α subunit.5 
HIF-1α in the presence of O2 is hydroxy-
lated on proline residue 402 and/or 564 by prolyl 
FIGuRE 1. Schematic overview of normoxic and hypoxic regulation of HIF-1α. (A) Solid tumors contain areas of vari-
able oxygen concentrations. Tumor cells closest to a perfused blood vessel have relatively high O2 concentrations 
(normoxic cells, highlighted in red). The O2 concentrations decline as distance from the vessel increases (hypoxic cells, 
highlighted in blue). (B) In normoxia, HIF-1α is hydroxylated by prolyl hydroxylases (PHDs), resulting in its interaction 
with the von Hippel-Lindau tumor suppressor protein (VHL), which recruits an E3 ubiquitin-protein ligase that subse-
quently catalyzes polyubiquitination of HIF-1α, thereby targeting it for proteasomal degradation. (C) Apart from strict 
oxygen-dependant regulation, HIF-1α is also regulated by several oxygen-independent mechanisms (hypoxia such as 
normoxia). Mutations of fumarate hydratase (FH) and succinate hydratase (SH) inhibit the PHDs. VHL mutations lead 
to constitutive activation of HIFs. RAF and MITF mutations are able to regulate HIF-1α under a normal level of O2. 
(D) Under hypoxic conditions, hydroxylation is inhibited and HIF-1α rapidly accumulates, dimerizes with HIF-1β, and 
binds to the HREs (hypoxia response elements) in target genes. HIF-1 thereby controls several important processes 
in tumor biology. Au
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hydroxylase domain protein 2 (PHD2), resulting 
in its interaction with the von Hippel-Lindau 
(VHL) tumor suppressor protein, which recruits 
an E3 ubiquitin-protein ligase that eventually 
catalyzes polyubiquitination of HIF-1α, thereby 
targeting it for proteosomal degradation 6 [Fig. 
1(b)]. Under hypoxic conditions, hydroxylation 
is inhibited and HIF-1α rapidly accumulates, 
dimerizes with HIF-1β, binds to the core DNA 
binding sequence 50-RCGTG-30 [R, purine (A 
or G)] in target genes, recruits coactivators, and 
activates transcription [Fig. 1(d)]. In addition, 
O2-dependent hydroxylation of asparagine-803 by 
factor-inhibiting HIF-1 (FIH-1) blocks interac-
tion of HIF-1α with the coactivators P300/CBP 
under normoxic conditions.7 Both PHD2 and 
FIH-1 use O2 and α-ketoglutarate as substrates 
and generate CO2 and succinate as by-products of 
the hydroxylation reaction.8 Similar to HIF-1α, 
HIF-2α is also regulated by oxygen-dependent 
hydroxylation.9 HIF-1α and HIF-2α are struc-
turally similar in DNA binding and dimerization 
domains but differ in their transactivation domains. 
Consistently, they share overlapping target genes, 
whereas each also regulates a set of unique tar-
gets.10 HIF-3α lacks the transactivation domain 
and may function as an inhibitor of HIF-1α and 
HIF-2α and its expression is transcriptionally 
regulated by HIF-1.11
Apart from strict oxygen-dependant regula-
tion of HIFs, HIF-1α and HIF-2α are regulated 
by several oxygen-independent mechanisms.12 It 
has been reported that mutation of VHL, PTEN, 
B-RAF, SDH, FH, and MITF are able to regulate 
HIF-1α under normal level of O2 (hypoxia like 
normoxia) [Fig. 1(c)]. This stability of HIF-1α 
under normoxia leads to its increased transcrip-
tional activity and may have a huge impact on cell 
biology and cancer development.
A large body of clinical data shows a positive 
correlation between increased hypoxic expression 
of HIF-1α and HIF-2α and patient mortality.8 
Both HIF-1α and HIF-2α have common target 
genes as well as their respective target genes. The 
genes induced by hypoxia-dependent HIF-1α and 
HIF-2α play important roles in regulating differ-
ent aspects of tumor biology such as angiogenesis, 
cell survival, chemo- and radioresistance, prolifera-
tion, invasion and metastasis, pH regulation and 
metabolism, resistance to immune system, and 
maintenance of cancer stem cells.13,14
Interestingly, HIF-1α and HIF-2α can have 
opposing effects on the cell cycle and on cell pro-
liferation. The best example of this is in clear cell 
renal carcinoma, in which HIF-2α is described to 
drive the tumor growth while HIF-1α may restrict 
proliferation.15 This opposite effect of HIF-1α and 
HIF-2α could be related to the mechanism involv-
ing the regulation of c-Myc. Indeed, it has been 
suggested that HIF-1α antagonizes the activity of 
Myc while HIF-2α enhances Myc activity.16
In this review, we will discuss how cells of the 
immune system (both innate and adaptive) respond 
to hypoxia in terms of their survival and effector 
functions. We will show the ways in which hypoxic 
tumor microenvironment promotes the recruit-
ment, activation, and survival of innate immune 
cells while inhibiting the adaptive immunity. We 
will outline how hypoxic stress confers resistance 
to tumor cells, and describe the molecular aspects 
of the cross talk between hypoxia induced factors 
(HIF-1α, p-stat3 and mir- [AQ: 1], etc.) and 
resistance to cytotoxic treatments. We will also 
illustrate the relationship between hypoxia and 
cancer stem cells. Finally, we will discuss whether 
the inhibition of hypoxic signaling pathways in dif-
ferent compartments of the solid tumor microen-
vironment will open new therapeutic opportunities 
in cancer immunotherapy. 
II. HyPOxIA AFFECTInG THE IMMunE 
SySTEM 
The effects of hypoxia on immune cells are proposed 
to be critical factors for the development of tumor 
immune escape. The innate and adaptive immune 
systems respond differentially to decreased oxygen 
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levels with a global amplification of the innate 
responses and a direct or indirect (via the innate 
system) shortcoming of the adaptive ones. These 
diverse effects are summarized in Fig. 2. 
A. Hypoxia Interferes with Innate Immunity
Hypoxia promotes neutrophils survival by inhib-
iting apoptosis and inducing the release of the 
neutrophil survival factor MIP-1β.17,18 It also 
increases neutrophil blood vessel extravasation by 
modulating β integrin expression19 and neutro-
phil tumor infiltration through the secretion of 
hypoxia-induced chemokines by hypoxic epithelial 
and endothelial cells.20 Hypoxic zones in tumors 
are also able to attract macrophages leading to 
macrophage accumulation.21 The presence of HIF-
1α in tumor-associated macrophages suppresses 
cytotoxic T-cell function, and loss of HIF-1α 
in macrophages is sufficient to relieve tumor-
infiltrating lymphocytes (TILs) from immune 
suppression and decrease tumor growth.22 TAM 
and tumor-infiltrating neutrophils play a key role 
in cancer development and metastasis.23,24 TAM 
can also be issued from myeloid-derived suppres-
sor cell (MDSC) differentiation following HIF1α 
stabilization in MDSC within the hypoxic tumor 
FIGuRE 2. Influence of hypoxia on the innate and adaptive immune systems. Diverse effects of hypoxia on innate 
immune system (macrophage, DC, MDSC, NK, and neutrophil) and adaptive immune system (CTL, Treg, and B cells). 
In general, hypoxia amplifies the activity of innate immune cells while suppressing the response of the adaptive im-
mune system. DC, dendritic cells; MDSC, myeloid-derived suppressor cells; NK, natural killer cells; CTL, cytotoxic T 
lymphocyte; Treg, T regulatory cells. 
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microenvironment. HIF-1α in MDSC makes them 
able to suppress antigen-specific T-cell functions, 
which further supports the immunosuppressive 
environment observed within tumors.25
The presence of HIF-1α in dendritic cells 
(DCs) seems to have contradictory effects. Indeed, 
low oxygen levels are reported to inhibit DC 
maturation and differentiation but to enhance 
DC inflammatory functions. This leads to an 
inhibition of adaptive immune functions of DC 
but reinforcing their innate immune ones.26 In 
contrast, other studies show that hypoxia induces 
human DC maturation and differentiation.27,28 
These mature DCs overexpress HIF-1α and their 
coculture with T cells induces T-cell maturation. 
These conflicting results could be explained by 
differences in the experimental approaches with 
regard to the source and purity of DC precursors, 
the protocols used for maturation and differentia-
tion of DC, and the hypoxic stimulus (duration, 
level, hypoxic chambers versus CoCl2). Future 
research is needed to further dissect the cross talk 
between hypoxia/HIFs [AQ: 2] and DCs, which 
represents a critical issue for our understanding of 
host responses to tumors.
B. Influence of Hypoxia on Adaptive 
Immunity 
Hypoxia leads to the development of a proinflam-
matory microenvironment that promotes innate 
immunity while it inhibits adaptive immunity.18 
Nonetheless, the role of hypoxia and HIFs on 
the adaptive immune system is not well char-
acterized. It is reported that hypoxia promotes 
T-cell lymphocyte apoptosis.29,30 Other studies 
show on the contrary that hypoxia prevents T-cell 
activation–induced cell death resulting in increased 
survival.31 Deficiency for HIF-1α in thymocytes 
from mice also results in increased caspase-8–me-
diated apoptosis.32 These conflicting results need 
to be reconciled. With regard to T-cell functions, 
hypoxia depresses CTL functions by inhibiting 
TCR signaling.29 It also induces increased local 
concentration of extracellular adenosine33,34 that 
acts on T-cell A2A adenosine receptors (A2AR) 
causing intracellular cAMP accumulation and 
subsequent inhibition of activated T cells. The 
use of A2AR antagonists or genetic depletion of 
A2AR weakens inhibition of antitumor T cells 
and inhibits or delays tumor growth.35 These 
findings imply that hypoxia-mediated inhibition 
of T cells confers protection to the hypoxic tissue. 
Accordingly, in an inflammatory context, target-
ing of HIF-1α in activated T cells is reported to 
increase T-cell responses suggesting that HIF-1α, 
in addition to mediating physiological responses 
to hypoxia, also plays a negative regulatory role 
on T-cell functions.36,37 Recently, HIF-1α has 
been shown to mediate Th17 differentiation and 
to inhibit regulatory T cells (Tregs) differentiation 
from naive T cells by activation of the glycolytic 
pathway.38
With regard to B cell lymphocytes, HIF-1α 
deficiency in chimeric mice causes lineage-specific 
defects in B-cell development with decreased 
proliferation of B-cell progenitors, appearance 
of abnormal B-cell population, and, similarly to 
the enhancement of T-cell functions in HIF-1α-
targeted T cells, autoimmune disorders.39 In this 
context, it has been shown that HIF-1α is required 
for efficient glycolysis in B cells in a stage-specific 
differentiation manner.40 Thus, a potential role 
of HIF-1α in autoimmunity has been proposed 
through the regulation of the development, 
metabolism, and functions of B cells.
III. IMPACT OF HyPOxIA On TuMOR 
CEllS
A. Influence of Hypoxia-Induced 
Regulation of Tumor Cell Susceptibility to 
Cell-Mediated Cytotoxicity
It is now well established that hypoxic tumor 
microenvironment favors the emergence of tumor 
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variants with increased metastatic and invasive 
potential.41 Several other evidences suggest that 
HIF-1α may have a protective role under hypoxic 
conditions.42,43 Since these tumor variants are 
resistant to radiotherapy and chemotherapy, one 
might postulate that the exposure to low levels of 
oxygen may lead to adaptive responses allowing 
tumor cells to escape from immune surveillance. 
Fink and colleagues reported the inhibition of natu-
ral killer (NK) cytotoxicity toward liver cell lines 
under hypoxic conditions.44 Siemens et al. have 
recently reported that hypoxia contributes to tumor 
cell shedding of the MHC class I chain-related 
molecule (MIC) through a mechanism involving 
impaired nitric oxide (NO) signaling.45 These find-
ings suggest that hypoxia is able to confer tumoral 
cell resistance to effector cell cytotoxicity.
Recently, we have shown46 that hypoxic expo-
sure of target tumor cells inhibits the CTL clone-
induced autologous target cell lysis. Interestingly, 
the observed lysis inhibition was not associated 
with an alteration of CTL reactivity and tumor 
cell recognition indicating that tumor-induced 
priming of the autologous CTL clone was not 
affected after exposure of tumor target cells to 
hypoxia. We further demonstrated that HIF-1α 
induction and STAT3 activation are associated 
with hypoxia-induced lysis inhibition. Our results 
suggest a new role for hypoxia-dependent induc-
tion of HIF and activation of STAT3 in tumor 
resistance to the immune system.46
B. Role of Hypoxia-Activated STAT3 in 
Modulating Antitumor Immune  
Response 
STAT3 activation within tumor microenvironment 
is known to be associated with cytokine-induced 
proliferation, antiapoptosis, and transformation.47,48 
Moreover, it is now well established that STAT3 
modulates the cross talk between tumor and 
immune cells.49 A novel small-molecule inhibitor 
of STAT3 has been reported to reverse immune 
tolerance in malignant glioma patients.50 Another 
inhibitor, sunitinib, was shown to positively change 
the immunosuppressive phenotype in RCC 
tumors,51 and more interestingly, Ozao-Choy et 
al. have shown that sunitinib malate, a receptor 
tyrosine kinase inhibitor, could reverse MDSC-
mediated immune suppression and modulate the 
tumor microenvironment by increasing higher 
percentage and infiltration of CD8 and CD4 cells, 
thereby improving the efficacy of immune-based 
therapies.52 This points to the potential role of 
STAT3 in tumor adaptation induced by hypoxia. 
The proposed role for STAT3 suggests that the 
effect of hypoxic induction of STAT3 extends 
beyond its critically important role in controlling 
cell survival and apoptosis. This emphasizes that a 
better understanding of the tumor behavior and its 
interplay with the killer cells in the context of the 
complexity and plasticity of a hypoxic microenvi-
ronment will be a critical determinant in a rational 
approach to tumor immunotherapy.
Although resistance of tumor targets to killer 
cells is likely to be regulated by multiple factors,53 
we believe that hypoxic microenvironment is a 
key determinant involved in the control of target 
sensitivity to CTL-mediated lysis. Therefore, the 
possibility that novel approaches targeting HIF-1α 
and STAT3 with potent small-molecule drugs, 
being actively developed, may provide an exciting 
novel approach for cancer immunotherapy.
C. Role of Hypoxia-Induced Autophagy 
in the Adaptation of Tumor Cells to 
Anticancer Therapies 
Autophagy is an evolutionarily conserved cel-
lular process involving the formation of double-
membrane vesicles called autophagosomes. These 
autophagosomes sequester organelles and cyto-
plasmic contents to deliver them to lysosomes 
for degradation.54 The autophagic process allows 
cells to recycle damaged proteins and organelles to 
maintain nutrient and energy homeostasis during 
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sublethal stress including nutrient or growth factor 
deprivation, reactive oxygen species, and hypoxia.55 
It has been well documented that hypoxia activates 
the autophagy pathway in cancer cells [Fig. 3(a)]. 
The activation of autophagy under hypoxia depends 
on the induction of HIF-1α, which activates the 
transcription of the BH3-only proteins BNIP3 and 
BNIP3L leading to the disruption of the inhibi-
tory interaction between Beclin 1 and Bcl-2 [Fig. 
3(b)].56,57 In addition to BNIP3 and BNIP3L, it 
has been reported that hypoxia, through the tran-
scription factors ATF4 and CHOP, increases the 
transcription of LC3 and ATG5,58 two essential 
genes involved in the formation and maturation of 
autophagosomes. Several other pathways have been 
described to activate autophagy under hypoxia.55 
Autophagy has also recently been demonstrated 
as important for conferring resistance to different 
anticancer therapies including immunotherapy.59 In 
several human cancer cell lines, hypoxia increased 
transcription of the essential autophagy genes such 
as LC3. This transcriptional induction replenished 
LC3 protein that was turned over during extensive 
hypoxia-induced autophagy in order to maintain 
the autophagic process during hypoxia and thereby 
promotes the survival of cancer cells.58 Consistent 
with these data, autophagy induction occurred pref-
erentially in hypoxic regions of human tumor xeno-
grafts. Furthermore, pharmacological inhibition of 
autophagy sensitized human tumor cells to hypoxia, 
reduced the fraction of viable hypoxic tumor cells, 
and sensitized xenografted human tumors to anti-
cancer therapy.58 Collectively, these studies strongly 
argue that autophagy is an important mediator of 
the hypoxic tumor microenvironment and that it 
contributes to resistance to treatment. Beside its 
function as a protein degradation process, recent 
evidence points to a novel role of autophagy 
in innate and adaptive immunity.60 Indeed, the 
autophagy pathway can modulate key steps in the 
development of adaptive immunity. In this context, 
it has been proposed that autophagy regulates the 
development and survival of lymphocytes as well as 
the modulation of antigen processing and presen-
tation.61 Autophagy induction in target cells also 
increases their potential to serve as immunogens 
for dendritic cell cross-presentation to CD8+ T 
cells. Furthermore, the autophagy pathway can 
also modulate the selection and survival of some 
CD4+ T cells in the thymus.62 However, much 
still remains to be learned about the relationship 
between hypoxia-induced autophagy and the tumor 
immunotherapy. Obviously, targeting autophagy in 
hypoxic tumor cells may have a major impact on 
cancer immunotherapy.
FIGuRE 3. (A) Hypoxia induction of autophagy in MCF-7 
breast adenocarcinoma cell line. Cells transfected with the 
autophagy marker LC3 fused with GFP were cultured under 
normoxia (pO2 21%) or hypoxia (pO2 1%). The induction 
of autophagy was monitored by the formation of green 
dot–like structures corresponding to autophagosomes; 
bar, 10 mm. (B) Involvement of HIF-1α in the induction of 
autophagy. Under hypoxia, HIF-1α activates the transcrip-
tion of BNIP3/BNIP3L proteins. The overexpression of 
these proteins dissociates the autophagy inhibitory protein 
complex between Beclin 1 and Bcl-2, and consequently 
activates autophagy. 
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d. Role of Hypoxia-Regulated Micro-
RnAs in the Control of Tumor Behavior
 Micro-RNAs (miRNAs) are about 18–24 nucle-
otides, and are small noncoding RNAs. They 
negatively regulate mRNA expression by repress-
ing translation or directly cleaving the targeted 
mRNA.63 Over the past few years, the role of 
miRNA has expanded from their functions in the 
development of roundworms to ubiquitous regula-
tor implicated in several critical processes, includ-
ing proliferation, cell death and differentiation, 
metabolism, and, importantly, tumorigenesis.64
1. Hypoxia-Regulated Micro-RNAs (HRMs) 
Hypoxia as an essential component of tumor 
microenvironment is capable of stabilizing tran-
scription factor HIF-1α, which in turn is capable 
of regulating its target genes (classical pathway 
of response to hypoxia), but also much of micro-
RNAs (new pathway of response to hypoxia). These 
micro-RNAs regulated by hypoxia are known as 
hypoxia-regulated micro-RNAs (HRMs) (Fig. 4). 
These HRMs are capable of repressing the expres-
sion of different target genes, thereby influencing 
important processes in tumor development such 
as angiogenesis, cell survival and cell death, etc.65,66 
Recently, it has been shown that certain HRMs 
are capable of affecting HIF-1α expression.67 
2. Mir-210: Mediator of Hypoxic Response
Among these HRMs, miR-210 is the only miRNA 
consistently upregulated in both normal and 
transformed hypoxic cells, and it is also generally 
FIGuRE 4. A proposed model of how hypoxia regulates hypoxia-inducible genes and hypoxia-regulated micro-RNAs 
(HRMs) leading to better adaptation to the hypoxic microenvironment. Hypoxia activates HIF-1α, which in turn regulates 
the hypoxia-inducible genes (left side) such as VEGF, GLUT-1, PGK-1, CA-IX, and CXCR4. On the other hand, hypoxia 
regulates several micro-RNAs called hypoxia-regulated micro-RNAs (HRMs). Once induced, HRMs such as miR20b, 
miR199a, and miR424 affect HIF-1α expression under hypoxia. One of the HRMs, miR-210, is able to repress several 
genes implicated in various physiopathological pathways.
Au
th
r P
ro
of
Volume 31, Number X, 2011
Microenvironmental Hypoxia Orchestrating the Cell Stroma Cross Talk, Tumor Progression, and Antitumor Response 9
recognized as a robust HIF target.68 Mir-210 has 
been considered as an in vivo marker of tumor 
hypoxia.69 Mir-210 has been correlated positively 
to poor patient prognosis in head and neck cancers, 
and mir-210 has been detected in the serum of 
breast cancer patients.70–72 Mir-210 also partici-
pates in the hypoxic response of endothelial and 
neuronal cells.73
More importantly, the increased expression of 
miR-210 also correlates with the improved survival 
of transplanted mesenchymal stem cells (MSCs) 
in a rat model. By downregulating caspase-8–as-
sociated protein 2 (CASP8-AP2), a proapoptotic 
regulator of Fas-mediated apoptosis,74 miR-210 
protects MSC from cell death. Finally, mir-210 
is capable of regulating several cellular processes 
by regulating the expression of genes involved in 
angiogenesis, cell cycle, cell survival, and tumor 
initiation68 (Fig. 4). 
In summary, miR-210 plays a crucial role in 
mediating the cellular response to hypoxia resulting 
in a better adaptation of hypoxic cells to tumor 
microenvironment. Manipulating miR-210 within 
the tumor microenvironment may therefore lead to 
novel diagnostic and therapeutic approaches.
E. Hypoxia and Epithelial to 
Mesenchymal Transition 
Epithelial to mesenchymal transition (EMT) is a 
complex molecular process during which epithelial 
cells lose apico-basal polarity and acquire mesen-
chymal motile phenotype. A hallmark of the EMT 
is the downregulation of epithelial markers such 
as cadherin and cytokeratin, and the upregulation 
of mesenchymal markers such as vimentin leading 
to an organized disassembly of epithelial cell-cell 
contact.75–77 EMT has a central role in cancer 
progression and metastasis.78,79 Several signaling 
pathways (TGF B, Wnt, Notch, etc.) and tran-
scriptional factors (Snail, Slug, Twist, etc.) can 
induce EMT.79 Recently, hypoxic signaling through 
HIF was implicated as an important trigger and 
modulator of EMT.80,81
1. Hypoxic Regulation of EMT Triggering 
Signaling Pathways
Under hypoxic microenvironment, different signal-
ing pathways, directly involved in triggering EMT, 
are activated80 (Fig. 5). Members of TGF β are 
major inducers of EMT during embryonic devel-
opment, fibrotic diseases, and cancer progression.82 
TGF β, after binding to serine/threonine kinase 
receptors TβRI and II, recruits and phosphorylates 
TGF β cytoplasmic mediators SMADs. SMADs 
interact with EMT transcriptional factors (Snail, 
Slug, and SIP) and thereby inducing mesenchymal 
transition.83 TGF β can also trigger EMT through 
cooperation with oncogenic pathways such as Ras, 
Wnt/β catenin, and NF-κB in order to maintain 
mesenchymal and invasive tumor cells’ properties.84 
Several studies reported the existence of coopera-
tion between hypoxia and TGF β in activating 
EMT. In fact, hypoxia induces an increase in 
TGF β production from mesenchymal and cancer 
cells.85,86 In hepatocytes, it was demonstrated that 
TGF-β signaling pathway is downstream of HIF 
activation and that hypoxia-induced EMT depends 
on TGF β signaling.87 On the other hand, HIF-1 
and TGF β co-regulate some gene targets such 
as the cyclooxygenase-2, which is implicated in 
enhancing EMT.88
NF-κB induces expression of the master 
EMT regulators Snail, Slug, ZEB1, ZEB2, and 
Twist, which repress expression of genes encod-
ing epithelial markers. NF-κB also promotes a 
mesenchymal phenotype, migration, and invasion 
of tumor cells.89 Different studies highlight the 
implication of hypoxia in the induction of EMT via 
the NF-κB pathway most likely through cross talk 
between NF-κB and HIF signaling pathways.90 
For example, it was demonstrated that inhibition 
of oxygen-dependent hydroxylases under hypoxia 
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leads to the activation of both HIF and NF-κB 
pathways.91
The Notch signaling pathway can induce EMT 
via increasing Snail expression or by interacting 
with TGF β/SMADs and NF-κB pathways.92 
It has been shown that HIF-1 binds the Notch 
intracellular domain and stabilizes its transcrip-
tional activity leading to the regulation of the 
Notch pathway under hypoxia.93 Recent findings 
demonstrated that Notch pathway inhibition 
abrogated the hypoxia-mediated increase in Slug 
and Snail expression, as well as decreased breast 
cancer cell migration and invasion.94
2. Hypoxic Regulation of EMT 
Transcription Factors
After hypoxia or constitutive HIF expression, epi-
thelial cell lines regulate the expression of major 
EMT-associated transcription factors. Under 
hypoxic conditions, Twist [AQ: 3] protein level 
is significantly upregulated in different tumor 
cell lines. Reduced endogenous HIF-1 reverted 
the Twist level in cells, indicating the key role of 
HIF in Twist expression regulation.95 Twist over-
expression induced in hypoxia conditions leads to 
repression of E-cadherin and promotes EMT and 
metastatic ability. Additionally, coexpression of 
Twist, Snail, and HIF-1α was recently correlated 
with bad prognosis and metastasis.96,97
Snail, a zinc-finger transcription factor, is 
involved in the repression of many epithelial 
markers expression and plays a crucial role in 
carcinoma cells invasion. It has been associated 
with decreased recurrence-free survival.98 Increased 
Snail expression, under hypoxia, accompanied by 
decreased E-cadherin expression, has been reported 
in ovarian cancer cell lines.99 Exposure of human 
breast cell lines to hypoxia also induced EMT 
with elevated Snail and vimentin expression.100 
Additionally, some hypoxia targets [lysyl oxidase 
like 2, urokinase plasminogen activator (uPA) and 
its receptor [AQ: 4]] could regulate Snail and 
FIGuRE 5. Schematic representation of the EMTs occurred under hypoxia. Cells located in the well oxygenated areas 
(normoxic areas) closest to blood vessel display an epithelial phenotype; however, cells located in poorly oxygenated 
areas lose their epithelial phenotype and gain mesenchymal properties following the activation of several transcription 
factors and pathways involved in the induction of the EMT. 
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trigger EMT.101,102 Recently, Luo et al. identi-
fied a hypoxia-responsive element within close 
proximity of the minimal Snail promoter, which 
binds both HIF-1 and HIF-2 target genes and 
activates Snail transcription.103 Hypoxia can also 
increase the expression of epithelial repressor Slug 
via HIF-1α promoting cancer cells invasiveness. 
Recently, Chen et al. reported that induced Slug 
and Snail expression by hypoxia-mediated Notch 
signaling is associated with increased breast cancer 
cell migration and invasion.94
Thus, it is well established that hypoxia-
regulated EMT is directly implicated in tumor 
growth, invasion, and metastasis. In the future, 
we have to consider targeting both hypoxia and 
EMT in the design of new drugs. 
F. Hypoxia and Cancer Stem Cells
Tumor growth is dependent on the presence of a 
subpopulation with stemlike properties called cancer 
stem cells (CSCs) within the tumor.104 CSCs, which 
are in an undifferentiated state, undergo self-renewal 
and when implanted in immune-deficient mice are 
able to develop tumors and to reestablish the bulk 
tumoral heterogeneity.105 CSCs also have the prop-
erty to resist conventional antitumor therapies,106 
which makes them a probable cause of tumor 
recurrences after treatment. Therefore, their eradi-
cation in the tumor is a therapeutic challenge that 
justifies a better understanding of their emergence 
and persistence in the tumoral tissue.
In this regard, hypoxia and HIFs have been 
described to induce tumor cell dedifferentiation 
toward an immature phenotype and similarly to 
maintain tumor cells with stem cell properties.13 
Several reports show the role of hypoxia and HIFs 
in promoting a stemlike phenotype through the 
expression of genes such as OCT4, SOX2, and 
NANOG required for self-renewal maintenance in 
stem cells or the activation of the Notch signaling 
pathway that regulate cell self-renewal and differ-
entiation.13 A study from Jogi et al. has shown that 
culturing neuroblastoma cells under hypoxia led 
to an increase of neural crest gene expression and 
a decrease of neuron lineage marker expression.107 
In glioblastoma, Mc Cord et al. have reported that 
glioblastoma neurospheres under hypoxia show an 
increased proportion of CD133+ stemlike cells and 
induction of embryonic markers such as OCT4 
and SOX2. This was associated with a selective 
increase of HIF-2α.108 Hypoxia was reported by 
Chen et al. to activate Notch signaling pathway in 
lung adenocarcinoma, which revealed to be essen-
tial since using a Notch signaling inhibitor under 
hypoxia induced cell death.109 However, Notch 
pathway can also promotes cell differentiation in 
keratinocytes and certain neural stem cells.110,111 
This ability of hypoxia to increase the stem cell–
like subset inside a tumor cell population reflects 
the plasticity of the CSC compartment and the 
role of microenvironmental stimuli in shaping this 
particular subset. 
Some of the effects of hypoxia on tumor cell 
differentiation are directly mediated by the HIFs. 
Li et al. reported that targeting HIF-1α and 
HIF-2α in CD133+ glioma stem cells decreased 
their survival and their tumorigenic and angiogenic 
potentials.112 They also reported a preferential 
expression of HIF-2α in CD133+ glioma stem 
cells, whereas HIF-1α was present in both stem 
and nonstem tumor cells and needed more severe 
hypoxia to be stabilized. Another study using 
human neuroblastoma cells also found a selective 
expression of HIF-2α in an immature cell subset, 
with induction of differentiation when targeting 
HIF-2α.113 Overexpression of HIF-2α in non-
glioma stem cells was sufficient to induce a stem 
cell–like phenotype (sphere-forming ability, larger 
tumors after mice engraftment).114 At a clinical 
level, HIF-2α expression in patients correlated 
with poorer prognosis.112,113 These findings support 
a preferential targeting of HIF-2α for selective 
eradication of CSCs without adverse effects on 
normal progenitor cells. HIF-1α is not outdone 
since a recent study by Wang et al. using human 
leukemia showed a selective activation of HIF-1α 
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in CSCs under normoxic conditions due to VHL 
deficiency, and that blocking HIF-1α activity was 
able to eliminate leukemia stem cells without affect-
ing the normal hematopoietic stem cells.115
These studies and others describe the effects 
of hypoxia in converting differentiated cancer cells 
into stemlike cancer cells, and the possibility that 
stabilized HIF-1α or HIF-2α may represent criti-
cal targets for eradicating the tumoral stem cell 
compartment. Thereby, HIF protein functions in 
tumors go beyond mediating adaptation to hypoxia 
by modulating cell metabolism and survival and 
driving vessel development. Intriguingly, CSCs 
were proposed to localize more within a tumor 
and hypoxic niches than in perivascular and con-
sequently oxygenated regions. In this regard, it has 
been proposed that both hypoxic and nonhypoxic 
mechanisms of CSC regulation [AQ: 5], although 
this hypothesis remain to be investigated.116 
G. Hypoxia-like normoxia: Oxygen-
Independent Regulation of HIF1α and 
HIF2α 
Apart from oxygen-dependent strict regulation of 
HIFs, HIF1α and HIF2α can also be regulated 
by oxygen-independent mechanisms, leading to 
increased HIF transcriptional program under 
normal level of O2 and promoting tumor growth.8 
Here, we will discuss how genetic alterations such 
as gain of function mutations of oncogene or 
loss of function of tumor suppressor gene can be 
responsible for overexpression of HIFs in a cell 
type–specific manner. Recently, it has been shown 
that inducers of HIFα such as reactive oxygen4 
and nitrogen species117 can also be found in the 
microenvironment.
1. Constitutive HIF Activation through 
Inactivation of VHL Gene
A constitutive HIF gene activation can be observed 
in VHL diseases (renal cell carcinomas patients 
and most of sporadic clear cell RCCs) character-
ized by an inactivation of VHL gene. The double 
allele loss of function (deletion, mutation, CpG 
island hypermethylation) VHL-/- gives rise to 
an increased level of HIF-1α and HIF-2α118,119 
or only of HIF-2α, which seems to be necessary 
and sufficient for tumor growth in VHL-/- RCC 
cell lines contrary to HIF1α.119,120
2. Constitutive HIF Activation by RAS/
RAF/MITF Overactivation
Activating mutation of RAS121 and RAF122 were 
also linked to enhanced levels of HIFα protein, 
even in normoxic conditions. In colon cancer, it 
was described that RAS and RAF mutation enable 
a better response of cancer cells to hypoxia. This 
underlines their differential impact on HIF1α 
or HIF2α and justifies phenotypic differences in 
KRAS or BRAF colon cancer.123 Furthermore, in 
melanoma cells, mutant BRAF can enhance HIF1α 
expression in normoxia124 and is also described 
as a regulator of microphthalmia-associated 
transcription factor (MITF) through a “tricky” 
process implying an increase in ERK-induced 
MITF degradation in parallel with an increase of 
MITF transcription by BRN2.125 MITF is itself 
described as a transcriptional activator of HIF1α 
in melanoma.126
3. Constitutive HIF Activation through 
Inactivation of Fumarate and Succinate 
Hydratase Gene
Inactivation by germ line mutations of fumarate 
and succinate hydratase genes in renal cancer cell 
predisposes to hereditary leiomyomatosis syndrome 
(HLRCC) and induces hereditary paraganglioma 
syndrome, respectively. It has been shown that 
accumulation of fumarate or succinate is accom-
panied by a  high level of HIF under normoxia. 
This accumulation seems to be mediated by an 
inhibition of PHD.127,128 
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4. Growth Factor, Oncogenic Signaling 
Pathways, and Increase of HIF Level
HIF1α levels can be increased by growth factor 
stimulation. It is noteworthy that a hypoxia-
dependent increase of HIF-1α in cell-type specific 
is not due to its reduced degradation, as observed 
under hypoxia, but rather to a stimulation of HIF1α 
synthesis through oncogenic signaling pathways.12 
For example, insulin, insulinlike growth factor, epi-
dermal growth factor, and fibroblast growth factor 
can induce expression of HIF-1α in normoxia via 
mitogen-activated protein kinase (MAPK) and 
PI3K/Akt pathways.129 It is interesting to note 
that the Akt pathway can be overactivated in cells 
displaying either a loss of function of PTEN130 or 
an overexpression of HER2.131
5. Constitutive HIF Activation by Src 
Overactivation
Hyperactivity of Src can be responsible for a high 
level of HIF-1α under normoxia. The high level of 
HIF-1α in cells displaying activated Src is related 
to the production of ROS, which reduces cellular 
vitamin C required for the activity of PHD2. 
A defect of PHD2 activation leads to HIF-1α 
accumulation by preventing its hydroxylation-
dependent ubiquitinylation.132 
Overall, constitutively active HIF-1α and 
HIF-2α play a major role in cancer by inducing 
adaptation of tumor cell to hypoxia microenviron-
ment. However, activated HIFs in normoxic cells 
seems to be cell specific.12
IV. dOES TARGETInG OF HyPOxIA 
RESulT In A MORE EFFICIEnT 
IMMunOTHERAPy?
Clinical vaccination trials aimed at triggering or 
enhancing antitumor immunity are at present 
disappointing, given the different mechanisms 
of tumor escape from immunosurveillance that 
represent the last series of hurdles to be overcome 
in formulating truly effective cancer immuno-
therapy.133,134 Clearly, tumor-induced alterations 
to the patient’s immune system may subvert 
anticancer responses and even promote tumor 
growth. To provide a significant clinical advance-
ment, new concepts have to be introduced to aid 
the design of new tools for therapy. In addition, 
there are increasing indications that tumor stroma 
components including hypoxia play a crucial role 
in the control of immune protection and contain 
many overlapping mechanisms to maintain tumor 
functional disorder and evasion of antigenic-
specific immunotherapy. Therefore, in parallel 
to the efforts oriented toward the identification 
of potential candidate antigens for vaccination, 
closer attention should be paid to the complexity 
of the tumor ecosystem in deviating the functions 
of tumor infiltrating cells. It seems obvious that 
more could be achieved by combining therapies 
that tackle malignancies from multiple angles, 
with the tumor microenvironment conditioned 
to support a powerful effector arm generated by 
immunotherapy. Tumor immunotherapy in the 
clinic has not taken it into account the hypoxic 
microenvironment and its impact on the thera-
peutic outcome. Because the hypoxia-inducible 
factor (HIF) was recently shown to regulate the 
tumorigenic capacity of tumor and cancer stem cells 
under hypoxic conditions,112 further investigation 
is required to demonstrate if HIF-1 is prevalent 
enough in human cancer to be a general target. 
One of the challenges of cancer immunotherapy 
is how to design combination therapies that 
modify the hypoxic tumor microenvironment so 
as to promote immunity and better design more 
adapted immunotherapy approaches. Whether 
the suppression of HIF-1α expression may be a 
promising strategy that is selective for facilitating 
immunotherapeutic efficacy in cancer patients is 
at present under investigation.
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V. COnCluSIOnS
The growth and spread of cancer depends as much 
on the host response to tumor as on the biological 
characteristics of the tumor itself. This interaction is 
at its most intimate and dynamic within the tumor 
microenvironment. The role of the latter during 
the initiation and progression of carcinogenesis is 
now realized to be of critical importance for both 
enhanced understanding of fundamental cancer 
immunology and biology and exploiting this source 
of relatively new knowledge for improved molecular 
diagnostics, therapeutics, and immune intervention. 
It has become clear now that tumor stroma com-
ponents including hypoxia are engaged in an active 
molecular cross talk that has serious implications 
for immunological recognition of tumor in shaping 
the microenvironment. Indeed, hypoxia incapacitates 
several different types of immune effector cells, 
enhances the activity of immunosuppressive cells, 
and provides new avenues that help “blind” immune 
cells to detect the presence of tumor cells. Obviously, 
understanding the tumor microenvironment and its 
targeting to awaken or reawaken immune cells, or 
to redirect it from a protumor to an antitumor state, 
will help to instruct clinical immunotherapy.
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Despite the impressive progress over the past decade, in the ﬁeld of tumor immunology,
such as the identiﬁcation of tumor antigens and antigenic peptides, there are still many
obstacles in eliciting an effective immune response to eradicate cancer. It has become
increasingly clear that tumor microenvironment plays a crucial role in the control of immune
protection.Tumors have evolved to utilize hypoxic stress to their own advantage by activat-
ing key biochemical and cellular pathways that are important in progression, survival, and
metastasis. Hypoxia-inducible factor (HIF-1) and vascular endothelial growth factor (VEGF)
play a determinant role in promoting tumor cell growth and survival. Hypoxia contributes
to immune suppression by activating HIF-1 and VEGF pathways. Accumulating evidence
suggests a link between hypoxia and tumor tolerance to immune surveillance through the
recruitment of regulatory cells (regulatory T cells and myeloid derived suppressor cells).
In this regard, hypoxia (HIF-1α and VEGF) is emerging as an attractive target for cancer
therapy. How the microenvironmental hypoxia poses both obstacles and opportunities for
new therapeutic immune interventions will be discussed.
Keywords: hypoxia, HIFα, angiogenesis, immune tolerance, tumor progression
INTRODUCTION
Cancer vaccines are expected to augment already established anti-
tumor immune responses and to induce de novo immunity or
reverse tolerance. Major advances have led to several immuniza-
tion strategies to boost immune responses against some tumor-
associated antigens. In this regard, strategies involving various
forms of peptides either alone or in combination with different
cytokines, adjuvant, or dendritic cells have been used to enhance
speciﬁc immune responses. Despite the enthusiasm for current
vaccination approaches, it should be noted that tumor rejection
in patients does not always follow successful induction of tumor-
speciﬁc immune responses by cancer vaccines. Even, if a strong and
sustained cytotoxic response is induced, complex issues remain
such as tumor evasion, tolerance and selection of tumor resis-
tant variants (Rosenberg et al., 1998, 2004; Hamai et al., 2010).
Nevertheless, systemic administration of monoclonal antibodies
targeting immune modulatory receptors: cytotoxic T-lymphocyte
antigen 4 (CTLA-4; Eggermont et al., 2010) and Programmed
Death 1 (PD1) on T reg and effector cells have been recently
reported to increase anti-tumor immunity both experimentally
and clinically (Alexandrescu et al., 2010; Callahan et al., 2010;
Eggermont and Robert, 2011; Mansh, 2011; Mellman et al., 2011;
Pandolﬁ et al., 2011). In early phase I trials, PD1 have shown
good activity in a variety of cancer types and have a toxicity
proﬁle that seems safer than ipilimumab (Brahmer et al., 2010).
A recent clinical trial with the longest follow-up of melanoma
patients treated with ipilimumab has shown that ipilimumab can
induce durable, potentially curative tumor regression in a small
percentage of patients with metastatic melanoma (Prieto et al.,
2012).
It has become increasingly clear that tumor microenvironment
plays a crucial role in the control of immune protection and
contains many overlapping mechanisms to evade antigenic spe-
ciﬁc immunotherapy (Zou, 2005; Nagaraj and Gabrilovich, 2007;
Marigo et al., 2008). Several reports underscore the contribu-
tion of the microenvironment to tumor development and it is
well admitted that tumors are not merely masses of neoplastic
cells, but instead, are complex tissues composed of both non-
cellular (matrix proteins) and cellular components, in addition
to the ever-evolving neoplastic cells. Tumor microenvironment
is a complex and highly dynamic environment, providing very
important clues to tumor development and progression (Petrulio
et al., 2006). In the context of microenvironment complexity and
plasticity, tumor cells orchestrate the modiﬁcation of the microen-
vironment by attracting or activating many non-tumoral cells,
including ﬁbroblasts, blood and lymphatic endothelial cells, bone
marrow-derived cells, immune and inﬂammatory cells. Moreover,
it is now acknowledged that tumor cells and their stroma co-evolve
during tumorigenesis and tumor progression (Hiscox et al., 2011).
Therefore, tumor growth and spread depend as much on the host
response as on the biologic characteristics of the tumor itself and
on the inﬂuence of the tumor microenvironment (Petrulio et al.,
2006).
The hypoxia’s critical role in radio-resistance, chemoresistance,
tumor stemness, and its signiﬁcance as an adverse prognosis fac-
tor have been well established and at present hypoxia-induced
www.frontiersin.org February 2012 | Volume 3 | Article 21 | 1
115 172
116 173
117 174
118 175
119 176
120 177
121 178
122 179
123 180
124 181
125 182
126 183
127 184
128 185
129 186
130 187
131 188
132 189
133 190
134 191
135 192
136 193
137 194
138 195
139 196
140 197
141 198
142 199
143 200
144 201
145 202
146 203
147 204
148 205
149 206
150 207
151 208
152 209
153 210
154 211
155 212
156 213
157 214
158 215
159 216
160 217
161 218
162 219
163 220
164 221
165 222
166 223
167 224
168 225
169 226
170 227
171 228
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chouaib et al. Hypoxia, angiogenesis, and immune escape
angiogenesis has become an attractive target for cancer therapy
(Semenza, 2010). Hypoxia-inducible factor (HIF-1α) overexpres-
sion and its associationwithpoor treatment response andoutcome
has been demonstrated in an extensive range of human tumors
(Semenza, 2010; Wilson and Hay, 2011). In addition, a direct link
between tumor hypoxia and tolerance through the recruitment
of regulatory cells has been established (Facciabene et al., 2011).
Hypoxia-induced vascular endothelial growth factor (VEGF) pro-
duced by most tumors plays an important role in tumor angio-
genesis (Takenaga, 2011). It also plays a key role in immune escape
by licensing invasion, metastasis, impacting therapeutic response
and favoring immune escape mechanisms.
Hypoxia is therefore attracting a particular attention in the
ﬁeld of tumor immune biology since hypoxic stress impact angio-
genesis, tumor progression and immune tolerance. Modulating
the stromal hypoxia may constitute in fact a very potent strat-
egy for targeted therapeutic approaches. How peripheral immune
tolerance and angiogenesis programs are closely connected and
cooperate under hypoxic conditions to sustain tumor growth will
be discussed in this article.
HYPOXIA-INDUCED ANGIOGENESIS AND RESISTANCE TO
CYTOTOXIC TREATMENTS
HYPOXIA-INDUCIBLE FACTORS: DETERMINANT FACTORS IN TUMOR
CELL ADAPTATION TO HYPOXIC STRESS
Tumor cells adapt to hypoxic microenvironment by the regulation
of HIFs family of transcription factors. This family is composed
of three members namely HIF-1, HIF-2, and HIF-3. HIFs are a
heterodimeric proteins composed of a constitutively expressed
HIF-β subunit and an O2-regulated HIF-α subunit (Wang et al.,
1995). Both HIF-1α and HIF-2α have common target genes as
well as their respective target genes (Lau et al., 2007). The genes
induced by hypoxia-dependent HIF-1α and HIF-2α play impor-
tant roles in regulating different aspects of tumor biology espe-
cially angiogenesis, cell survival, chemo- and radio-resistance,
proliferation, invasion and metastasis, pH regulation and metab-
olism, resistance to immune system, and maintenance of cancer
stem cells (Keith and Simon, 2007; Lukashev et al., 2007; Keith
et al., 2011).
In thepresence of O2,HIF-1α is hydroxylatedonproline residue
402 and/or 564 by prolyl hydroxylase domain protein 2 (PHD2),
resulting in its interaction with the von Hippel–Lindau (VHL)
protein, which recruits an E3 ubiquitin-protein ligase that even-
tually catalyzes polyubiquitination of HIF-1α thereby targeting
it for proteasomal degradation (Salceda and Caro, 1997). Under
hypoxic conditions, hydroxylation is inhibited and HIF-1α rapidly
accumulates, translocates to the nucleus, dimerizes with HIF-1β
and activates transcription. Similar toHIF-1α,HIF-2α is also regu-
latedbyoxygen-dependent hydroxylation (Patel andSimon,2008).
HIF-1α and HIF-2α differ in their transactivation domains but are
structurally similar in DNA binding and dimerization domains.
HIF-3α lacks the transactivation domain and may function as an
inhibitor of HIF-1α and HIF-2α and its expression is transcrip-
tionally regulated by HIF-1 (Makino et al., 2007). HIF-1α and
HIF-2α are also regulated by several oxygen-independent mech-
anisms involving mutation of VHL, PTEN, BRAF, SDH, FH, and
MITF (Semenza, 2010; Noman et al., 2011c).
HYPOXIA-INDUCED VEGF AS A KEY EVENT IN PROMOTING
ANGIOGENESIS
Growing tumor mass requires neo-vascularization to provide
rapidly proliferating tumor cellswith an adequate supply of oxygen
and metabolites. Diffusion distances from the existing vascula-
ture increases as tumor expands resulting in local hypoxia (Harris,
2002; Brahimi-Horn et al., 2007; Dewhirst et al., 2008). Increasing
evidence shows that the hypoxic stress plays a key role in the reg-
ulation of angiogenesis that is required for invasive tumor growth
and metastasis (Semenza, 2010). HIF-1α stabilization and nuclear
accumulation results in the subsequent activation of a wide range
of target genes belonging to angiogenesis and promoting endothe-
lial cell proliferation, migration, permeability, and survival (Wang
et al., 1995). HIF-2 is also able to promote tumor angiogenesis
through mobilization of circulating progenitor endothelial cells
(Kim et al., 2009) and through VEGF induction (Raval et al.,
2005; Li et al., 2009). HIF-1α and HIF-2α can also be regulated by
oxygen-independent mechanisms leading to increased HIF tran-
scriptional program under normal level of O2 and promoting
tumor growth and angiogenesis (Semenza, 2010). In this regard,
the double allele loss of function (deletion, mutation, CpG island
hypermethylation) VHL−/− gives rise to increased constitutive
level of HIF-1α and/or HIF-2α (Baldewijns et al., 2010). VHL can
also directly regulate the stability of certain mRNAs such as that
of VEGF (Datta et al., 2005) and mRNAs related to growth factor
signaling, suggesting that mRNA changes observed after VHL loss
are not solely due to the subsequent HIF accumulation (Kaelin,
2008).
Although vessel growth andmaturation are complex and highly
coordinated processes requiring the sequential activation of a
multitude of factors, there is a consensus that VEGF signaling
represents a crucial step in tumor angiogenesis (Liao and Johnson,
2007). It should also be noted that antiangiogenic drugs and vas-
cular destructive agents may in turn promote tumor cell invasion
and metastasis in association with drug-induced tumor hypoxia.
HYPOXIA-INDUCED ANGIOGENESIS LEADS TO INCREASED
RESISTANCE TO CYTOTOXIC TREATMENTS
Tumor hypoxia-induced abnormal neo-angiogenesis leads to
increased resistance to cytotoxic treatments. Indeed, tumor ves-
sels are labyrinthine and branched in an irregular and chaotic
manner with uneven diameters due to the compression of their
walls by tumor or stromal cells (Jain, 1988, 2005; Nagy et al.,
2010). These abnormalities in hypoxia-induced tumor vessels have
been found in a wide range of tumor types, in mice both in
transplantable tumors and in spontaneous tumors arising from
exposure to carcinogens or expression of oncogenes (Baluk et al.,
2005; Hamzah et al., 2008; Van de Veire et al., 2010) and in tumors
from patients (Willett et al., 2004; Batchelor et al., 2007). Tumor
vessel blood ﬂow is compromised and stagnant due to increased
vascular resistance and improper vasoregulation (Jain,2005; Fuku-
mura et al., 2010). Similarly hypoxia-induced tumor endothelial
cells are abnormal. Normal vessels are lined with a monolayer of
interconnected endothelial cells, whereas tumor endothelial cells
are often leaky, with wide open junctions and many fenestrations
resulting in limited tissue perfusion (Jain, 1988). These abnor-
mal neo-vessels with leaky walls facilitate the escape of tumor
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cells (Jain, 2005). All these abnormalities lead to a decrease in
uniform and efﬁcient delivery of nutrients and drugs (Jain, 2005;
Jain and Stylianopoulos, 2010) as well as inﬂux of immune cells
(Hamzah et al., 2008). As irradiation and certain chemothera-
peutics rely on the formation of reactive oxidative species to kill
cancer cells, tumor hypoxia also reduces the efﬁcacy of conven-
tional anticancer treatments (Moeller et al., 2007). Thus, it is clear
that hypoxia-induced angiogenesis is responsible for an abnormal
tumor vasculature (Carmeliet and Jain, 2011), which can inﬂu-
ence tumor response to anticancer treatments as well as tumor
inﬁltration by immunocompetent cells.
ROLE OF HYPOXIA-INDUCED VEGF IN MODULATING TUMOR RESPONSE
TO CYTOTOXIC T-LYMPHOCYTES
Wehave shown that hypoxic exposure of tumor cells inhibits autol-
ogous cytotoxic T-lymphocytes (CTL)-mediated lysis (Noman
et al., 2009, 2011b). We provided evidence indicating that HIF-1α
induction and signal transducer and activator of transcription-3
(STAT3) activation are associated with hypoxia-induced lysis inhi-
bition. This suggests a new role for hypoxia-dependent induction
of HIF-1α and activation of STAT3 in tumor resistance to the
immune system.
Signal transducer and activator of transcription-3 activation
within tumor microenvironment is known to be associated with
cytokine-induced proliferation, anti-apoptosis, and transforma-
tion. Moreover, STAT3 modulates the cross-talk between tumor
and immune cells (Wang et al., 2004; Yu et al., 2007). More inter-
estingly, we have shown that VEGF neutralization resulted in the
attenuation of hypoxic tumor target resistance to CTL-mediated
killing (Noman et al., 2009). We have also demonstrated that
STAT3 phosphorylation can be stimulated by autocrine signaling
throughVEGF, suggesting that tumor microenvironment through
hypoxia-induced VEGF may play a key role in the induction of
active form of STAT3. In this regard, it is very likely that STAT3
activation is associated with the regulation of gene expression
potentially involved in the alteration of hypoxic tumor target-
speciﬁc killing. Therefore, understanding how VEGF and other
soluble factors lead to STAT3 activation via the tumor microenvi-
ronment may provide a more effective cancer treatment strategy
for hypoxic tumorswith elevatedP-STAT3 levels. This also suggests
that reduction of VEGF release in tumor microenvironment may
favor induction of a stronger anti-tumor CTL response against
tumors expressingVEGF receptor (VEGFR). In this regard, inhibi-
tion of VEGF may be a valuable adjuvant in the immunotherapy of
cancer (Gabrilovich et al., 1996) pointing to the existence of a syn-
ergy between tumor immunotherapy and antiangiogenic therapy
(Nair et al., 2003).
HYPOXIA INDUCES EPITHELIAL-TO-MESENCHYMAL TRANSITION
Epithelial-to-mesenchymal transition (EMT) is a complex mole-
cular process during which epithelial cells lose their apico-basal
polarity and acquire a mesenchymal and motile phenotype. The
hallmarks of EMT are the down regulation of epithelial mark-
ers (E-cadherin) and the up regulation of mesenchymal markers
(Vimentin, Fibronectin, the transcriptional factors Snail, Slug,
Twist, and Zeb1/2) leading to an organized disassembly of epithe-
lial cell-to-cell contacts enablingmotility and invasiveness (Thiery,
2002). EMT has therefore become a prominent program involved
in carcinogenesis, metastasis, tumor recurrence and resistance
to apoptosis and to chemotherapy (Barrallo-Gimeno and Nieto,
2005, p. 172; Thiery and Sleeman, 2006, p. 173). The activation
of EMT in tumor cells has been reported to be associated with
interactions of tumor cells with tumor-associated stromal cells,
implicatingneoplasticmicroenvironmental stimuli inEMT induc-
tion. In this regard, tumor hypoxia through HIF-1α has recently
been proposed to be an important trigger and modulator of EMT
(Lundgren et al., 2009; Sleeman and Thiery, 2011).
During hypoxic stress, different signaling pathways seem to be
involved in triggering EMT (Jiang et al., 2011). In this regard,
the existence of cooperation between hypoxia and TGFβ signal-
ing resulting in EMT activation has been reported (Schaffer et al.,
2003; Nishi et al., 2004). Recent ﬁndings also demonstrate that,
in breast cancer cells, the Notch pathway plays a role in hypoxia-
activated EMT since its inhibition abrogates hypoxia-mediated
increase in Slug and Snail expression, and decreases cell migra-
tion and invasion (Chen et al., 2010). Lysyl oxidase (LOX) and
the related LOX-like 2 (LOXL2) have recently been reported to
be direct transcriptional targets of HIF-1α that are sufﬁcient to
repress E-cadherin and induce EMTunder hypoxia (Schietke et al.,
2010). Urokinase plasminogen activator receptor (uPAR), another
direct transcriptional target of HIF-1α (Buchler et al., 2009), is
described to be involved in E-cadherin repression and EMTactiva-
tion during hypoxic stress in medulloblastoma cells (Gupta et al.,
2011). Interestingly, Luo et al. (2011) have recently identiﬁed a
hypoxia-response element in close proximity with the minimal
promoter of human and mouse Snail, which binds both HIF-1
and HIF-2 proteins and which activates snail transcription. This
provides new evidence of the direct involvement of HIFs in Snail
activation and EMT-regulation.
It should be noted that EMT contributes to malignancy not
only by enhancing motility, invasiveness, resistance to apoptosis
and drugs, but also by inducing immune escape. In fact, Kudo-
Saito et al. report that Snail expression in melanoma cells resulted
in the impairment of dendritic cell maturation, expansion of T
regulatory cells, and resistance to CTL-mediated lysis. Moreover,
intratumoral targeting of Snail in melanoma signiﬁcantly inhib-
ited tumor growth and metastasis in correlation with an increase
of tumor-speciﬁc tumor-inﬁltrating lymphocytes and of systemic
immune responses (Kudo-Saito et al., 2009). It seems that EMT
program in tumors is able to redirect the immune system toward
immune tolerance. Since hypoxia has been also reported to medi-
ate immune tolerance, the role of EMT factors in this process
remains to be investigated.
TUMOR HYPOXIA PROMOTES ANGIOGENESIS AND IMMUNE
TOLERANCE
It is well known that immune system can effectively inhibit tumor
growth (Zhang et al., 2003; Koebel et al., 2007; Fridman et al.,
2011). However, tumors are known to establish diverse potent
mechanisms,which help them to escape the immune system (Zou,
2005; Nagaraj and Gabrilovich, 2007; Marigo et al., 2008; Hamai
et al., 2010). Emerging evidence indicates a link between hypoxia-
induced angiogenesis and tolerance to immune system (Manning
et al., 2007; Buckanovich et al., 2008; Tartour et al., 2011). Tumor
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hypoxia drives angiogenesis by inducing synthesis of VEGF and
other pro-angiogenic factors in tumor cells via HIFs and promotes
immunosuppression (Noman et al., 2009, 2011a). The association
between angiogenesis and immunosuppression comes from the
immunosuppressive activities of angiogenic factors such as VEGF,
a cytokine secreted by most tumors (Toi et al., 1996a,b), making
it a critical actor in tumor angiogenesis and immune tolerance
(Motz and Coukos, 2011). Hypoxic zones in tumors attract a vari-
ety of immune cells in which HIF stabilization is associated with
the acquisition of both pro-angiogenic and immunosuppressive
phenotype (Noman et al., 2011c).
MYELOID CELLS
Myeloid cells are perhaps the best-studied cell types in terms of
their ability to promote immunosuppression and angiogenesis in
tumors (Gabrilovich and Nagaraj, 2009; Motz and Coukos, 2011).
Tumor-associated macrophages
Macrophages constitute a major component of the immune inﬁl-
trate seen in tumors (Bingle et al., 2002). In the tumor microen-
vironment, they differentiate into tumor-associated macrophages
(TAM) with expression of TAM markers such as CD206 (Man-
tovani et al., 2002). High TAM numbers in tumors in major-
ity of cases are correlated with reduced survival (Bingle et al.,
2002). Exposure of TAM to tumor-derived cytokines such as IL-
4 and IL-10 is able to convert them into polarized type II or
M2 macrophages with immune-suppressive activities and pro-
angiogenic effects, resulting in tumor progression (Mantovani
et al., 2002). TAM are found to be preferentially located in tumor
hypoxic areas, where they accumulate HIF-1 and HIF-2 and up
regulate VEGF and other pro-angiogenic factors (Lewis et al.,
2000). The relative contribution of HIF-1 and HIF-2 in the regu-
lation of gene expression in TAM is not yet completely elucidated.
In human macrophages, HIF-2 has been reported to be a cru-
cial inducer of pro-angiogenic molecules (White et al., 2004).
In another study, Werno et al. (2010) proposes that HIF-1 is
indispensable for angiogenic-promoting properties of TAM, at
least in murine macrophages. Besides this angiogenesis promoting
activity, HIF-1α was also reported to be crucial for macrophage-
mediated inhibition of T cells in hypoxic conditions (Doedens
et al., 2010). In hypoxic areas of tumors, TAM also up-regulate the
expression of MMP-7 protein in hypoxic areas of tumors (Burke
et al., 2003). MMP-7 is known to cleave the Fas ligand from neigh-
boring cells, making tumor cells less responsive to lysis by NK and
T cells (Fingleton et al., 2001). MMP-7 is also known to stimulate
endothelial cell proliferation and migration, which can support
tumor angiogenesis (Nishizuka et al., 2001).
Myeloid derived suppressor cells
Myeloid derived suppressor cells (MDSCs) have also been demon-
strated to directly promote angiogenesis (Yang et al., 2004) and
immune tolerance (Gabrilovich and Nagaraj, 2009). In tumor
bearing hosts, tumor-derived factors such as VEGF, GM-CSF,
prostaglandins also restrainDCmaturation andpromote the accu-
mulation of MDSCs in tumoral tissues and secondary lymphoid
organs (Gabrilovich, 2004). In these sites, MDSCs induce T cell
anergy, restrain the effector phase of the CD8+ T cell, and can
promote antigen-speciﬁc T reg proliferation (Gabrilovich, 2004;
Seraﬁni et al., 2008). Moreover, HIF-1α has been directly shown
to regulate the function and differentiation of MDSC within the
hypoxic tumor microenvironment (Corzo et al., 2010). A cross-
talk between MDSC and macrophages has been reported, propos-
ing that MDSC down-regulate IL-12 production by macrophages
and increase their own production of IL-10 in response to sig-
nals from macrophages. This interaction between MDSC and
macrophages polarizes classically activated (M1) macrophages
toward a type 2 and immunosuppressive phenotype and accen-
tuates the M2 phenotype of M2 macrophages, which is likely
to establish an environment that skew CD4+ and CD8+ T cell
immunity toward a tumor-promoting type 2 response (Trinchieri,
2003). As a result, MDSC directly and through their cross-talk
with macrophages, suppress both adaptive and innate anti-tumor
immunity, which facilitate tumor growth. MDSC also have pro-
angiogenic activities that can mediate tumor refractoriness to
anti-VEGF treatment (Shojaei et al., 2007).
Dendritic cells
The dendritic cell subset is also diverted by VEGF from its
highly specialized antigen-presenting and T cell activating func-
tions. Indeed, production of VEGF by human tumors inhibits
the functional maturation of dendritic cells and thereby pro-
motes immune escape of tumor cells (Gabrilovich et al., 1996).
Recombinant VEGF administered to tumor-free mice resulted
in repressed dendritic cell development associated with accu-
mulation of Gr-1+ immature myeloid-derived suppressor cells
(MDSC) that inhibit T cell functions (Gabrilovich et al., 1998),
illustrating the proper immune-suppressive functions of VEGF.
Tumor-associated myeloid dendritic cells, in response to tumor-
derivedVEGF, increase the expression of PDL-1which is a negative
regulator of T cell function (Curiel et al., 2003). Moreover, anti-
VEGF therapywas associatedwith a decrease in immaturemyeloid
and dendritic cells in patients (Osada et al., 2008).
LYMPHOCYTES
Lymphocytes play a crucial role in immunosuppression and tol-
erance (Fridman et al., 2011). In an ovarian cancer model, very
recently, it has been shown that hypoxia promotes the recruitment
of the immunosuppressive CD4+ CD25+ FOXP3+ T regula-
tory cells (T reg) through the induction of CCL28 expression
by hypoxic tumor cells. T reg in turn secrete VEGF, contribut-
ing to the VEGF pool in the tumor microenvironment and to
immune tolerance (Facciabene et al., 2011). Moreover, CD4-
deﬁcient mice have an impaired angiogenesis response to hypoxia
during ischemia (Stabile et al., 2003). Moreover VEGF targeting
reduces intratumoral T regulatory cells and increases the efﬁcacy
of cancer immunotherapy in B16 melanoma and the CT26 colon
carcinoma models (Li et al., 2006). In addition, an inverse cor-
relation between angiogenesis and tumor-inﬁltrating T cells has
already been reported (Zhang et al., 2003; Buckanovich et al., 2007,
2008; Kandalaft et al., 2009). Other lymphocyte cells (including
regulatory B cells, NK cells, and NKT cells) with immunosup-
pressive functions have been reported to produce VEGFA (Motz
and Coukos, 2011). However, the precise role of these cells in
tumor angiogenesis remains largely unknown. Therefore, the exact
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FIGURE 1 | Role of hypoxia-inducedVEGF in mediating immune
tolerance. Diverse effects of hypoxia-induced VEGF on different
components of the immune system (TAM, MDSC, DC, CTL, andT reg).
In general, hypoxia-induced VEGF pool in tumor microenvironment
(VEGF secreted by hypoxic tumor cells, TAM, MDSC, DC, andT reg)
ampliﬁes the activity of TAM, MDSC, andT reg while suppressing the
function of CTL and delaying the maturation of DC cells. TAM,
tumor-associated macrophages; MDSC, myeloid derived suppressor
cells; DC, dendritic cells; CTL, cytotoxic T-lymphocyte; T reg, T
regulatory cells.
contribution of these lymphocytes in mediating VEGF-induced
immune suppression requires further investigation.
Different facets of VEGF-induced immunosuppression in
diverse cell types in hypoxic tumor microenvironment is sum-
marized in Figure 1.
HYPOXIA, PRO-INFLAMMATORY MEDIATORS, AND IMMUNE
SUPPRESSION
Hypoxia induces both angiogenesis and immunosuppression also
by upregulating COX-2 in tumor cells (Greenhough et al., 2009).
COX-2 is an inﬂammatory enzyme converting arachidonic acid
into prostaglandin PGE2 which has angiogenic properties by pro-
moting VEGF expression (Jain et al., 2008) and immunosuppres-
sive functions by causing, in cooperation with hypoxia-induced
increased extra-cellular adenosine, cAMPaccumulation in effector
T cells resulting in the suppression of their anti-tumor functions
(Whiteside et al., 2011). PGE2 can also inhibit tumor immunity
by inhibiting dendritic cell maturation, their expression of co-
stimulatory molecules, and their production of IL-12. In addition,
PGE2 enhances the suppressive activity of T reg and is involved
in the conversion of CD4+ CD25− into T reg. Finally, PGE2 can
stimulate the immunosuppressive functions of MDSC by binding
the EP-4 receptor (Rodriguez et al., 2005; Sinha et al., 2007).
Thus hypoxia connects peripheral immune tolerance and
angiogenic programs to sustain tumor growth. The counter-
activation of tolerance mechanisms at the site of tumor hypoxia is
therefore a crucial condition for maintaining the immunological
escape of tumors.
THERAPEUTIC INTERVENTIONS TARGETING ANGIOGENESIS
Hypoxia-inducedVEGFproducedbymost tumors plays an impor-
tant role in tumor angiogenesis (Takenaga, 2011). Recognition
of the VEGF pathway as a key regulator of angiogenesis has led
to the development of several VEGF-targeted molecules (Porta
et al., 2011). These molecules include neutralizing antibodies to
VEGF (Escudier et al., 2008) or VEGFRs, mTOR kinase inhibitors
(Azim et al., 2010), and tyrosine kinase inhibitors (TKIs; Porta
et al., 2011) with selectivity for VEGFRs. The pioneers in the
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ﬁeld of angiogenesis inhibitors are bevacizumab (an anti-VEGF
monoclonal antibody that binds speciﬁcally to the VEGF ligand
and neutralizes its activity; Ferrara et al., 2004) and two multi-
targeted kinase inhibitors (sorafenib and sunitinib; non-speciﬁc
small molecules that inhibit multiple kinase receptors; Zhong and
Bowen, 2011). Indirectly, the macrocyclic lactones temsirolimus
and everolimus, inhibit also VEGF (Azim et al., 2010). These mol-
ecules inhibit the mTOR complex formation targeting mTORC1
that inhibits HIF-1α expression and consequently inhibits HIF-
1α dependent VEGF transcription decreasing angiogenesis (Azim
et al., 2010). These angiogenesis inhibitors have proven their ther-
apeutic efﬁcacy in several mouse models of cancer and in a large
number of human cancers (Porta et al., 2011). However, clini-
cal beneﬁts are often followed by a restoration of tumor growth
and progression (Burger et al., 2011; Perren et al., 2011). The
Bevacizumab-chemotherapy combination seems to be successful
in second-line settings in the treatment of patients with advanced
colorectal cancer, compared to the disappointing efﬁcacy of com-
bining bevacizumab with chemotherapy in the ﬁrst-line treatment
of the patients (Jenab-Wolcott and Giantonio, 2010). Several
intrinsic and adaptive mechanisms were shown to be involved
in resistance to angiogenic therapy (Bergers and Hanahan, 2008).
Antiangiogenic therapy can lead to hypoxia as a compensatory
mechanism (Casanovas et al., 2005; Bergers and Hanahan, 2008).
It is now clear that hypoxia-induced by angiogenesis inhibitors
might further elevate VEGF and other pro-angiogenic factors
expression in tumors (Shaked et al., 2005; Mancuso et al., 2006).
Sathornsumetee et al. (2008) have shown that hypoxic proﬁles
can predict survival in malignant astrocytoma patients treated
with bevacizumab. Another mechanism underlying resistance to
anti-VEGF therapy involves inﬁltration of various pro-angiogenic
bone marrow-derived cells, in part through increases in HIF-1α
and its downstream effectors such as VEGF (Ceradini et al., 2004;
Shaked et al., 2006). In a metastatic colorectal cancer model, beva-
cizumab therapy improved the impairment of lymphocyte subsets,
especially for T cells. These effects correlated with more favorable
clinical outcome (Manzoni et al., 2011). Interestingly, anti-VEGF
agents can have contradictory effects on immune system (Seliger
et al.,2010). Sorafenib appears to impair,while sunitinib stimulates
terminal DC maturation (Hipp et al., 2008). Sunitinib induces Th-
1 immune response (IFN-γ expression) while reducing T reg in
renal cell carcinoma patients (Finke et al., 2008). Sunitinib, but not
Sorafenib has been shown to inhibit MDSC immune-suppressive
activity and reduces MDSC and T reg circulating numbers (Ko
et al., 2009). Another study has shown that sunitinib adminis-
tration in mouse renal cell carcinoma tumor bearing mice led to
the inhibition of Stat3 in tumor-associatedmyeloid cells, including
dendritic cells andMDSCs,whichwas accompanied by a reduction
of tumor T reg (Xin et al., 2009). Du et al. (2008) have shown that
impairment of VEGF signaling leads to an adaptive pro-invasive
tumor phenotype.
A better understanding of the complex interaction between
cancer cells, immune system and anti-VEGF agents is therefore
needed for improving and sustaining the beneﬁts of antiangio-
genic therapy.
CONCLUSION
Advances in immunology and molecular biology have shown
that cancers are potentially immunogenic and that host immune
responses inﬂuence survival (Galon et al., 2006). However,
immune surveillance and activation is frequently ineffective in
preventing and/or controlling tumor growth. In fact, an active and
bi-directional molecular cross-talk between tumor microenviron-
ment and host cells has profound implications for immunological
recognition and progression of tumor cells (Petrulio et al., 2006;
Lorusso and Ruegg, 2008). The cross-talk between tumor cells
and stromal cells within the tumor microenvironment medi-
ates tumor initiation, progression, and response to anticancer
therapy. In this regard, microenvironmental components includ-
ing hypoxia appear to regulate gene expression in tumor cells
thereby directing the tumor toward aggressiveness, angiogenesis,
and metastasis. It is well documented that inﬂammation is an
important part of hypoxic tumor microenvironment (Eltzschig
and Carmeliet, 2011). Increasing evidence suggest the existence
of a link between hypoxic stress and several inﬂammatory mol-
ecules (PEG2, COX-2, chemokines, and cytokines) responsible
for tumor initiation and progression. These pro-inﬂammatory
mediators not only support tumor survival and expansion but
also the function of several immune cells notably dendritic and
effector cells (Chow et al., 2011). Therefore, a well-integrated
understanding of this intricate microenvironment may offer
new opportunities for therapeutic intervention. Recent insights
into cellular and molecular cross-talk suggest a model in which
hypoxia, HIF, VEGF, and several other HIF target genes partici-
pate in the coordinated collaboration between tumor, endothelial,
inﬂammatory/hematopoietic, and circulating endothelial precur-
sor cells to enhance and promote tumor vascularization. Given
its central role in tumor progression and resistance to therapy,
tumor hypoxia might well be considered as one potential tar-
get that has yet to be exploited in oncology. Its targeting may
be therefore an innovative approach to design new approaches
in cancer therapy. Recently, a growing number of drugs that
inhibit HIF-1 have been identiﬁed and validated as anticancer
agents (Semenza, 2010; Wilson and Hay, 2011). It is also becom-
ing evident that characterizing the tumor microenvironment can
provide important prognostic and predictive information about
tumors, independently of the tumor cell phenotype. Whether
the inhibition of hypoxic signaling pathways in different com-
partments of the solid tumor microenvironment will open new
therapeutic opportunities in cancer immunotherapy has to be
established.
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Résumé 
L’hypoxie est une caractéristique commune des tumeurs solides et l’une des spécificités du microenvironnement 
tumoral. L’hypoxie tumorale joue un rôle important dans l’angiogénèse, la progression maligne, le 
développement de métastases, la chimio/radio-résistance et favorise l’échappement au système immunitaire du 
fait de l’émergence de variant tumoraux avec un potentiel de survie et de résistance à l’apoptose augmenté. 
Cependant, très peu de travaux ont étudié l’impact de l’hypoxie tumorale sur la régulation de la susceptibilité des 
tumeurs à la lyse induite par la réponse immune cytotoxique. Nous nous sommes donc demandé si l’hypoxie 
pouvait conférer aux tumeurs une résistance à la lyse induite par les lymphocytes T cytotoxiques (CTL).   
Nous avons démontré que l’exposition de cellules cibles tumorales à l’hypoxie possédait un effet inhibiteur sur 
la lyse de ces cellules tumorales par des CTL autologues. Cette inhibition n’est pas associée à des altérations de 
la réactivité de CTL ou de la reconnaissance des cellules cibles. Cependant, nous avons montré que l’induction 
hypoxique concomitante de la phosphorylation de STAT3 (pSTAT3) au niveau de la tyrosine 705 et du facteur 
HIF-1α (Hypoxia Inducible Factor-1 alpha) est liée fonctionnellement à l’altération de la susceptibilité de 
cellules tumorales bronchiques non à petites cellules (NSCLC) à la mort induite par les CTL.  
Nous avons aussi montré que la résistance de cellules tumorales bronchiques à la lyse CTL induite par l’hypoxie 
était associée à une induction d’autophagie dans les cellules cibles. En effet, l’inhibition de l’autophagie 
empêche la phosphorylation de STAT3 (via l’inhibition de la kinase Src) et restaure la susceptibilité des cellules 
tumorales hypoxiques à la lyse induite par les CTL. De plus, l’inhibition in vivo de l’autophagie par 
l’hydroxychloroquine (HCQ) dans le modèle murin portant la tumeur B16F10 and chez les souris vaccinée avec 
le peptide TRP2 augmente de façon drastique l’inhibition de la croissance tumorale. Collectivement, cette étude 
établit un nouveau lien fonctionnel entre l’autophagie induite par l’hypoxie et la régulation de la lyse induite par 
les cellules T spécifique d’antigènes et souligne le rôle majeur de l’autophagie dans le contrôle de la croissance 
tumorale in vivo. 
Finalement, étant donné que le la résistance tumorale à la lyse induite par les cellules tueuses est très 
probablement régulée par de multiples facteurs, nous avons aussi eu pour but d’identifier les micro-ARNs 
(miRs) régulés par l’hypoxie dans des modèles de NSCLC et de mélanome et leur implication putative dans la 
régulation de la susceptibilité tumorale à la lyse induite par les cellules T spécifique d’antigènes. Le micro-ARN 
210 (miR-210) est ainsi significativement induit de manière dépendante de HIF-1α dans des cellules de NSCLC 
et de mélanome, et miR-210 est exprimé dans les zones hypoxiques de tissus issus de NSCLC. De plus, nous 
avons démontré que l’induction de miR-210 par l’hypoxie régule la susceptibilité tumorale à la lyse induite par 
les CTL en partie grâce à l’inhibition de l’expression de PTPN, HOXA1 et TP53I11, indiquant que miR-210 
joue un rôle potentiel dans la régulation de la réponse immune antitumorale. 
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